日本臨牀　増刊　血管炎

出版社： 日本臨牀社
発行日： 2013-02-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 血管炎　基礎と臨床のクロストーク
電子書籍版： 2013-02-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

18,150 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

18,150 円(税込)

購入する

目次

  • 日本臨牀　増刊　血管炎

    ―目次―

    特集　血管炎　基礎と臨床のクロストーク

    ?． 我が国の血管炎研究のオーバービュー 　 　
    　１． 血管炎臨床研究の歴史　
    　２． 我が国で命名された血管炎 　 　
    　３． 難治性血管炎研究 　
    　４． 難治性血管炎の病理と基礎　
    　５． 血管炎の国際的疫学研究の重要性
    　　　　　―ANCA関連血管炎を中心に―　

    II． 血管炎の分類と診断基準 　 　
    　１． 我が国の血管炎の分類と診断基準：現在と今後 　
    　２． 新しい国際分類と診断基準(CHCC2012とDCVAS) 　 　
    　３． 血管炎の活動性と障害性の評価　BVAS，VDI 　

    III． 川崎病の病因・病理、診断・治療 　 　
    　１． 川崎病の発症機序 　 　
    　２． 川崎病心血管病変の病理　
    　３． 川崎病全国調査 　
    　４． 急性期川崎病の臨床像 　
    　５． 川崎病の診断　
    　６． 川崎病の治療　
    　７． 川崎病冠動脈病変の治療 　 　
    　８． 川崎病の臨床研究の新しいアプローチ

    IV． 大型血管炎の病因・病理、診断・治療 　 　
    　１． 大型血管炎の病理 　
    　２． 高安動脈炎 　 　
    　３． 巨細胞性動脈炎(側頭動脈炎)の診断と治療　
    　４． バージャー病 　 　

    V． ANCA関連血管炎の病因・病理、診断・治療 　 　
    　１． ANCA関連血管炎(AAV)の基礎研究から臨床へのアプローチ
    　２． 顕微鏡的多発血管炎の診断と治療
    　３． 多発血管炎性肉芽腫症の診断と治療
    　４． 好酸球性肉芽腫性多発血管炎(Churg-Strauss症候群(CSS)，
    　　　　　アレルギー性肉芽腫性血管炎) 　
    　５． ANCA関連血管炎の臓器障害 　 　
    　６． ANCA関連血管炎の臨床研究 　 　

    VI． その他の血管炎の診断と治療 　 　
    　１． 結節性多発動脈炎 　 　
    　２． ヘノッホ・シェーンライン紫斑病の診断と治療
    　３． クリオグロブリン血症の診断と治療
    　４． 低補体血症性蕁麻疹様血管炎
    　５． 抗GBM抗体疾患(グッドパスチャー症候群と抗基底膜病)の
    　　　　診断と治療　
    　６． ベーチェット病 　
    　７． Cogan(コーガン)症候群の診断と治療 　
    　８． リウマトイド血管炎(＝悪性関節リウマチ)の診断と治療　

    VII． 血管炎の血管新生療法と免疫療法 　 　
    　１． 血管新生療法におけるバイオマテリアル工学　
    　２． 生体吸収性ゼラチンハイドロゲルを用いた血管新生療法　
    　３． 骨髄細胞移植による血管再生療法　
    　４． 次世代血管新生療法開発の展望　
    　５． 慢性炎症性血管炎におけるinterleukin 6 (IL-6) による
    　　　　　急性期タンパクの発現機序　
    　６． 免疫グロブリン療法 亀岡　洋祐 487

    VIII． 最新の研究トピックス―AP-VAS 2012から
    　１． 血管炎の基礎研究
    　２． 血管炎の臨床研究

    IX． 特　論 　 　
    　１． 炎症と免疫応答における樹状細胞　
    　２． サイトカインと関節炎モデルマウス　
    　３． 血管炎におけるIL-17産生ヘルパーT細胞(Th17細胞)の役割
    　４． 難治性血管炎における補体系の重要性　
    　５． CAWS血管炎モデルの特徴と応用　
    　６． 慢性肉芽腫症の病態解析　−遺伝子と病態解析−　
    　７． 肺に限局する顕微鏡的多発血管炎　
    　８． ANCA関連血管炎のANCA陰性再発 　
    　９． ミゾリビンによるANCA関連血管炎維持療法　
    　10． 炎症性自己免疫疾患における治療標的としてのIL-6 　
    　11． 膠原病における自己抗体の産生機序とその臨床的意義　
    　12． 多発性筋炎・皮膚筋炎における自己抗体研究の最前線 　
    　13． 我が国における大動脈瘤手術の現況　
    　14． 血管炎と突然死 　
    　15． ANCA関連血管炎の診療ガイドラインの要点
    　16．「血管炎・血管障害ガイドライン」の要点
    　17．「血管炎」疾患概念の(プライマリーケア医師への)普及と
    　　　　　今後の展開 　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.12 掲載の参考文献
1) Basu N,et al:EULAR points to consider in the development of classification and diagnos-tic criteria in systemic vasculitis.Ann Rheum Dis 69:1744-1750,2010.
 
2) Falk RJ,et al;American College of Rheumatology;the American Society of Nephrol-ogy;the European League Against Rheumatism:Granulomatosis with polyangiitis(Wegener's):an alternative name for Wegener's granulomatosis.Arthritis Rheum 63(4):863-864,2011.
 
3) Fujimoto S,et al:Incidence of ANCA-associated primary renal vasculitis in Miyazaki Pre-fecture:The first population-based,retrospective epidemiological survey in Japan.Clin J Am Soc Nephrol 1:1016-1022,2006.
 
4) Ito-Ihara T,et al:Acomparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe.Clin Exp Rheumatol 26:1027-1033,2008.
 
5) Watts RA,et al:Renal vasculitis in Japan and the UK-are there differences in epidemiol-ogy and clinical phenotype? Nephrol Dial Transplant 23:3928-3931,2008.
 
6) Kobayashi S,et al:Anti-neutrophil cytoplasmic antibody-associated vasculitis,large ves-sel vasculitis and Kawasaki disease in Japan.Kidney Blood Press Res 33(6):442-455,2010.
 
7) Fujimoto S,et al:Comparison of the epidemiology of anti-neutrophil cytoplasmic anti-body-associated vasculitis between Japan and the U.K.Rheumatology(Oxford)50(10):1916-1920,2011.
 
8) AP-VAS 2012オンライン要旨[http://www0.nih.go.jp/niid/bioimaging/proceedings.html].
 
9) Arimura Y,et al:Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis.Clin Nephrol 40:256-264,1993.
PubMed
10) Minoshima S,et al:Increased release of myeloperoxidase in vitro from neutrophils of patients with myeloperoxidase-specific anti-neutrophil cytoplasmic antibody(MPO-ANCA)related glomerulonephritis.Nephrology 3:527-534,1997.
 
11) Fujii A,et al:Epitope analysis of myeloperoxidase-specific anti-neutrophil cytoplasmic antibody(MPO-ANCA)associated glomerulonephritis.Clin Nephrol 53:242-252,2000.
PubMed
12) Ito-Ihara T,et al:Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.Nephron Clin Pract 102:c35-c42,2005.
PubMed
13) Joh K,et al:Renal pathology of ANCA-related vasculitis:proposal for standardization of pathological diagnosis in Japan.Clin Exp Nephrol 12:277-291,2008.
PubMed
14) Sugiyama H,et al:Japan Renal Biopsy Registry:the first nationwide,web-based,and prospective registry system of renal biopsies in Japan.Clin Exp Nephrol 15:493-503,2011.
PubMed
15) Tomizawa K,et al:Reduction of MPO-ANCA epitopes in SCG/Kj mice by 15-deoxysper-gualin treatment restricted by IgG2b associated with crescentic glomerulonephritis.Rheu-matology(Oxford) 49:1245-1256.2010.
 
16) Nagai-Miura N,et al:Induction of coronary arteritis with administration of CAWS(Candida albicans water-soluble fraction)depending on mouse strains.Immunopharma-col Immunotoxicol 26:527-543,2004.
 
17) Fugo K,et al:The role of the thymus in development of necrotizing arteritis in trans-genic rats carrying the env-pX gene of human T-cell leukemia virus type-I.Am J Pathol 161:755-761,2002.
 
18) Nagao T,et al:Direct activation of glomerular endothelial cells by anti-moesin activity of anti-myeloperoxidase antibody.Nephrol Dial Transplant 26(9):2752-2760.2011.
PubMed

I 我が国の血管炎研究のオーバービュー

P.22 掲載の参考文献
1) 川崎富作:指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜リンパ腺症症候群.アレルギー 16:178-222,1967.
 
2) Bloch DA,et al:The American College of Rheumatology 1990 criteria for the classification of vasculitis.Patients and methods.Arthritis Rheum 33:1068-1073,1990.
PubMed
3) Rus V,Handwerger BS:Clinical value of antineutrophil cytoplasmic antibodies.Curr Rheumatol Rep 2:383-389,2000.
PubMed
4) Jennette JC,et al:Nomenclature of systemic vasculitis,Arthritis Rheum 37:187-192,1994.
PubMed
5) Takeuchi T,Abe T:Vasculitis and adhesion molecules.Int Med 41:42-45,2002.
 
6) Ozen S,et al:EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.Ann Rheum Dis 65:936-941,2006.
PubMed
7) Jennette JC,et al:2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.Arthritis Rheum,2012.[Epub ahead of print]
 
P.32 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemi vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
 
2) 矢数道明:脈なし病記載の漢方医書とその著者山本鹿洲翁.日本医事新報 57:27-30,1966.
 
3) 高安右人:奇異ナル網膜中心血管ノ変化ノ一例.日本眼科学会雑誌 12:554-555,1908.
 
4) Shimizu K,Sano K:Pulseless disease.J Neuropathol Clin Neurol 1:37-47,1951.
PubMed
5) Caccamise WC,Whitman JF:Pulseless disease.A preliminary case report.Am Heart J 44:629-633,1952.
 
6) Ueda H,et al:Immunological studies of aortitis syndrome.Jap Heart J 8:4-18,1967.
 
7) Seko Y,et al:Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock pro-tein in aortic tissue of patients with Takayasu's arteritis.J Clin Invest 93:750-758,1994.
 
8) Arend WP,et al:The American College of Rheumatology 1990 criteria for the classification of Takay-asu arteritis.Arthritis Rheum 33(8):1129-1134,1990.
 
9) Hunder GG,et al:The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.Arthritis Rheum 33(8):1122-1128,1990.
PubMed
10) Maksimowicz-McKinnon K,et al:Takayasu arteritis and giant cell arteritis:a spectrum within the same disease? Medicine(Baltimore)88(4):221-226,2009.
PubMed
11) Mukhtyar C,et al:EULAR recommendations for the management of large vessel vasculitis.Ann Rheum Dis 68(3):318-323,2009.
PubMed
12) 沼野藤夫ほか:厚生省特定疾患免疫疾患調査研究班 難治性血管炎分科会 1998年度研究報告書,P171-184,1999年.
 
13) 沼野藤夫ほか:厚生科学研究費補助金特定疾患対策研究事業 難治性血管炎に関する調査研究 2000年度総括研究報告書,p207-209,2001年3月.
 
14) 小林靖:厚生科学研究費補助金特定疾患対策研究事業 難治性血管炎に関する調査研究 2003年度総括研究報告書,p127,2004年3月.
 
15) 稲葉 裕ほか:厚生科学研究費補助金 特定疾患対策研究事業 難治性血管炎に関する調査研究 2001年度総括研究報告書,p21-25,2002年3月.
 
16) 黒沢美智子ほか:厚生科学研究費補助金 特定疾患対策研究事業難治性血管炎に関する調査研究 2007年度総括・分担研究報告書,p136-143,2008年3月.
 
17) 安田慶秀ほか:厚生省特定疾患免疫疾患調査研究班 難治性血管炎分科会 1998年度研究報告書,p31-37,1999年.
 
18) Ohigashi H,et al:Improved prognosis of Takayasu arteritis over the past decade-comprehensive analysis of 106 patients.Circ J 76:1004-1011,2012.
PubMed
19) Numano F,et al:HLA antigens in Takayasu disease.Am Heart J 88:153-159,1979.
 
20) 沼野藤夫ほか:厚生省特定疾患免疫疾患調査研究班 難治性血管炎分科会 1997年度研究報告書,P15-19,1998年3月.
 
21) Takamura C,et al:New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis.Circ J 76:1697-1702,2012.
PubMed
22) Kobayashi Y, et al:Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT.J Nucl Med 46:917-922,2005.
PubMed
23) Tezuka D,et al:Role of FDG PET-CT in Takayasu arteritis:sensitive detection of recurrences.JACC Cardiovasc Imaging 5:422-429,2012.
PubMed
24) 吉田俊二ほか:厚生科学研究費補助金特定疾患対策研究事業 難治性血管炎に関する調査研究 2001年度総括研究報告書,p232-234,2002年3月.
 
25) 加藤智啓:厚生科学研究費補助金特定疾患対策研究事業 難治性血管炎に関する調査研究 2004年度総括研究報告書,p139-143,2005年3月.
 
26) Karasawa R,et al:Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in sys-temic vasculitis.Clin Exp Immunol 161:459-470,2010.
 
27) 唐澤里江:プロテオミクスを用いた血管炎症候群における疾患特異的マーカーの検出.聖マリアンナ医科大学雑誌 37:105-109,2009.
Medical*Online
28) Ishihara T,et al:Sensitive assessment of activity of Takayasu's arteritis by pentraxin3,a new biomarker.J Am Coll Cardiol 57:1712-1713,2011.
PubMed
29) Koga T,et al:Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu's arteritis.Rheumatol Int 30:561-563,2010.
PubMed
30) Nishino Y,et al:Serum levels of BAFF for assessing the disease activity of Takayasu arteritis.Clin Exp Rheumatol 28:14-17,2010.
PubMed
31) Hata A,et al:Angiographic findings of Takayasu arteritis:new classification.Int J Cardiol 54(Suppl):S155-163,1996.
 
32) Numano F,et al:Takayasu arteritis-the role of genetic factors on its pathogenesis.In:Proceed-ings of International Symposium on Intractable Vasculitis Syndrome(ed by Nagasawa T),Research Committee of Intractable Vasculitis Syndromes of the Ministry of Health and Welfare of Japan,p50-60,1996.
 
33) Miyata T:Long-term result of surgical treatment of Takayasu's arteritis.In:Proceedings of Interna-tional Symposium on Primary Systemic Vasculitides(ed by Ozaki S),Research Committee of Intracta-ble Vasculitis Syndromes of the Ministry of Health,Labour and Welfare of Japan,p33-35,2008.
 
34) 小林靖:高安動脈炎.難治性血管炎の診療マニュアル(橋本博史編),厚生科学研究費補助金特定疾患対策研究事業 難治性血管炎に関する調査研究班,p1-8,2002年3月.
 
35) 那須毅:高安幹動脈炎.血管炎アトラス(京極方久編),p1-7,京極方久教授開講十周年記念出版,1988.
 
36) 由谷親夫,小林靖:高安動脈炎.血管炎アトラス(尾崎承一監,吉木敬編),厚生科学研究費補助金特定疾患対策研究事業 難治性血管炎に関する調査研究班,p5-8,2005年3月.
 
37) 日本循環器学会:循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告).血管炎症候群の診療ガイドライン.Circulation Journal 72(Suppl IV),1253-1318,2008.[http://www.j-circ.or.jp/guideline/pdf/JCS2008_ozaki_h.pdf]
 
P.39 掲載の参考文献
1) 川崎富作:非猩紅熱性落屑症候群について.千葉医学会雑誌 38:279-280,1962.
 
2) 川崎富作:指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群-自験例50例の臨床的観察-.アレルギー 16:178-222,1967.
Medical*Online
3) 松見富士夫ほか:Stevens-Johnson症候群の3例.小児科診療 30:615-616,1967.
 
4) 山本高治郎ほか:心炎を合併したStevens-Johnson症候群の1例.小児科診療 30:1027,1967.
 
5) 山本高治郎ほか:急性熱性皮膚粘膜淋巴腺症候群の臨床知見について.小児科診療 30:1544,1967.
 
6) 神前章雄ほか:急性熱性皮膚粘膜リンパ節症候群死亡例検討会.小児科臨床 24:2545-2559,1971.
 
7) 浜田勇ほか:急性熱性皮膚粘膜リンパ節症候群の心血管系合併症:特に僧帽弁閉鎖不全と冠動脈瘤について.臨床小児医学 21:163-182,1973.
 
8) 浅井利夫ほか:急性熱性皮膚粘膜淋巴腺症候群(MCLS)の冠動脈造影所見.日本医事新報 2594:37-40,1974.
 
9) Kato H,et al:Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome.J Pediatr 86:892-898,1975.
PubMed
10) Onouchi Z,et al:Cardiac involvement and prognosis in acute mucocutaneous lymph node syndrome.Chest 68:297-301,1975.
PubMed
11) Suzuki A,et al:Natural history of coronary artery lesions in Kawasaki disease.Prog Pediatr Cardiol 6:211-218,1997.
 
12) 松尾裕英ほか:急性熱性皮膚粘膜リンパ節症候群(MCLS)における冠動脈瘤の超音波像について.扇形電了走査型超音波心臓断層法(第9法).日本超音波医学会講演論文集,p139-140,1977.
 
13) 柳澤信義ほか:川崎病(MCLS)の心臓障害,昭和51年度厚生省心身障害研究班「川崎病(MCLS)の心臓障害に関する研究」研究報告書,p71-73,1977.
 
14) Yoshikawa J,et al:Cross-sectional echocardiographic diagnosis of coronary artery aneurysms in patients with the mucocutaneous lymph node syndrome.Circulation 59:133-139,1979.
PubMed
15) Hiraishi S,et al:Noninvasive visualization of coronary arterial aneurysm in infants and young chil-dren with mucocutaneous lymph node syndrome with two dimensional echocardiography.Am J Car-diol 43:1225-1233,1979.
 
16) Yoshida H,et al:Mucocutaneous lymph node syndrome-a cross sectional echocardiographic diag-nosis of coronary aneurysms.Am J Dis Child 133:1244-1247,1979.
 
17) Furusho K,et al:High-dose intravenous gammaglobulin for Kawasaki disease.Lancet 2:1055-1058,1984.
PubMed
18) Newburger JW,et al:A single intravenous infusion of gamma globulin as compared with four infu-sions in the treatment of acute Kawasaki syndrome.N Engl J Med 324:1633-1639,1991.
 
P.47 掲載の参考文献
1) 吉木敬(編),尾崎承一(監):血管炎アトラス,厚生労働省難治性疾患克服研究事業,難治性血管炎に関する調査研究班,平成17年3月発行.
 
2) Yoshiki T,et al:The structural proteins of murine leukemia virus and the pathogenesis of necrotiz-ing arteritis and glomerulonephritis in SL/Ni mice.J Immunol 122:1812-1820,1979.
 
3) Miyazawa M,et al:Pathogenesis of arteritis of SL/Ni mice.Possible lytic effect of anti-gp70 anti-bodies on vascular smooth muscle cells.J Exp Med 166:890-908,1987.
 
4) 吉木敬ほか:Retrovirusと壊死性血管炎-二つの免疫学的発生機序-厚生省特定疾患・系統的血管病変に関する調査研究班 1978年度研究報告書,p5-17,昭和54年3月.
 
5) Murata H:Experimental Candida-induced arteritis in mice.Relation to arteritis in the mucocutane-ous lymphnode syndrome.Microbiol Immunol 23:825-831,1979.
 
6) 高橋啓ほか:カンジダ菌体抽出物によるマウス系統的血管炎誘発モデルと川崎病.脈管学 43:673-678,2003.
 
7) Oharaseki T,et al:Susceptibility loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans-derived substances.Microbiol Immunol 49:181-189,2005.
PubMed
8) 鈴木和男:好中球自己抗体MPO-ANCAの病原性と血管炎の病態.日臨免疫会誌 29:94-101,2006.
 
9) 長沢俊彦,吉田雅治:ウェゲナー肉芽腫症の好中球細胞質に対する自己抗体の特異性について,厚生省特定疾患系統的脈管障害調査研究班 1988年度研究報告書,p32-33,平成元年3月.
 
10) 吉田雅治ほか:難治性血管炎諸疾患におけるANCAの意義,厚生省特定疾患難治性血管炎調査研究班 1994年度研究報告書,p100-103,平成7年3月.
 
11) Kinjoh K,et al:Genetic selection for crescent formation yields mouse strain with rapidly progres-sive glomerulonephritis and small vessel vasculitis.Proc Natl Acad Sci USA 90:3413-3417,1993.
 
12) 鈴木和男:MPO-ANCA関連血管炎モデルマウスの新知見.脈管学 49:21-29,2009.
 
13) Hamano Y,et al:Genetic dissection of vasculitis,myeloperoxidase-specific antineutrophil cytoplas-mic autoantibody production,and related traits in spontaneous crescentic glomerulonephritis-forming/Kinjoh mice.J Immunol 176:3662-3673,2006.
 
14) Yamazaki H:A wide spectrum of collagen vascular and autoimmune diseases in transgenic rats carry-ing the env-pX gene of human T lymphocyte virus type I.Int Immunol 9:339-346,1997.
 
15) 石津明洋:血管炎の発症機構解明と新しい分子標的治療法の開発に関する研究,厚生労働省科学研究費補助金難治性疾患克服研究事業・難治性血管炎に関する調査研究平成23年度総括・分担研究報告書,p73-76,平成24年(2012年)3月.
 
P.53 掲載の参考文献
1) 難治性血管炎の診療マニュアル,厚生科学研究特定疾患対策研究事業,難治性血管炎に関する調査研究班(班長橋本博史),2002.
 
2) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
3) Watts R,et al:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.Ann Rheum Dis 66:222-227,2007.
PubMed
4) 橋本博史ほか:全国疫学調査による抗好中球細胞質抗体(ANCA)関連血管炎の臨床的検討.厚生省特定疾患免疫疾患調査研究班 難治性血管炎分科会(分科会長橋本博史),平成10年度研究報告書,p213-229,1999.
 
5) Koyama A,et al:Anationwide survey of rapidly progressive glomerulonephritis in Japan:etiology,prognosis and treatment diversity.Clin Exp Nephrol 13:633-650,2009.
 
6) Reinhold-Keller E,et al:Stable incidence of primary systemic vasculitides over five years:results from the German vasculitis register.Arthritis Rheum(Arthritis Care Res)53:93-99,2005.
 
7) Mahr AD,et al:Epidemiology of Wegener's granulomatosis:Lesson from descriptive studies and analysis of genetic and environmental risk determinants.Clin Exp Rheumatol 24:S82-S91,2006.
 
8) Mahr A,et al:Prevalences of polyarteritis nodosa,microscopic polyangiitis,Wegener's granulomatosis,and Churg-Strauss syndrome in a French urban multiethnic population in 2000:acapture-recapture estimate.Arthritis Rheum(Arthritis Care Res)51:92-99,2004.
 
9) Gibson A,et al:The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region.Rheumatology 45:624-628,2006.
 
10) Fujimoto S,et al:Incidence of ANCA-associated primary renal vasculitis in the Miyazaki prefecture:the first population-based,retrospective,epidemiologic survey in Japan.Clin J Am Soc Nephrol 1:1016-1022,2006.
PubMed
11) Fujimoto S,et al:Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associ-ated vasculitis between Japan and the UK.Rheumatology(Oxford) 50:1916-1920,2011.
 
12) Ito-Ihara T,et al:Acomparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe.Clin Exp Rheumatol 26:1027-1033,2008.
 
13) Westman KWA,et al:Relapse rate,renal survival,and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement.J Am Soc Nephrol 9:842-852,1998.
PubMed
14) Malenica B,et al:Antineutrophil cytoplasmic antibodies(ANCA):diagnostic utility and potential role in the pathogenesis of vasculitis.Acta Dermatovenerol Croat 12:294-313,2004.
PubMed
15) Heckmann M,et al:The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterized by tagSNP genotyping.Ann Rheum Dis 67:972-979,2008.
PubMed
16) 土屋尚之:血管炎と疾患感受性遺伝子.血管炎(長澤俊彦監,橋本博史編),p13-18,朝倉書店,2001.
 

II 血管炎の分類と診断基準

P.63 掲載の参考文献
1) Fries JF,et al:The American College of Rheumatology 1990 criteria for the classhication of vasculitis:summary.Arthritis Rheum 33:1135-1136,1990.
PubMed
2) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
3) Watts RA,et al:Systemic vasculitis-is it time to reclassify? Rheumatology 50:643-645,2011.
PubMed
4) Watts R,et al:Development and validation of a consensus methodology for the classification of the ANCA associated vasculitides and polyarteritis nodosa for epidemiological studies.Ann Rheum Dis 66:222-227,2007.
PubMed
5) 尾崎承一ほか:ANCA関連血管炎の診療ガイドライン,2011.
 
6) Luqmani RA,et al:Nomenclature and classification of vasculitis-update on the ACR/EULAR Diag-nosis and Classification of Vasculitis Study(DCVAS).Clin Exp Immunol 164(Suppl 1):11-13,2011.
 
7) Lanham JG,et al:Systemic vasculitis with asthma and eosinophilia:a clinical approach to the Churg-Strauss syndrome.Medicine(Baltimore) 63:65-81,1984.
 
P.68 掲載の参考文献
1) Jennette JC,et al:2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.Arthritis Rheum'Accepted article',DOI:10.1002/art.37715.
 
2) Jennette JC,et al:Nomenclature of systemic vasculitides,proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
3) Kussmaul A,Maier R:Uber eine bisher nicht beschriebene eigenth Uliche Arterienerkrankung(Peri-arteritis nodosa),die mit Morbus Brichtii unf rapid fortschretender allgemeien Muskellahmung einhergeht.Deutsch Arch Klin Med 1:484,1866.
 
4) Arkin A:A clinical and pathological study of periarteritis nodosa.A report of five cases,one histo-logically healed.Am J Pathol 6:401-425,1930.
 
5) Zeek PM:Periarteritis nodosa:clinical review.Am J Clin Pathol 22:777-790,1952.
 
6) Hunder GG,et al:The American College of Rheumatology 1990 Criteria for the Classification of Vasculitis.Arthritis Rheum 33:1065-1136,1990.
PubMed
7) 厚生科学研究特定疾患対策研究事業難治性血管炎に関する調査研究班(班長:橋本博史):難治性血管炎の診療マニュアル,2002.
 
8) Falk RJ,et al:Granulomatosis with polyangiitis(Wegener's):An alternative name for Wegener's granulomatosis.Arthritis Rheum 63:863-864,2011.
 
9) Jennette JC:Nomenclature and classification of vasculitis:lessons learned from granulomatosis with polyangiitis(Wegener's granulomatosis).Clin Exp Immunol 164(Suppl 1):7-10,2011.
 
P.73 掲載の参考文献
1) Hunder G,et al:The American College of Rheumatology 1990 criteria for the classification of vasculitis.Introduction.Arthritis Rheum 33(8):1065-1067,1990.
PubMed
2) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37(2):187-192,1994.
PubMed
3) Lie JT:Nomenclature and classification of vasculitis:plus ca change,plus c'est la meme chose.Arthritis Rheum 37(2):181-186,1994.
 
P.87 掲載の参考文献
1) Guillevin L,et al:Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis:a study in 165 patients.Br J Rheumatol 27:258-264,1988.
PubMed
2) De Groot K,et al:Development and validation of a disease extent index for Wegener's granulo-matosis.Clin Nephrol 55:31-38,2001.
 
3) Luqmani RA,et al:Birmingham vasculitis activity score(BVAS)in systemic necrotizing vasculitis.QJM 87:671-678,1994.
PubMed
4) Luqmani RA,et al:Disease assessment and management of the vasculitides.Baillieres Clin Rheu-matol 11:423-446,1997.
 
5) Exley AR,et al:Development and initial validation of the vasculitis damage index for the standard-ized clinical assessment of damage in the systemic vasculitides.Arthritis Rheum 40:371-380,1997.
 
6) 湯村和子:BVAS(Birmingham vasculitis activity score)とVDI(vasculitis damage index).リウマチ科 37:268,2007.
 
7) Hoffman GS,et al:Wegener granulomatosis:an analysis of 158 patients,Ann Intern Med 116:488-498,1992.
PubMed
8) 伊藤千春,湯村和子:ANCA関連血管炎の評価法においてBVASの意義と問題点.リウマチ科 40:17-25,2008.
 
9) Ozaki S,et al:Severity-based treatment for Japanese patients with MPO-ANCA-associated vascu-litis:the JMAAV study.Mod Rheumatol 22:394-404,2012.
 
10) Hellmich B,et al:EULAR recommendation for conducting clinical studies and/or clinical trials in systemic vasculitis:focus on ANCA-associated vasculitis.Ann Rheum Dis 66:605-617,2007.
 
11) Abu-Shakra M,et al:Outcome of polyarteritis nodosa and Churg-Strauss syndrome.An analysis of twenty-five patients.Arthritis Rheum 37:1798-1803,1994.
PubMed
12) Exley AR,et al:Damage occurs early in systemic vasculitis and is an index of outcome.QJM 90:391-399,1997.
PubMed
13) 湯村和子,伊藤千春:ANCA関連血管炎の活動性と臓器障害の評価.脈管学 49:63-73,2009.
 
14) Mukhtyar CB,et al:Clinical and biological assessment in systemic necrotizing vasculitides.Clin Exp Rheumatol 24:S92-99,2006.
PubMed
15) Mohammad AJ,et al:The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index(VDI).Scand J Rheumatol 38:268-275,2009.
PubMed
16) Itabashi M,et al:Long-term damage assessment in patients with microscopic polyangitis and renal-limeted vasculitis using the Vaculitis Damage Index.Mod Rheumatol(in press)
 
17) Wegener's Granulomatosis Etanercept Trial(WGET)Research Group:Etanercept plus standard therapy for Wegener's granulomatosis.N Engl J Med 352:351-361,2005.
 
18) Seo P,et al:Damage caused by Wegener's granulomatosis and its treatment:Prospective data from the Wegener's Granulomatosis Etanercept Trial(WGET).Arthritis Rheum 52:2168-2178,2005.
PubMed
19) Kamali S,et al:Predictors of damage and survival in patients with Wegener's granulomatosis:analy-sis of 50 patients.J Rheumatol 37:374-378,2010.
 
20) Suppiah R,et al:Measurement of damage in systemic vasculitis:a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.Ann Rheum Dis 70:80-85,2011.
PubMed
21) 中林公正ほか:顕微鏡的多発血管炎(microscopic polyangitis:MPA)のVascular damage index(VDI)に関する研究-prospective study-厚生労働科学研究費(難治性疾患克服研究事業)「難治性血管炎」研究班(尾崎承一代表研究者) 中小型血管炎の臨床研究分科会研究報告書,p81-88,2007.
 
22) 小林茂人ほか:活動性評価委員会 Vascular damage index(VDI)の評価結果研究報告書 厚生労働科学研究費補助金(難治性疾患克服研究事業)「血管炎のわが国における治療法の確立のための多施設共同前向き臨床研究」研究班(尾崎承一代表研究者),p38-45,2009.
 
23) 小林茂人ほか:疾患評価検討委員会研究報告書 厚生労働科学研究費補助金(難治性疾患克服研究事業)「血管炎のわが国における治療法の確立のための多施設共同前向き臨床研究」研究班(尾崎承一代表研究者),p15-20,2010.
 

III 川崎病の病因・病理, 診断・治療

P.95 掲載の参考文献
1) 村田久雄:川崎病の実験モデル.日本臨牀 41(9):2075-2079,1983.
Medical*Online
2) Murata H:Experimental Candida-induced arteritis in mice.Relation to arteritis in the mucocutane-ous lymph node syndrome.Microbiol Immunol 23:825-831,1979.
 
3) Ohno N:Chemistry and biology of angitis inducer,Candida albicans water-soluble mannoprotein-beta-glucan complex(CAWS).Microbiol Immunol 47:479-490,2003.
 
4) 大原関利章ほか:マウス冠状動脈炎部の拡張ならびに瘤形成機序に関する検討.日小児循環器会誌 16:860-866,2000.
 
5) Takahashi K,et al:Histopathological features of murine systemic vasculitis caused by Candida albi-cans extract-an animal model of Kawasaki disease-.Inflamm Res 53:72-77,2004.
 
6) Oharaseki T,et al:Susceptibility loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans-derived substances.Microbiol Immunol 49:181-189,2005.
PubMed
7) Takahashi K,et al:Administration of human immunoglobulin suppresses development of murine systemic vasculitis induced with Candida albicans water-soluble fraction:an animal model of Kawa-saki disease.Mod Rheumatol 20:160-167,2010.
 
8) Lehman TJA,et al:Coronary arteritis in mice following the systemic injection of group B Lactobacil-lus casei cell walls in aqueous suspension.Arthritis Rheum 28:652-659,1985.
 
9) 吉野加津哉:川崎病モデルと考えられる実験的マウス血管炎について-その発生メカニズムと治療的試み-.Prog Med 17:1765-1775,1997.
Medical*Online
10) Rosenkranz ME,et al:TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coro-nary arteritis in mouse of Kawasaki disease.Circulation 112:2966-2973,2005.
 
11) Hui-Yuen JS,et al:TNF-alpha is necessary for induction of coronary inflammation and aneurysm formation in an animal model of Kawasaki disease.J Immunol 176:6294-6301,2006.
 
12) Lee Y,et al:Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.Circulation 125:1542-1550,2012.
 
13) Nishio H,et al:Nod1 ligands induce site-specific vascular inflammation.Arterioscler Thromb Vasc Biol 31:1093-1099,2011.
PubMed
14) Onouchi Z,et al:Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbit.Angiology 46:679-687,1995.
 
15) Philip S,et al:A swine model of horse serum-induced coronary vasculitis:an implication for Kawa-saki disease.Pediatr Res 55:211-219,2004.
 
P.101 掲載の参考文献
1) Onouchi Y,et al:ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms.Nat Genet 40:35-42,2008.
PubMed
2) Onouchi Y,et al:Common variants in CASP3 confer susceptibility to Kawasaki disease.Hum Mol Genet 19:2898-2906,2010.
 
3) Khor CC,et al:Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease.J Med Genet 48:467-472,2011.
PubMed
4) Khor CC,et al:Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.Nat Genet 43:1241-1246,2011.
PubMed
5) Onouchi Y,et al:A genome-wide association study identifies three new risk loci for Kawasaki disease.Nat Genet 44:517-521,2012.
PubMed
6) Asano K,et al:A genome-wide association study identifies three new susceptibility loci for ulcera-tive colitis in the Japanese population.Nat Genet 41:1325-1329,2009.
 
7) Ikeda K,et al:Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease.Clin Exp Immunol 160:246-255,2010.
PubMed
8) Lee YC,et al:Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis.Nat Genet 44:522-525,2012.
PubMed
9) Burgner D,et al:A genome-wide association study identifies novel and functionally related suscep-tibility loci for Kawasaki disease.PLoS Genet 5:e1000319,2009.
 
10) Tsai FJ,et al:Identification of novel susceptibility Loci for Kawasaki disease in a Han Chinese popu-lation by a genome-wide association study.PLoS One 6:e16853,2011.
 
11) Kim JJ,et al:A genome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease.Hum Genet 129:487-495,2011.
PubMed
12) Onouchi Y,et al:ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coro-nary artery lesion formation in Kawasaki disease.Pharmacogenomics J,2011.[Epub ahead of print]
 
P.108 掲載の参考文献
1) 川崎富作:指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群.アレルギー 16:178-222,1967.
Medical*Online
2) Nakamura Y,et al:Monthly observation of the number of patients with Kawasaki disease and its incidence rates in Japan.Epidemiology 18:273-279,2008.
PubMed
3) Abe J,et al:Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease.Proc Natl Acad Sci USA 89:4066-4070,1992.
PubMed
4) Yoshioka T,et al:Polyclonal expansion of TCRBV2-and TCRBV6-bearing T cells in patients with Kawasaki disease.Immunology 96:465-472,1999.
PubMed
5) Rowley AH,et al:Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bron-chial epithelium during acute Kawasaki disease.J Infect Dis 192:1757-1766,2005.
 
6) Rowley AH,et al:IgA plasma cells in vascular tissue of patients with Kawasaki syndrome.J Immu-nol 159:5946-5955,1997.
 
7) 水谷哲也ほか:ウイルスの網羅的解析による川崎病の原因究明.次世代シークエンサーによる川崎病の原因究明.日小児会誌 114:242,2010.
 
8) 黒田誠ほか:次世代シークエンサー網羅的配列解読法による川崎病の病原体候補カタログの作製.第26回関東川崎病研究会レポート[http://www.kawasaki-disease.org/tokyoren/pdf/26report.pdf].
 
9) Kuroda M,et al:Comprehensive detection of possible pathogens associated with Kawasaki disease using next-generation direct DNA sequencing.Pediatr Int 54(Suppl 1):70,2012.
 
10) The Human Microbiome Project Consortium:Structure,function and diversity of the healthy human microbiome.Nature 486:207-214,2012.
PubMed
11) The Human Microbiome Project Consortium:A framework for human microbiome research.Nature 486:207-214,2012.
 
12) Hooper LV,et al:Interactions between the microbiota and the immune system.Science 336:1268-1273,2012.
PubMed
P.112 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
2) Takahashi K,et al:Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease.Pediatr Int 47:305-310,2005.
PubMed
3) 増田弘毅ほか:川崎病(MCLS)における冠状動脈の病理学的検討-特に冠状動脈炎と動脈瘤の形態発生の関連について-.脈管学 21:899-912,1981.
 
4) Takahashi K,et al:A half-century of autopsy results-incidence of pediatric vasculitis syndromes,especially Kawasaki disease.Circ J 76:964-970,2012.
 
5) Sunagawa K,et al:Ruptured giant aneurysm of the left anterior descending coronary artery in Kawa-saki disease.Pediatr Cardiol 29:1115-1119,2008.
 
6) Takahashi K,et al:Pathological study of postcoronary arteritis in adolescents and young adults:with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis.Pedi-atr Cardiol 22:138-142,2001.
 
7) 高橋啓ほか:他の原因にて死亡した川崎病罹患既往児の病理組織学的検討.Prog Med 7:21-25,1987.
 
8) 高橋啓:瘤を確認できなかった冠状動脈の狭窄性病変への進展の可能性について.Prog Med 22:1676-1678,2002.
Medical*Online
9) Landing BH,Larson EJ:Pathological features of Kawasaki disease(mucocutaneous lymph node syndrome).Am J Cardiovasc Pathol 1:218-229,1987.
PubMed
10) Naoe S,et al:Kawasaki disease with particular emphasis on arterial lesions.Acta Pathol Jpn 41:785-797,1991.
PubMed
11) Amano S,et al:Pathology of Kawasaki disease:II.Distribution and incidence of the vascular lesions.Jpn Circ J 43:741-748,1979.
PubMed
12) Takahashi K,et al:Kawasaki disease as a systemic vasculitis in childhood.Ann Vasc Dis 3:173-181,2010.
PubMed
13) Harada M,et al:Histopathological characteristics of myocarditis in acute-phase Kawasaki disease.Histopathology 61:1156-1167,2012.
PubMed
P.117 掲載の参考文献
1) 川崎病の疫学:30年間の総括(柳川洋ほか編),診断と治療社,2002.
 
2) Epidemiology of Kawasaki Disease:A30-Year Achievement(ed by Yanagawa H,et al),Shindan-To-Chiryosha,Tokyo,2004.
 
3) 屋代真弓ほか:第21回川崎病全国調査成績,小児科診療 75:507-523,2012.
Medical*Online
4) Nakamura Y,et al:Epidemiologic features of Kawasaki disease in Japan:results of the 2009-2010 nationwide survey.J Epidemiol 22:216-221,2012.
PubMed
5) Uehara R Belay ED:Epidemiology of Kawasaki disease in Asia,Europe,and the United States.J Epidemiol 22:79-85,2012.
PubMed
6) 中村好一ほか:川崎病全国調査からみた川崎病疫学の特徴とその変遷.日小児循環器会誌 28:148-156,2012.
Medical*Online
7) Wu MH,et al:State-of-the-art basic and clinical science of Kawasaki disease:the 9th Interna-tional Kawasaki Disease Symposium 10-12 April 2008,Taipei,Taiwan.Pediatric Health 2:405-409,2008.
 
8) 上原里程:疫学から(川崎病の本態にせまる:古くて新しい研究から).小児科診療 74:1097-1102,2011.
 
9) Fujita Y,et al:Kawasaki disease in families.Pediatrics 84:666-669,1989.
PubMed
10) 中村好一:川崎病の地域集積性および時間集積性に関する記述疫学的研究.日小児会誌 91:896-910,1987.
 
11) 竹内せち子ほか:沖縄県宮古島における川崎病の異常発生.日小児会誌 86:1965-1972,1982.
 
12) 屋内善広:川崎病罹患感受性遺伝子の同定.日小児臨床薬理会誌 24:133-140,2011.
 
13) Burns JC,Newburger JW:Genetics insights into the pathogenesis of Kawasaki disease.Circ Cardio-vasc Genet 5:277-278,2012.
 
14) Uehara R et al:Parents with a history of Kawasaki disease whose child also had the same disease.Pediatr Int 53:511-514,2011.
PubMed
15) Piram M,et al:Effect of race/ethnicity on risk,presentation and course of connective tissue dis-eases and primary systemic vasculitides.Curr Opin Rheumatol 24:193-200,2012.
 
P.122 掲載の参考文献
1) Terai M,et al:Prognostic impact of vascular leakage in acute Kawasaki disease.Circulation 108(3):325-330,2003.
PubMed
2) Suddleson EA,et al:Hydrops of the gallbladder associated with Kawasaki syndrome.J Pediatr Surg 22:956-959,1987.
PubMed
3) Edwards KM,et al:Intrahepatic cholangitis associated with mucocutaneous lymph node syndrome.J Pediatr Gastroenterol Nutr 4(1):140-142,1985.
PubMed
4) Umezawa T,et al:Chest X-ray findings in the acute phase of Kawasaki disease.Pediatr Radiol 20:48-51,1989.
PubMed
5) Dengler LD,et al:Cerebrospinal fluid profile in patients with acute Kawasaki disease.Pediatr Infect Dis J 17:478-481,1988.
 
6) Wright H,et al:Facial nerve palsy complicating Kawasaki disease.Pediatrics 122(3):e783-785,2008.
PubMed
7) Laxer RM,Petty RE:Hyponatremia in Kawasaki disease.Pediatrics 70(4):655,1982.
PubMed
8) Shin JI,et al:Kawasaki disease and hyponatremia.Pediatr Nephrol 21(10):1490-1491,2006.
PubMed
9) Nakamura Y,et al:Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease.Pediatr Int 46(1):33-38,2004.
PubMed
10) Rauch AM:Kawasaki syndrome:critical review of U.S.epidemiology.Prog Clin Biol Res 250:33-44,1987.
PubMed
11) Hung MC,et al:Kawasaki disease resembling a retropharyngeal abscess-case report and literature review.Int J Cardiol 115:e94-96,2007.
PubMed
12) Newburger JW,et al:The treatment of Kawasaki syndrome with intravenous gamma globulin.N Engl J Med 315:341-347,1986.
PubMed
13) Newburger JW:Treatment of Kawasaki disease:corticosteroids revisited.J Pediatr 135:411-413,1999.
PubMed
14) Fuse S,et al:Standard method for ultrasound imaging of coronary artery in children.Pediatr Int 52(6):876-882,2010.
PubMed
15) Matsuura H,et al:Gallium-67 myocardial imaging for the detection of myocarditis.Br Heart J 58:385-392,1987.
PubMed
P.130 掲載の参考文献
1) 厚生労働省川崎病研究班:川崎病診断の手引き,改訂5版,2002.
 
2) Uehara R,et al:Serum alanine aminotransferase concentrations in patients with Kawasaki disease.Pediatr Infect Dis J 22:839-843,2003.
PubMed
3) 第21回日本川崎病学会全国調査成績[http://www.jichi.ac.jp/dph/kawasakibyou/20110915/mcls21report.pdf]
 
4) Burns JC,et al:Intravenous gamma-globulin treatment and retreatment in Kawasaki disease.US/Canadian Kawasaki Syndrome Study Group.Pediatr Infect Dis J 17:1144-1148,1998.
 
5) Kobayashi T,et al:Prediction of intravenous immunoglobulin unresponsiveness in patients with Ka-wasaki disease.Circulation 113:2006-2012,2006.
 
6) Egami K,et al:Prediction of intravenous immunoglobulin treatment in patients with Kawasaki disease.J Pediatr 149:237-240,2006.
PubMed
7) Sano T,et al:Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.Eur J Pediatr 166:131-137,2007.
PubMed
8) Blake GJ,Ridker PM:Novel clinical markers of vascular wall inflammation.Circ Res 89:763-771,2001.
PubMed
9) Mantovani A,et al:The long pentraxin PTX3 in vascular pathology.Vascul Pharmacol 45:326-330,2006.
 
10) Katsube Y,et al:PTX3,a new biomarker for vasculitis,predicts intravenous unresponsiveness in patients with Kawasaki disease.J Am Coll Cardiol 57:E2038,2011.
 
P.136 掲載の参考文献
1) 川崎富作:指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群(自験例50例の臨床的観察).アレルギー 16:178-222,1967.
Medical*Online
2) 荻野廣太郎:初期治療の歴史的変遷.小児科 41:41-56,2009.
Medical*Online
3) Kato H,et al:Kawasaki disease:Effect of treatment on coronary artery involvement.Pediatrics 63:175-179,1979.
PubMed
4) Furusho K,et al:High-dose intravenous gammaglobulin for Kawasaki disease.Lancet 2:1055-1058,1984.
PubMed
5) Newburger JW,et al:A single intravenous infusion of gamma globulin as compared with four infu-sions in the treatment of acute Kawasaki syndrome.N Engl J Med 324:1633-1639,1991.
 
6) 佐地勉ほか:川崎病急性期治療のガイドライン.日小循環誌 20:54-62,2004.
 
7) Kobayashi T,et al:Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.Circulation 113(22):2606-2612,2006.
PubMed
8) Egami K,et al:Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.J Pediatr 149(2):237-240,2006.
PubMed
9) Sano T,et al:Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.Eur J Pediatr 166(2):131-137,2007.
PubMed
10) Kobayashi T,et al:Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease(RAISE study):arandomised,open-label,blinded-endpoints trial.Lancet 379(9826):1613-1620,2012.
PubMed
11) Suzuki H,et al:Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.Pediatr Infect Dis J 30:871-876,2011.
PubMed
12) Kanai T,et al:Ulinastatin,a urinary trypsin inhibitor,for the initial treatment of patients with Kawa-saki disease:a retrospective study.Circulation 124(25):2822-2828,2011.
 
13) Burns JC,et al:Infliximab treatment intravenous immunoglobulin-resistant Kawasaki disease.J Pediatr 153(6):833-838,2008.
PubMed
14) Lee TJ,et al:Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.Yonsei Med J 49:714-718,2008.
PubMed
15) Mori M,et al:Efficacy of plasma exchanges therapy for Kawasaki disease intractable to intravenous gamma-globulin.Mod Rheumatol 14:43-47,2004.
PubMed
P.143 掲載の参考文献
1) Zacca NM,et al:Treatment of symptomatic peripheral atherosclerotic disease with a rotational ath-erectomy device.Am J Cardiol 63:77-80,1989.
 
2) Fourrier JL,et al:Percutaneous coronary rotational angioplasty in humans:preliminary report.J Am Coll Cardiol 14:1278-1282,1989.
PubMed
3) Bertrand ME,et al:Percutaneous transluminal coronary rotary ablation with Rotablator(European experience).Am J Cardiol 69:470-474,1992.
PubMed
P.150 掲載の参考文献
1) Kitamura S,et al:Aortocoronary bypass grafting in a child with coronary artery obstruction due to mucocutaneous lymphnode syndrome:Report of a case.Circulation 53:1035-1040,1976.
 
2) Suma K,et al:Early and late postoperative studies in coronary arterial lesions resulting from Kawa-saki disease in children.J Thorac Cardiovasc Surg 84:224-229,1982.
 
3) Kitamura S,et al:Long-term outcome of myocardial revascularization in patients with Kawasaki coronary artery disease;A multicenter cooperative study.J Thorac Cardiovasc Surg 107:663-674,1994.
PubMed
4) Yoshikawa H,et al:Result of surgical treatments in patients with coronary-arterial obstructive dis-ease after Kawasaki disease.Eur J Cardiothorac Surg 17:515-519,2000.
 
5) Kitamura S,et al:Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawa-saki disease.Circulation 120:60-68,2009.
 
6) Kitamura S,et al:Severe Kawasaki heart disease treated with an internal mammary artery in pedi-atric patients;A first successful report.J Thorac Cardiovasc Surg 89:860-866,1985.
 
7) Kitamura S,et al:Excellent patency and growth potential of internal mammary artery grafts in pediatric coronary artery bypass surgery;New evidence for a"Live"conduit.Circulation 78(Suppl I):I-129-139,1988.
 
8) Takeuchi Y,et al:Coronary revascularization in a child with Kawasaki disease:Use of right gas-troepiploic artery.Ann Thorac Surg 50:294-296,1990.
 
9) Patel MR,et al:ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization.Circulation 119:1330-1352,2009.
PubMed
10) Wijns W,et al:Guidelines on myocardial revascularization.Eur J Cardiothorac Surg 38(Suppl):S1-S52,2010.
 
11) 小川俊一ほか:循環器病の診断と治療に関するガイドライン(2007年度合同研究班報告):川崎病心臓血管後遺症の診断と治療に関するガイドライン(2008年改訂版).
 
12) Ogawa S,et al:Estimation of myocardial hemodynamics before and after intervention in children with Kawasaki disease.J Am Coll Cardiol 43:653-661,2004.
PubMed
13) Tsuda E,et al:Competition between native flow and graft flow after coronary artery bypass grafting:impact on indications for coronary artery bypass grafting for localized stenosis with giant aneurysms due to Kawasaki disease.Pediatr Cardiol 29:266-270,2008.
PubMed
14) Kato H,et al:Long-term consequences of Kawasaki disease:a 10 to 21-year follow-up study of 594 patients.Circulation 94:1379-1385,1996.
PubMed
15) Suzuki A,et al:Clinical significance of morphologic classification of coronary arterial segmental stenosis due to Kawasaki disease.Am J Cardiol 71:1169-1173,1993.
PubMed
16) Kato H,et al:Myocardial infarction in Kawasaki disease,clinical analysis in 195 cases.J Pediatr 108:923-927,1986.
 
P.155 掲載の参考文献
1) 川崎富作:指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群(自験例50例の臨床的観察).アレルギー 16:178-222,1967.
Medical*Online
2) 川崎病全国調査担当グループ:第21回川崎病全国調査成績[http://www.jichi.ac.jp/dph/kawasakibyou/20110915/mcls21report.pdf].
 
3) 佐地勉ほか:川崎病急性期治療のガイドライン.日小児会誌 107:1713-1715,2003.
 
4) Yanagawa H,et al:Incidence survey of Kawasaki disease in 1997 and 1998 in Japan.Pediatrics 107:E33,2001.
PubMed
5) 川崎病(MCLS,小児急性熱性皮膚粘膜リンパ節症候群)診断の手引き(厚生労働省川崎病研究班作成改訂5版)[http://www.jskd.jp/info/pdf/tebiki.pdf].
 
6) Manlhiot C,et al:Complete and incomplete Kawasaki disease:two sides of the same coin.Eur J Pediatr 171:657-662,2012.
PubMed
7) Sudo D,et al:Coronary artery lesions of incomplete Kawasaki disease:a nationwide survey in Japan.Eur J Pediatr 171:651-656,2012.
PubMed
8) Sonobe T,et al:Prevalence of coronary artery abnormality in incomplete Kawasaki disease.Pediatr Int 49:421-426,2007.
PubMed
9) Newburger JW,et al:Diagnosis,treatment,and long-term management of Kawasaki disease.Cir-culation 110:2747-2771,2004.
 
10) Yellen ES,et al:Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease.Pediatrics 125:e234-241,2010.
PubMed
11) de Zorzi A,et al:Coronary artery dimensions may be misclassified as normal in Kawasaki disease.J Pediatr 133:254-258,1998.
PubMed
12) Kurotobi S,et al:Coronary diameter in normal infants,children and patients with Kawasaki disease.Pediatr Int 44:1-4,2002.
PubMed
13) McCrindle BW,et al:Coronary artery involvement in children with Kawasaki disease:risk factors from analysis of serial normalized measurements.Circulation 116:174-179,2007.
PubMed
14) Dallaire F,Dahdah N:New equations and a critical appraisal of coronary artery Z scores in healthy children.J Am Soc Echocardiogr 24:60-74,2011.
 
15) Cole TJ,Green PJ:Smoothing reference centile curves:The LMS method and penalized likelihood.Stat Med 11:1305-1319,1992.
PubMed
16) 布施茂登ほか:小児の心エコー検査による冠動脈内径の標準曲線の作成LMS法(歪度,中央値,変動係数により分布を変化させる統計学的手法)による.日小児会誌 113:928-934,2009.
 
17) Abe O,et al:Quantitative evaluation of coronary artery wall echogenicity by integrated backscatter analysis in Kawasaki disease.J Am Soc Echocardiogr 23:938-942,2010.
PubMed
18) Yu JJ,et al:Perivascular brightness of coronary arteries in Kawasaki disease.J Pediatr 159:454-457.e1,2011.
 
19) Newburger JW,et al:Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.N Engl J Med 356:663-675,2007.
PubMed
20) Kobayashi T,et al:Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease(RAISE study):a randomised,open-label,blinded-end-points trial.Lancet 379:1613-1620,2012.
 
21) Kobayashi T,et al:Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.Circulation 113:2606-2612,2006.
PubMed
22) Egami K,et al:Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.J Pediatr 149:237-240,2006.
PubMed
23) Sano T,et al:Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.Eur J Pediatr 166:131-137,2007.
PubMed

IV 大型血管炎の病因・病理, 診断・治療

P.161 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an International Consensus Conference.Arthritis Rheum 37:187-192,1994.
PubMed
2) 松本俊治:血管Behcet病の病理.医学のあゆみ 215:89-92,2005.
Medical*Online
3) Vuong PN,Berry C:Vasculitis.In:The Pathology of Vessels,p237-288,Springer-Verlag France,Paris,2002.
 
4) 由谷親夫:高安動脈炎(大動脈炎症候群),病理編.血管炎アトラス(尾崎承一監,吉木敬編),厚生労働省難治性疾患克服研究事業,難治性血管炎に関する調査研究班,p7-8,2005.
 
5) 中島豊,居石克夫:側頭動脈炎(巨細胞性動脈炎),病理編.血管炎アトラス(尾崎承一監,吉木敬編),厚生労働省難治性疾患克服研究事業,難治性血管炎に関する調査研究班,p3-4,2005.
 
6) Matsumoto T,et al:Vasculo-Behcet's disease:A pathological study of eight cases.Hum Pathol 22:45-51,1991.
PubMed
P.165 掲載の参考文献
1) Numano F:The story of Takayasu arteritis.Rheumatology(Oxford) 41:103-106,2002.
PubMed
2) Nasu T:Takayasu's truncoarteritis.Pulseless disease or aortitis syndrome.Acta Pathol Jpn 32(Suppl 1):117,1982.
 
3) Pryshchep O,et al:Vessel-specific toll-like receptor profiles in human medium and large arteries.Circulation 118:1276-1284,2008.
PubMed
4) Grayson PC,et al:Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis.Ann Rheum Dis 71:1329-1334,2012.
PubMed
5) Seko Y,et al:Expression of costimulatory molecules(4-1bbl and Fas)and major histocompatibility class I chain-related a(Mica)in aortic tissue with Takayasu's arteritis.J Vasc Res 41:84-90,2004.
 
6) Bauer S,et al:Activation of NK cells and t cells by nkg2d,a receptor for stress-inducible mica.Sci-ence 285:727-729,1999.
 
7) Arnaud L,et al:Absence of mycobacterium tuberculosis in arterial lesions from patients with Taka-yasu's arteritis.J Rheumatol 36:1682-1685,2009.
 
8) Hotchi M:Pathological studies on Takayasu arteritis.Heart Vessels Suppl 7:11-17,1992.
PubMed
9) Seko Y,et al:Perforin-secreting killer cell infiltration and expression of a 65-kd heat-shock pro-tein in aortic tissue of patients with Takayasu's arteritis.J Clin Invest 93:750-758,1994.
 
10) Matsuyama A,et al:Matrix metalloproteinases as novel disease markers in Takayasu arteritis.Cir-culation 108:1469-1473,2003.
 
11) Hoffman GS,et al:Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.Arthritis Rheum 50:2296-2304,2004.
PubMed
12) Molloy ES,et al:Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis:long-term followup.Ann Rheum Dis 67:1567-1569,2008.
PubMed
13) Nishimoto N,et al:Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.Arthritis Rheum 58:1197-1200,2008.
PubMed
14) Tobon GJ,et al:Are autoantibodies triggering endothelial cell apoptosis really pathogenic? Autoim-mun Rev 8:605-610,2009.
 
15) Nishino Y,et al:Serum levels of Baff for assessing the disease activity of Takayasu arteritis.Clin Exp Rheumatol 28:14-17,2010.
PubMed
16) Hoyer BF,et al:Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.Ann Rheum Dis 71:75-79,2012.
 
P.172 掲載の参考文献
1) 尾崎承一ほか:循環器病の診断と治療に関するガイドライン(2006年-2007年度合同研究班報告).血管炎症候群の診療ガイドライン.Circulation Journal 72(Suppl IV):1253-1318,2008.
 
2) Arend WP,et al:The American College of Rheumatology 1990 criteria for the classification of Taka-yasu arteritis.Arthritis Rheum 33:1129-1134,1990.
 
3) Matsuyama A,et al:Matrix metalloproteinases as novel disease markers in Takayasu arteritis.Cir-culation 108(12):1469-1473,2003.
 
4) Ishihara T,et al:Sensitive assessment of activity of Takayasu's arteritis by pentraxin3,a new biomarker.J Am Coll Cardiol 57(16):1712-1713,2011.
PubMed
5) Ishihara T,et al:Diagnosis and assessment of Takayasu arteritis by multiple biomarkers.Circ J,on line publication 2012.10.26.
 
6) Inoue K,et al:Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.Arterioscler Thromb Vasc Biol 27(1):161-167,2007.
PubMed
7) Latini R,et al:Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.Circulation 110(16):2349-2354,2004.
 
8) Dagna L,et al:Pentraxin-3 as a marker of disease activity in Takayasu arteritis.Ann Intern Med 155(7):425-433,2011.
PubMed
9) Kitamura H,et al:Association of clinical manifestations with HLA-B alleles in Takayasu arteritis.Int J Cardiol 66(Suppl 1):S121-126,1998.
 
10) Takamura C,et al:New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis.Circ J 76(7):1697-1702,2012.
PubMed
11) Ohigashi H,et al:Improved prognosis of Takayasu arteritis over the past decade-comprehensive analysis of 106 patients.Circ J 76(4):1004-1011,2012.
PubMed
12) Andrews J,Mason JC:Takayasu's arteritis-recent advances in imaging offer promise.Rheumatol-ogy 46(1):6-15,2007.
 
13) Tezuka D,et al:Role of FDG PET-CT in Takayasu arteritis:sensitive detection of recurrences.JACC Cardiovasc Imaging 5(4):422-429,2012.
PubMed
P.178 掲載の参考文献
1) 尾崎承一ほか:循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告).血管炎症候群の診療ガイドライン.Circulation Journal 72(Suppl IV):1253-1318,2008.
 
2) Kitamura H,et al:Association of clinical manifestations with HLA-B alleles in Takayasu arteritis.Int J Cardiol 66:S121-S126,1998.
PubMed
3) Maksimowicz-McKinnon K,et al:Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients.Arthritis Rheum 56:1000-1009,2007.
 
4) Shelhamer JH,et al:Takayasu's arteritis and its therapy.Ann Intern Med 103:121-126,1985.
PubMed
5) Hoffman GS,et al:Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate.Arthritis Rheum 37:578-582,1994.
 
6) Valsakumar AK,et al:Role of immunosuppressive therapy on clinical,immunological,and angio-graphic outcome in active Takayasu's arteritis.J Rheumatol 30:1793-1798,2003.
 
7) Fearfield LA,et al:Pyoderma gangrenosum associated with Takayasu's arteritis responding to cyclosporin.Br J Dermatol 141:339-343,1999.
PubMed
8) Shinjo SK,et al:Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis.Clin Rheumatol 26:1871-1875,2007.
PubMed
9) Hoffman GS,et al:Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.Arthritis Rheum 50:2296-2304,2004.
PubMed
10) Molloy ES,et al:Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis:long-term follow-up.Ann Rheum Dis 67:1567-1569,2008.
PubMed
11) Mekinian A,et al:Efficacy and tolerance of infliximab in refractory Takayasu arteritis:French mul-ticentre study.Rheumatology 51:882-886,2012.
 
12) Schmidt J,et al:Tumor necrosis factor inhibitors in patients with Takayasu arteritis:experience from a referral center with long-term follow-up.Arthritis Care Res 64:1079-1083,2012.
 
13) Noris M,et al:Interleukin-6 and RANTES in Takayasu arteritis:aguide for therapeutic decisions? Circulation 100:55-60,1999.
 
14) Nishimoto N,et al:Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.Arthritis Rheum 58:1197-1200,2008.
PubMed
15) Seitz M,et al:Rapid induction of remission in large vessel vasculitis by IL-6 blockade.Swiss Med Wkly 141:w13156,2011.
PubMed
16) Salvarani C,et al:Tocilizumab:a novel therapy for patients with large-vessel vasculitis.Rheumatol-ogy 51:151-156,2012.
 
17) Unizony S,et al:Tocilizumab for the treatment of large vessel vasculitis(giant cell arteritis,Taka-yasu arteritis)and polymyalgia rheumatica:a case series.Arthritis Rheum 63:S589,2011.
 
18) Nakaoka Y,et al:Tocilizumab for the treatment of refractory patients with Takayasu arteritis:A case series.(submitted)
 
19) Miyata T,et al:Long-terms urvival after surgical treatment of patients with Takayasu's arteritis.Circulation 108:1474-1480,2003.
 
20) Ogino H,et al:Overview of late outcome of medical and surgical treatment for Takayasu arteritis.Circulation 118:2738-2747,2008.
PubMed
21) Regina G,et al:Endovascular repair of thoracic stent-graft bulging rupture in a patient with multi-ple thoracic aneurysms due to Takayasu disease.J Vasc Surg 45:391-394,2007.
 
P.182 掲載の参考文献
1) Nordborg E,Nordborg C:Giant cell arteritis:strategies in diagnosis and treatment.Curr Opin Rheumatol 16:25-30,2004.
PubMed
2) Kobayashi S,et al:Clinical and epidemiological analysis of giant cell(temporal)arteritis from a nationwide survey in 1998 in Japan:the first government-supported nationwide survey.Arthritis Rheum 49(4):594-598,2003.
PubMed
3) Dasgupta B,Hassan N:Giant cell arteritis:recent advances and guidelines for management.Clin Exp Rheumatol 25:S62-S65,2007.
PubMed
4) Hayreh SS,et al:Occult giant cell arteritis:ocular manifestations.Am J Ophthalmol 125:521-526,1998.
PubMed
5) Hunder GG,et al:The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.Arthritis Rheum 33:1122-1128,1990.
PubMed
6) Penn H,Dasgupta B:Giant cell arteritis.Autoimmun Rev 2:199-203,2003.
PubMed
7) 小林茂人:III.側頭動脈炎(巨細胞性動脈炎)-Temporal arteritis,(giant cell arteritis,GCA)-.難治性血管炎の診療マニュアル(厚生労働省厚生科学特定疾患対策研究事業 難治性血管炎に関する調査研究班 事務局編),p13-18,2002.
 
8) Mazlumzadeh M,et al:Treatment of giant cell arteritis using induction therapy with high-dose glu-cocorticoids:adouble-blind,placebo-controlled,randomized prospective clinical trial.Arthritis Rheum 54:3310-3318,2006.
 
9) Jover JA,et al:Combined treatment of giant-cell arteritis with methotrexate and prednisone:arandomized,double blind,placebo controlled trial.Ann Intern Med 134:106-114,2001.
 
10) Nesher G,et al:Low-dose aspirin and prevention of cranial ischemic complication in giant cell arteritis.Arthritis Rheum 50:1332-1337,2004.
PubMed
11) Hoffman GS,et al;for the Infliximab-GCA Study Group:Phase II study of the safety and efficacy of infliximab in giant cell arteritis(GCA):22 week interim analysis.Rheumatology(Oxford) 44:18,2005.
 
P.187 掲載の参考文献
1) von Winiwarter F:Uber eine eigenthumliche Form von Endarteritis und Endophlebitis mit Gangran des Fusses.Arch Klin Chir 23:202-226,1879.
 
2) Buerger L:Thrombo-angiitis obliterans:A study of the vascular lesions leading to presenile sponta-neous gangrene,Am J Med Sci 136:567-580,1908.
 
3) Buerger L:The veins in thromboangiitis obliterans.JAMA 52:1319,1909.
 
4) 田中苗太郎:特発脱疽について.日外会誌 5:120-143,1903.
 
5) Papa M,et al:Autoimmune mechanisms in thromboangiitis obliterans(Buerger's disease):the role of tobacco antigen and the major histocompatibility complex.Surgery 111:527-531,1992.
PubMed
6) Aerbajinai W,et al:HLA class II DNA typing in Buerger's disease.Int J Cardiol 54(Suppl):S197-202,1996.
 
7) Avcu F,et al:The role of prothrombotic mutations in patients with Buerger's disease.Thromb Res 100:143-147,2000.
PubMed
8) Glueck CJ,et al:Stromelysin-1 5A/6A and eNOS T-786C polymorphisms,MTHFR C677T and A1298C mutations,and cigarette-cannabis smoking:a pilot,hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease.Clin Appl Thromb Hemost 12:427-439,2006.
 
9) Eichhorn J,et al:Antiendothelial cell antibodies in thromboangiitis obliterans.Am J Med Sci 315:17-23,1998.
PubMed
10) Halacheva KS,et al:Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangi-itis obliterans(Buerger's disease).Scand J Immun 48:544-550,1998.
 
11) Iwai T,et al:Oral bacteria in the occluded arteries of patients with Buerger disease.J Vasc Surg 42:107-115,2005.
PubMed
12) Kurata A,et al:Thromboangiitis obliterans;classic and new morphological features.Virchows Arch 436:59-67,2000.
PubMed
13) Kobayashi M,et al:Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease(endarteritis obliterans).J Vasc Surg 29:451-458,1999.
PubMed
14) 阪口周吉,三島好雄:血管造影所見報告I:Buerger病について.1976年度厚生省特定疾患系統的血管病変に関する調査研究班分科会報告書,p1-38,1977.
 
15) Shionoya S:What is Buerger's disease? World J Surg 7:544-551,1983.
PubMed
P.194 掲載の参考文献
1) Shigematsu H,Shigematsu K:Factors affecting the long-term outcome of Buerger's disease(throm-boangiitis obliterans).Int Angiol 18:58-64,1999.
 
2) JCS Joint Working Group:血管炎症候群の診療ガイドライン(JCS2008).Circ J 72(Suppl IV):1253-1346,2008.
 
3) Ohta T,Shionoya S:Fate of the ischemic limb in Buerger's disease.Br J Surg 75:259-262,1988.
PubMed
4) Iwai T,et al:Oral bacteria in the occluded arteries of patients with Buerger disease.J Vasc Surg 42:107-115,2005.
PubMed
5) Norgren L,et al:Inter-society consensus for the management of peripheral arterial disease(TASC II).J Vasc Surg 45(Suppl):S5A-S67A,2007.
 
6) Castronuovo JJ Jr,et al:Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia.J Vasc Surg 26:629-637,1997.
PubMed
7) Ubbink DT,et al:Prediction of imminent amputation in patients with non-reconstructible leg ische-mia by means of microcirculatory investigations.J Vasc Surg 30:114-121,1999.
 
8) Sasajima T,et al:Role of infrainguinal by pass in Buerger's disease:an eighteen-year experience.Eur J Vasc Endovasc Surg 13:186-192,1997.
 
9) Ohta T,et al:Clinical and social consequences of Buerger disease.J Vasc Surg 39:176-180,2004.
PubMed
10) Graziani L,et al:Clinical outcome after extended endovascular recanalization in Buerger's disease in 20 consecutive cases.Ann Vasc Surg 26:387-395,2012.
PubMed
11) Bozkurt AK,et al:Surgical treatment of Buerger's disease.Vascular 12:192-197,2004.
PubMed
12) Shigematsu H,et al:Transfection of human HGF plasmid DNA improves limb salvage in Buerger's disease patients with critical limb ischemia.Int Angiol 30:140-149,2011.
PubMed
P.199 掲載の参考文献
1) Asahara T,et al:Isolation of putative progenitor endothelial cells for angiogenesis.Science 275:964-967,1997.
PubMed
2) Tateish-Yuyama E,et al:Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells:a pilot study and a randomised controlled trial.Lancet 360:427-435,2002.
 
3) Matoba S,et al:Long-term clinical outcome after intramuscular implantation of bone marrow mono-nuclear cells(Therapeutic Angiogenesis by Cell Transplantation[TACT]trial)in patients with chronic limb ischemia.Am Heart J 156:1010-1018,2008.
 
4) Lachmann N,Nikol S:Therapeutic angiogenesis for peripheral artery disease:stem cell therapy.Vasa 36:241-251,2007.
PubMed
5) Minamino T,et al:Peripheral-blood or bone-marrow mononuclear cells for therapeutic angio-genesis? Lancet 360:2083-2084,2002.
 
6) Tateno K,et al:Critical roles of muscle-secreted angiogenic factors in therapeutic neovasculariza-tion.Circ Res 98:1194-1202,2006.
 
7) Moriya J,et al:Long-term outcome of therapeutic neovascularization using peripheral blood mono-nuclear cells for limb ischemia.Circ Cardiovasc Interv 2:245-254,2009.
 

V ANCA関連血管炎の病因・病理, 診断・治療

P.207 掲載の参考文献
1) Murphy ED,Roths JB:Autoimmunity and lymphoproliferation:Induction by mutant gene lpr,and acceleration by a male-associated factor in strain BXSB mice.In:Genetic Control of Autoimmune Disease(ed by Rose NR,et al),p207-220,Elsevier North Holland,New Ybrk,1978.
 
2) Watanabe-Fukunaga R,et al:Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.Nature 356:314-317,1992.
PubMed
3) Nose M,et al:Analysis of granulomatous arteritis in MRL/Mp autoimmune disease mice bearing lymphoproliferative genes.The use of mouse genetics to dissociate the development of arteritis and glomerulonephritis.Am J Pathol 135:271-280,1989.
PubMed
4) Horai R,et al:Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice.J Exp Med 191:313-320,2000.
PubMed
5) Nicklin MJ,et al:Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene.J Exp Med 191:303-312,2000.
 
6) Nishimura H,et al:Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.Science 291:319-322,2001.
PubMed
7) Nishimura H,et al:Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity 11:141-151,1999.
PubMed
8) Nose M,et al:Arteritis in a novel congenic strain of mice derived from MRL/lpr lupus mice:Genetic dissociation from glomerulonephritis and limited autoantibody production.Am J Pathol 149:1763-1769,1996.
 
9) Qu W-M,et al:Genetic dissection of vasculitis in MRL/lpr lupus mice:a novel susceptibility locus involving the CD72c allele.Eur J Immunol 30:2027-2037,2000.
PubMed
10) Yamada A,et al:Genetic basis of tissue-specificity of vasculitis in MRL/lpr mice.Arthritis Rheum 48:1445-1451,2003.
PubMed
11) Miyazaki T,et al:Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice.Eur J Immunol 35:1510-1520,2005.
PubMed
12) Mather K:Variation and selection of polygenic characters.J Genet 41:159-193,1941.
 
13) Falconer DS:Introduction of Quantitative Genetics,Longman,London,1960.
 
14) Nose M:A polygene network model for the complex pathological phenotypes of collagen disease.Pathol Int 61:619-629,2011.
PubMed
P.213 掲載の参考文献
1) Willcocks LC,et al:The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.Arthritis Res Ther 12:202,2010.
 
2) Fujimoto S,et al:Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associ-ated vasculitis between Japan and the UK.Rheumatology 50:1916-1920,2011.
 
3) Lyons PA,et al:Genetically distinct subsets within ANCA-associated vasculitis.N Engl J Med 367:214-223,2012.
PubMed
4) Heckmann M,et al:The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping.Ann Rheum Dis 67:972-979,2008.
PubMed
5) Stassen PM,et al:HLA-DR4,DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis.Rheumatology 48:622-625,2009.
PubMed
6) Mahr AD,et al:Alpha1-antitrypsin deficiency-related alleles Z and S and the risk of Wegenert's granulomatosis.Arthritis Rheum 62:3760-3767,2010.
PubMed
7) Rarok AA,et al:Neutrophil membrane expression of proteinase 3(PR3) is related to relapse in PR3-ANCA associated vasculitis.J Am Soc Nephrol 13:2232-2238,2002.
PubMed
8) Gencik M,et al:Proteinase 3 gene polymorphisms and Wegener's granulomatosis.Kidney Int 58:2473-2477,2000.
PubMed
9) Knight A,et al:Increased risk of autoimmune disease in families with Wegener's granulomatosis.J Rheumatol 37:2553-2558,2010.
PubMed
10) Martorana D,et al:PTPN22 R620W polymorphism in the ANCA-associated vasculitides.Rheuma-tology 51:805-812,2012.
 
11) Giscombe R,et al:Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis.J Rheumatol 29:950-953,2002.
PubMed
12) Wieczorek S,et al:A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener's granulomatosis.J Mol Med 88:413-421,2010.
 
13) Tsuchiya N,et al:Genetic background of Japanese patients with ANCA-associated vasculitis:Asso-ciation of HLA-DRB1 0901 with microscopic polyangiitis.J Rheumatol 30:1534-1540,2003.
 
14) Tsuchiya N,et al:Association of HLA-DRB1 0901-DQB1 0303 haplotype with microscopic poly-angiitis in Japanese.Genes Immun 7:81-84,2006.
 
15) Luo H,et al:The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associ-ated systemic vasculitis in Chinese patients.Hum Immunol 72:422-425,2011.
 
16) 土屋尚之:ANCA関連血管炎の遺伝因子.リウマチ科 46:421-426,2011.
 
17) Fairfax BP,et al:Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles.Nat Genet 44:502-510,2012.
PubMed
18) Miyashita R,et al:Association of killer cell immunoglobulin-like receptor(KIR) genotypes with microscopic polyangiitis.Arthritis Rheum 54:992-997,2006.
PubMed
19) Mamegano K,et al:Association of LILRA2(ILT1,LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis.Genes Immun 9:214-223,2008.
PubMed
P.222 掲載の参考文献
1) Risch N,Merikangas K:The future of genetic studies of complex human diseases.Science 273:1516-1517,1996.
PubMed
2) Ozaki K,et al:Functional SNPs in the lymphotoXin-alpha gene that are associated with susceptibil-ity to myocardial infarction.Nat Genet 32:650-654,2002.
 
3) Mouse Genome Sequencing Consortium:Initial sequencing and comparative analysis of the mouse genome.Nature 420:520-562,2002.
PubMed
4) Murphy ED,Roths JB:Autoimmunity and lymphproliferation:Induction by mutant gene lpr,and acceleration by a male-associated factor in strain BXSB mice.In:Genetic Control of Autoimmune Disease(ed by Rose NR,et al),p207-220,Elsevier North Holland,New York,1978.
 
5) Nose M:A polygene netWork model for the complex pathological phenotypes of collagen disease.Pathol Int 61:619-629,2011.
PubMed
6) Qu WM,et al:Genetic dissection of vasculitis in MRL/lpr lupus mice:a novel susceptibility locus involving the CD72c allele.Eur J Immunol 30:2027-2037,2000.
PubMed
7) Kinjoh K,et al:Genetic selection for crescent formation yields mouse strain with rapidly progres-sive glomerulonephritis and small vessel vasculitis.Proc Natl Acad Sci USA 90:3413-3417,1993.
 
8) Ishida-okawara A,et al:Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice.Nephrol Dial Transplant 19:1708-1715,2004.
 
9) Pisitkun P,et al:Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication.Science 312:1669-1672,2006.
PubMed
10) Mizutani H,et al:Gastrointestinal vasculitis in autoimmune-prone(NZW×BXSB)F1 mice:associa-tion with anticardiolipin autoantibodies.Proc Soc Exp Biol Med 209:279-285,1995.
 
11) Kono DH,et al:Genetic complementation in female(BXSB×NZW)F2 mice.J Immunol 171:6442-6447,2003.
 
12) Luzina IG,et al:Vasculitis in the Palmerston North mouse model of lupus:phenotype and cytokine production profile of infiltrating cells.Arthritis Rheum 42:561-568,1999.
PubMed
13) Kyogoku M,et al:Pathological studies on the kidney of systemic arteritis.II.Animal model:com-parative studies on the pathogenesis of arteritis and glomerulonephritis of SL/Ni and MRL/1.Nihon Jinzo Gakkai Shi 23:913-920,1981.
 
14) Miyazawa M,et al:Pathogenesis of arteritis of SL/Ni mice.Possible lytic effect of anti-gp70 anti-bodies on vascular smooth muscle cells.J Exp Med 166:890-908,1987.
 
15) Xiao H,et al:Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomeru-lonephritis and vasculitis in mice.J Clin Invest 110:955-963,2002.
 
16) Little MA,et al:Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leu-kocyte-microvascular interactions in vivo.Blood 106:2050-2058,2005.
 
17) Heeringa P,Little MA:In vivo approaches to investigate ANCA-associated vasculitis:lessons and limitations.Arthritis Res Ther 13:204,2011.
PubMed
18) Primo VC,et al:Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis.Clin Exp Immunol 159:327-337,2010.
PubMed
19) Little MA,et al:Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system.PLoS One 7:e28626,2012.
PubMed
20) Zhang Y,et al:Positional cloning of the mouse obese gene and its human homologue.Nature 372:425-432,1994.
PubMed
21) Green ED,et al:The human obese(OB) gene:RNA expression pattern and mapping on the physical,cytogenetic,and genetic maps of chromosome 7.Genome Res 5:5-12,1995.
PubMed
22) Li N,et al:Gain-of-function polymorphism in mouse and human Ltk:implications for the patho-genesis of systemic lupus erythematosus.Hum Mol Genet 13:171-179,2004.
 
23) Suzuki H,et al:Toll-like receptor 9 affects severity of IgA nephropathy.J Am Soc Nephrol 19:2384-2395,2008.
 
24) Morel L,et al:Polygenic control of susceptibility to murine systemic lupus erythematosus.Immu-nity 1:219-229,1994.
 
25) Morel L,et al:Functional dissection of systemic lupus erythematosus using congenic mouse strains.J Immunol 158:6019-6028,1997.
PubMed
26) Morel L,et al:Genetic reconstitution of systemic lupus erythematosus immunopathology with poly-congenic murine strains.Proc Natl Acad Sci USA 97:6670-6675,2000.
 
27) Rahman ZS,et al:Expression of the autoimmune Fcgr2b NZW allele fails to be upregulated in ger-minal center B cells and is associated with increased IgG production.Genes Immun 8:604-612,2007.
 
28) Wandstrat AE,et al:Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus.Immunity 21:769-780,2004.
PubMed
29) Boackle SA,et al:Cr2,a candidate gene in the murine Sle1c lupus susceptibility locus,encodes a dysfUnctional protein.Immunity 15:775-785,2001.
PubMed
30) Lee YH,et al:Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis:a meta-analysis.Lupus 18:727-734,2009.
PubMed
31) Cunninghame Graham DS,et al:Association of LY9 in UK and Canadian SLE families.Genes Im-mun 9:93-102,2008.
 
32) Wu H,et al:Association of a common complement receptor 2 haplotype with increased risk of sys-temic lupus erythematosus.Proc Natl Acad Sci USA 104:3961-3966,2007.
 
33) Hamano Y,et al:Genetic dissection of vasculitis,myeloperoxidase-specific antineutrophil cytoplas-mic autoantibody production,and related traits in spontaneous crescentic glomerulonephritis-forming/Kinjoh mice.J Immunol 176:3662-3673,2006.
 
34) Lyons PA,et al:Genetically distinct subsets within ANCA-associated vasculitis.N Engl J Med 367:214-223,2012.
PubMed
35) Manolio TA,et al:Finding the missing heritability of complex diseases.Nature 461:747-753,2009.
PubMed
P.226 掲載の参考文献
3) Guillevin L,et al:Microscopic polyangiitis:clinical and laboratory findings in eighty-five patients.Arthritis Rheum 42:421-430,1999.
PubMed
8) 陳 科榮:皮膚血管炎の分類と診断.MB Derma 156:1-7,2009.
 
P.242 掲載の参考文献
1) Nagao T,et al:Direct activation of glomerular endothelial cells by anti-moesin activity of anti-myeloperoxidase antibody.Nephrol Dial Transplant 26:2752-2760,2011.
PubMed
2) Ara J,et al:Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA Nephrol Dial Transplant 14:1667-1672,1999.
PubMed
3) Charles LA,et al:Antibodies against granule proteins activate neutrophils in vitro.J Leukoc 50:539-546,1991.
PubMed
4) Gross WL,et al:ANCA and associated disease:immunodiagnostic and pathogenetic aspects.Clin Exp Immunol 91:1-12,1992.
 
5) Kallenberg CG,et al:Antineutrophil cytoplasmic antibodies:current diagnostic and pathophysiologi-cal potential.Kidney Int 46:1-15,1994.
 
6) Goeken JA:Antineutrophil cytoplasmic antibody-A useful serological marker for vasculitis.J Clin Immunol 11:161-174,1991.
PubMed
7) Kettritz R et al:Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies.J Am Soc Nephrol 12(1):37-46,2001.
PubMed
8) De Oliviera J,et al:Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis.Am J Kidney Dis 25:380-389,1995.
PubMed
9) 大川原明子ほか:好中球の機能調節.生体防御医学辞典(鈴木和男監),p164-169,朝倉書店,2007.
 
10) Suzuki K:A model for MPO-ANCA associated vasculitis.J.Jpn Coll Angiol 49:21-29,2009.
 
11) Maini RN:The 2005 international symposium on advances in targeted therapies:what have we learned in the 2000s and where are we going? Ann Rheum Dis 64(Suppl 4):iv106-108,2005.
 
12) Kinjoh K,et al:Genetic selection for crescent formation yields mouse strain with rapidly progres-sive glomerulonephritis and small vessel vasculitis.Proc Natl Acad Sci USA 90:3413-3417,1993.
 
13) Ishida-okawara A,et al:Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice.Nephrol Dial Transplant 19:1708-1715,2004.
 
14) Tago F,et al:Repeated 0.5-Gy gamma irradiation attenuates autoimmune discase in MRL-lpr/lpr mice with suppression of CD3+CD4-CD8-B220+ T-cell proliferation and with up-regulation of CD4+CD25+Foxp3+ regulatory T-cells.Radiat Res 169:59-66,2008.
 
15) Neumann I,et al:SCG/Kinjoh mice:a model of ANCA-associated crescentic glomerulonephritis with immune deposits.Kidney Int 64:140-148,2003.
 
16) Peng SL,et al:Roles of interferon-gamma and interleukin-4 in murine lupus.J Clin Invest 99:1936-1946,1997.
PubMed
17) Xiao H,et al:Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomeru-lonephritis and vasculitis in mice.J Clin Invest 110:955-963,2002.
 
18) Nagao T,et al:Up-regulation of adhesion molecule expression in glomerular endothelial cells by anti-myeloperoxidase antibody.Nephrol Dial Transplant 22:77-87,2007.
PubMed
19) Mori T,et al:Structural basis for CD44 recognition by ERM proteins.J Biol Chem 283:29602-29612,2008.
PubMed
20) Thompson PW,et al:Intercellular adhesion molecule(ICAM)-1,but not ICAM-2,activates RhoA and stimulates c-fos and rhoA transcription in endothelial cells.J Immunol 269:1007-1013,2002.
PubMed
21) Espinoza JL,et al:Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-alpha through an ERK1/2-dependent pathway.Int Immunol 21:913-923,2009.
PubMed
22) Takamatsu H,et al:Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFN-gamma.J Immunol 182:703-710,2009.
 
23) Wagatsuma M,et al:Ezrin,radixin and moesin are possible auto-immune antigens in rheumatoid arthritis.Mol Immunol 33:1171-1176,1996.
PubMed
24) Amar S,et al:Moesin:a potential LPS receptor on human monocytes.J Endotoxin Res 7:281-286,2001.
PubMed
25) Wubbolts R,et al:Proteomic and biochemical analyses of human B cell-derived exosomes.Poten-tial implications for their function and multivesicular body formation.J Biol Chem 278:10963-10972,2003.
 
26) Nozu T,et al:A comparison of the clinical features of ANCA-positive and ANCA-negative idio-pathic pulmonary fibrosis patients.Respiration 77:407-415,2009.
 
27) Kurata A,et al:Systemic granulomatous necrotizing vasculitis in a MPO-ANCA-positive patient.Pathol Int 54:636-640,2004.
 
28) Choi HK,et al:Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis:prevalence among patients with high titers of antimyeloperoxidase antibodies.Arthritis Rheum 43:405-413,2000.
PubMed
29) Suzuki K,et al:A novel anti-neutrophil antibody in serum of patients with MPO-ANCA-associated vasculitis.Nephrol Dial Transplant in revision 2012.
 
30) http://www.a-clip.jp/product_service.html
 
P.248 掲載の参考文献
1) Falk RJ,et al:Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and pro-duce oxygen radicals in vitro.Proc Natl Acad Sci USA 87:4115-4119,1990.
 
2) Xiao H,et al:Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomeru-lonephritis and vasculitis in mice.J Clin Invest 110:955-963,2002.
 
3) Nakazawa D,et al:Abnormal conformation and impaired degradation of NETs induced by propylthi-ouracil:Implication of disordered NETs in MPO-ANCA-associated vasculitis.Arthritis Rheum(in press)
 
4) Brinkmann V,et al:Neutrophil extracellular traps kill bacteria.Science 303:1532-1535,2004.
PubMed
5) Kessenbrock K,et al:Netting neutrophils in autoimmune small-vessel vasculitis.Nat Med 15:623-625,2009.
PubMed
6) Hakkim A,et al:Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.Proc Natl Acad Sci USA 107:9813-9818,2010.
PubMed
7) Wada N,et al:Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies(MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole.Endocr J 49:329-334,2002.
PubMed
8) Waldhauser L Uetrecht J:Oxidation of propylthiouracil to reactive metabolites by activated neutrophils.Implications for agranulocytosis.Drug Metab Dispos 19:354-359,1991.
 
9) Li P,et al:PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps.J Exp Med 207:1853-1862,2010.
PubMed
10) Mark AL,et al:Early mortality in systemic vasculitis:relative contribution of adverse events and active vasculitis.Ann Rheum Dis 69:1036-1043,2010.
 
P.256 掲載の参考文献
1) Xiao H,et al:Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomeru-lonephritis and vasculitis in mice.J Clin Invest 110(7):955-963,2002.
 
2) Amulic B,et al:Neutrophil function:from mechanisms to disease.Annu Rev Immunol 30:459-489,2012.
PubMed
3) Kessenbrock K,et al:Netting neutrophils in autoimmune small-vessel vasculitis.Nat Med 15(6):623-625,2009.
PubMed
4) Hong Y,et al:Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles.J Am Soc Nephrol 23(1):49-62,2012.
PubMed
5) Schreiber A,et al:C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.J Am Soc Nephrol 20(2):289-298,2009.
PubMed
6) Woywodt A,et al:Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis.Lancet 361(9353):206-210,2003.
PubMed
7) Hu N,et al:Dysregulated neutrophil-endothelial interaction in antineutrophil cytoplasmic autoanti-body(ANCA)-associated vasculitides:implications for pathogenesis and disease intervention.Auto-immun Rev 10(9):536-543,2011.
 
8) Brinkmann V,et al:Neutrophil extracellular traps kill bacteria.Science 303(5663):1532-1535,2004.
PubMed
9) Steinberg BE,Grinstein S:Unconventional roles of the NADPH oxidase:signaling,ion homeostasis,and cell death.Sci STKE 2007(379):pe11,2007.
PubMed
10) Fuchs TA,et al:Novel cell death program leads to neutrophil extracellular traps.J Cell Biol 176(2):231-241,2007.
PubMed
11) Remijsen Q,et al:Neutrophil extracellular trap cell death requires both autophagy and superoxide generation.Cell Res 21(2):290-304,2011.
PubMed
12) Yousefi S,et al:Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacte-rial defense.Nat Med 14(9):949-953,2008.
 
13) von Kockritz-Blickwede M,et al:Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation.Blood 111(6):3070-3080,2008.
PubMed
14) Yousefi S,et al:Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps.Cell Death Differ 16(11):1438-1444,2009.
PubMed
15) Remijsen Q,et al:Dying for a cause:NETosis,mechanisms behind an antimicrobial cell death modality.Cell Death Differ 18(4):581-588,2011.
PubMed
16) Marcos V,et al:CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap forma-tion in cystic fibrosis airway inflammation.Nat Med 16(9):1018-1023,2010.
 
17) Li P,et al:PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps.J Exp Med 207(9):1853-1862,2010.
PubMed
18) Papayannopoulos V,et al:Neutrophil elastase and myeloperoxidase regulate the formation of neutro-phil extracellular traps.J Cell Biol 191(3):677-691,2010.
 
19) Beiter K,et al:An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extra-cellular traps.Curr Biol 16(4):401-407,2006.
 
20) Buchanan JT,et al:DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps.Curr Biol 16(4):396-400,2006.
PubMed
21) Clark SR,et al:Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood.Nat Med 13(4):463-469,2007.
PubMed
22) Nakazawa D,et al:Arthritis Rheum,2012.(in press)
 
23) Yasutomo K,et al:Mutation of DNASE1 in people with systemic lupus erythematosus.Nat Genet 28(4):313-314,2001.
PubMed
24) Hakkim A,et al:Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.Proc Natl Acad Sci USA 107(21):9813-9818,2010.
PubMed
25) Tomasson G,et al:Thromboembolic disease in vasculitis.Curr Opin Rheumatol 21(1):41-46,2009.
PubMed
26) Merkel PA,et al:Brief communication:high incidence of venous thrombotic events among patients with Wegener granulomatosis:the Wegener's Clinical Occurrence of Thrombosis(WeCLOT)Study.Ann Intern Med 142(8):620-626,2005.
 
27) Stassen PM,et al:Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors.Rheumatology(Oxford) 47(4):530-534,2008.
PubMed
28) Weidner S,et al:Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum 55(1):146-149,2006.
PubMed
29) Fuchs TA,et al:Extracellular DNA traps promote thrombosis.Proc Natl Acad Sci USA 107(36):15880-15885,2010.
PubMed
30) Lande R,et al:Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in sysstemic lupus erythematosus.Sci Transl Med 3(73):73ra19,2011.
PubMed
31) Zwaal RF,Schroit AJ:Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.Blood 89(4):1121-113,1997.
PubMed
32) Piccin A,et al:Circulating microparticles:pathophysiology and clinical implications.Blood Rev 21(3):157-171,2007.
PubMed
33) Brogan PA,et al:Endothelial and platelet microparticles in vasculitis of the young.Arthritis Rheum 50(3):927-936,2004.
 
34) Daniel L,et al:Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis.Kidney Int 69(8):1416-1423,2006.
PubMed
35) Erdbruegger U,et al:Diagnostic role of endothelial microparticles in vasculitis.Rheumatology(Oxford) 47(12):1820-1825,2008.
PubMed
36) Berden AE,et al:Histopathologic classification of ANCA-associated glomerulonephritis.J Am Soc Nephrol 21(10):1628-1636,2010.
PubMed
37) Xiao H,et al:Alternative complement pathway in the pathogenesis of disease mediated by anti-neu-trophil cytoplasmic autoantibodies.Am J Pathol 170(1):52-64,2007.
 
38) Huugen D,et al:Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bac-terial lipopolysaccharide:role of tumor necrosis factor-alpha.Am J Pathol 167(1):47-58,2005.
 
39) Xing GQ,et al:Complement activation is involved in renal damage in human antineutrophil cytoplas-mic autoantibody associated pauci-immune vasculitis.J Clin Immunol 29(3):282-291,2009.
 
P.261 掲載の参考文献
1) Klebanoff SJ:Myeloperoxidase:friend and foe.J Leukoc Biol 77:598-625,2005.
 
2) Nunoi H,et al:Prevalence of inherited myeloperoxidase deficiency in Japan.Microbiol Immunol 47:527-531,2003.
PubMed
3) Persad AS,et al:Arginine to cysteine mtltation(R499C) found in a Japanese patient with complete myeloperoxidase deficiency.Gene Expr 13:67-71,2006.
 
4) Nagao T,et al:Direct activation of glomerular endothelial cells by anti-moesin activity of anti-myeloperoxidase antibody.Nephrol Dial Transplant 26:2752-2760,2011.
PubMed
5) Ishida-Okawara A,et al:Contribution of myeloperoxidase to coronary artery vasculitis associated with MPO-ANCA production.Inflammation 25:381-387,2001.
PubMed
6) Brennan ML,et al:Increased atherosclerosis in myeloperoxidase-deficient mice.J Clin Invest 107:419-430,2001.
PubMed
7) Aratani Y,et al:Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase.Infect Immun 67:1828-1836,1999.
PubMed
8) Aratani Y,et al:Contribution of the myeloperoxidase-dependent oxidative system to host defense against Cryptococcus neoformans.J Med Microbiol 55:1291-1299,2006.
PubMed
9) Aratani Y,et al:Differential host susceptibility to pulmonary infection with bacteria and fungi in mice deficient in myeloperoxidase.J Infect Dis 182:1276-1279,2000.
PubMed
10) Yamamoto K,et al:Virucidal activity and viral protein modification by myeloperoxidase:a candidate for defense factor of human polymorphontlclear leukocytes against influenza virus infection.J Infect Dis 164:8-14,1991.
PubMed
11) Sugamata R,et al:Contribution of netltrophil-derived myeloperoxidase in the early phase of fulmi-nant acute respiratory distress syndrome induced by influenza virus infection.Microbiol Immunol 56:171-182,2012.
 
12) Takeuchi K,et al:Severe neutrophil-mediated lung inflammation in myeloperoxidase-deficient mice exposed to zymosan.Inflamm Res 61:197-205,2012.
PubMed
13) Haegens A,et al:Myeloperoxidase deficiency attenuates lipopolysaccharide-induced acute lung inflammation and subsequent cytokine and chemokine production.J Immunol 182:7990-7996,2009.
PubMed
14) Haegens A,et al:Asbestos-induced lung inflammation and epithelial cell proliferation are altered in myeloperoxidase-null mice.Cancer Res 65:9670-9677,2005.
PubMed
15) Komatsu J,et al:Earlier onset of neutrophil-mediated inflammation in the ultraviolet-exposed skin of mice deficient in myeloperoxidase and NADPH oxidase.Inflamm Res 55:200-206,2006.
PubMed
P.268 掲載の参考文献
1) Bosch X,et al:Antineutrophil cytoplasmic antibodies.Lancet 368:404-418,2006.
PubMed
2) Yoshida M,et al:Two types of myeloperoxidase antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis.Clin Exp Rheumatol 27(Suppl 52):S28-32,2009.
 
3) 吉田雅治,長澤俊彦:Wegener肉芽腫症に対する抗好中球細胞質抗体の意義.医学のあゆみ 145:649-650,1988.
 
4) 吉田雅治:抗好中球細胞質抗体と病態の関連はあるか.分子リウマチ治療 3:16-20,2010.
 
5) 吉田雅治:抗好中球細胞質抗体.臨床検査ガイド2011～2012,p682-685,文光堂,2011.
 
6) Kallenberg CGM:Antineutrophil cytoplasmic autoantibody associated small vessel vasculitis.Curr Opin Rheumatol 19:17-24,2007.
 
7) 吉田雅治:ANCAと腎障害.Mebio 20:21-27,2003.
 
8) 吉田雅治:ANCA関連血管炎,総論.リウマチ病学テキスト,p274-276,診断と治療社,2010.
 
9) 吉出雅治:血管炎に伴う腎症.腎疾患・透析 最新の治療2011-2013,p200-205,南江堂,2011.
 
10) 尾崎承一ほか:厚生労働省難治性疾患克服研究事業ANCA関連血管炎の診療ガイドライン,p1-94,2011.
 
11) 吉田雅治:ANCA関連腎炎の診断と治療.日本医事新報 4597:73-79,2012.
Medical*Online
12) Lin W,et al:Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis.Autoimmunity 42:198-202,2009.
PubMed
P.276 掲載の参考文献
1) 猪原登志子:抗好中球細胞質抗体(ANCA)測定の臨床的意義と留意点up-to-date.リウマチ科 47:635-643,2012.
 
2) Suzuki K,et al:Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population.Microbiol Immunol 51:1215-1220,2007.
PubMed
3) Csernok E,et al:Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis:first results from a multicentre study.Rheumatology(Oxford) 43:174-180,2004.
PubMed
4) Ito-lhara T,et al:A comparative study of the diagnostic accuracy of ELISA systems for the detec-tion of anti-neutrophil cytoplasm antibodies available in Japan and Europe.Clin Exp Rheumatol 26:1027-1033,2008.
 
5) Damoiseaux J,et al:A novel enzyme-linked immunosorbent assay using a miXture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cyto-plasmic antibody-associated vasculitis.Ann Rheum Dis 68:228-233,2009.
 
6) 白井剛志ほか:リコンビナント抗原を使用したELISA法によるANCA測定キット(コスミック社)の基礎的・臨床的検討.医学と薬学 65:517-523,2011.
Medical*Online
7) 松下雅和ほか:新しいANCA測定試薬ステイシアMEBLuxテストMPO-ANCAおよびPR3-ANCAの基礎性能および臨床的有用性の検討.医学と薬学 66:823-838,2011.
Medical*Online
8) 永渕裕子ほか:全自動臨床検査システムSTACIAによるANCA測定の臨床的有用性 ANCA関連血管炎の迅速検査対応への可能性.医学と薬学 67:767-776,2012.
 
9) 平田寛之ほか:自己抗体測定試薬エリア「MPOs-ANCA」「PR3s-ANCA」および「GBM」と従来法との比較検討.医学と薬学 66:1099-1108,2011.
Medical*Online
10) 糸島浩一ほか:エリアMPOs-ANCA・PR3s-ANCA測定試薬による抗好中球細胞質抗体の基礎的・臨床的検討.医学と薬学 67:477-484,2012.
Medical*Online
11) 松下雅和ほか:エリアMPOs-ANCA・PR3s-ANCA測定試薬による抗好中球細胞質抗体の臨床的有用性.医学と薬学 68:357-363,2012.
Medical*Online
12) Holle JU,et al:Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies:what is the optimal cut off? Ann Rheum Dis 64:1773-1779,2005.
PubMed
13) Trevisin M,et al:Antigen-specific ANCA ELISAs have different sensitivities for active and treated vasculitis and for nonvasculitic disease.Am J Clin Pathol 129:42-53,2008.
PubMed
14) Mukhtyar C,et al;European Vasculitis Study Group:EULAR recommendations for the manage-ment of primary small and medium vessel vasculitis.Ann Rheum Dis 68:310-317,2009.
 
15) 厚生労働省科学研究費補助金難治性疾患克服研究事業(ANCA関連血管炎のわが国における治療法の確立のための多施設共同前向き臨床研究班,難治性血管炎に関する調査研究班,進行性腎障害に関する調査研究班):ANCA関連血管炎の診療ガイドライン,2011.[http://minds4.jcqhc.or.jp/minds/ANCA/anca.pdf]
 
P.286 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37(2):187-192,1994.
PubMed
2) 橋本博史:ANCA関連血管炎の治療指針.難治性血管炎の診療マニュアル(厚生労働省厚生科学特定疾患対策研究事業難治性血管炎に対する調査研究班編),p50,2002.
 
3) Watts R,et al:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.Ann Rheum Dis 66(2):222-227,2007.
PubMed
4) 松尾清一ほか:急速進行性腎炎症候群の診療指針,第2版.日腎会誌 53:509-555,2011.
 
5) de Groot K,et al;EUVAS(European Vasculitis Study Group):Pulse versus daily oral cyclophospha-mide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis:a ran-domized trial.Ann Intern Med 150(10):670-680,2009.
 
6) Ito-Ihara T,et al:Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.Nephron Clin Pract 102(1):c35-42,2006.
PubMed
7) Jayne DR,et al;European Vasculitis Study Group:Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.J Am Soc Nephrol 18(7):2180-2188,2007.
PubMed
8) Sangle SR,et al:Infliximab in patients with systemic vasculitis that is diffilcult to treat:poor outcome and significant adverse effects.Ann Rheum Dis 66(4):564-565,2007.
PubMed
9) Hirayama K,et al:Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis.Am J Kidney Dis 44(1):57-63,2004.
PubMed
10) 有村義宏ほか:ANCA関連血管炎-顕微鏡的多発血管炎の臨床像・予後の変遷およびMPO-ANCA関連血管炎におけるミゾリビン治療についての検討.臨床リウマチ 17:290-298,2005.
 
11) Hiemstra T,et al:Randomized trial of mycophenolate mofetil vs azathioprine for maintenance ther-apy in ANCA associated vasculitis(IMPROVE).APMIS 117(Suppl):77,2009.
 
12) Han WK,et al:Serial ANCA titers:useful tool for prevention of relapses in ANCA-associated vasculitis.Kidney Int 63:1079-1085,2003.
PubMed
13) 有村義宏ほか:ANCA関連腎炎とRPGN.日腎会誌 51:88-93,2009.
 
14) 吉原堅,有村義宏:ANCAの力価と病態.腎と透析 68:95-99,2010.
Medical*Online
P.294 掲載の参考文献
1) Fauci AS,et al:Wegener's granulomatosis:prospective clinical and therapeutic experience with 85 patients for 21 years.Ann Intern Med 98:76-85,1983.
PubMed
2) 石田芳也ほか:ウェゲナー肉芽腫症16例の臨床的検討.耳鼻咽喉科臨床 97:997-1005,2004.
 
3) 吉田雅治:ウェゲナー肉芽腫症.難治性血管炎の診療マニュアル,難治性血管炎に関する調査研究班,p30-34,キタ・メディア,2002.
 
4) van der Wbude FJ,et al:Autoantibodies against neutrophils and monocytes:tool for diagnosis and marker of disease activity in Wegener's granulomatosis.Lancet 23:425-429,1985.
 
5) Kallenberg CG,et al:Mechanisms of Disease:pathogenesis and treatment of ANCA-associated vasculitides.Nat Clin Pract Rheumatol 2:661-670,2006.
PubMed
6) 岸部幹ほか:耳鼻咽喉・頭頸部画像アトラス 鼻副鼻腔Wegener肉芽腫症.JOHNS 26:388-390,2010.
 
7) Harabuchi Y,et al:Nasal natural killer(NK)/T-cell lymphoma:clinical,histological,virological,and genetic features.Int J Clin Oncol 14:181-190,2009.
PubMed
8) 荻野武,原渕保明:好酸球性中耳炎update 好酸球性中耳炎の類似疾患 ウェゲナー肉芽腫症.MB ENT 73:25-30,2007.
 
9) 原渕保明,岸部幹:中耳炎New Trends 慢性中耳炎をめぐって 成人難治性中耳炎の鑑別診断.JOHNS 24:76-81,2008.
 
10) Jayne D,et al:A randomized trial of maintenance therapy for vasculitis associated with antineutro-phil cytoplasmic autoantibodies.N Engl J Med 349:36-44,2003.
 
11) De Groot K,et al:Randomized trial of cyclophosphamide versus methotrexate for induction of remis-sion in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum 52:2461-2469,2005.
 
12) Pendergraft WF,et al:Autoimmunity is triggered by cPR-3(105-201),a protein complementary to human autoantigen proteinase-3.Nat Med 10:72-79,2004.
PubMed
13) Stegeman CA,et al:Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.Ann Intern Med 120:12-17,1994.
PubMed
P.302 掲載の参考文献
1) 厚生労働省難治疾患克服研究事業 ANCA関連血管炎の診療ガイドライン(尾崎承一ほか編),2011(非売品MindsのHPから参照可能).
 
2) Pagnoux C,et al:Churg-Strauss syndrome.Curr Opin Rheumatol 19(1):25-32,2007.
 
3) Guillevin L,et al:Churg-Strauss syndrome.Semin Respir Crit Care Med 25(5):535-545,2004.
PubMed
4) Pagnoux C:Churg-Strauss syndrome:evolving concepts.Discov Med 9(46):243-252,2010.
PubMed
5) Weller PF,et al:The relationship of asthma therapy and Churg-Strauss syndrome:NIH workshop summary report.J Allergy Clin Immunol 108(2):175-183,2001.
PubMed
6) Le Gall C,et al:Inhaled corticosteroids and Churg-Strauss syndrome:areport of five cases.Eur Respir J 15(5):978-981,2000.
 
7) Hauser T,et al:The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syn-drome:a case-crossover study.Thorax 63(8):677-682,2008.
 
8) 谷口正実:Churg-Strauss Syndrome(アレルギー性肉芽腫性血管炎).気管支喘息のすべて(大田健,一ノ瀬正和編),p358-363,文光堂,2007.
 
9) Sable-Fourtassou R,et al;French Vasculitis Study Group:Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome.Ann Intern Med 143(9):632-638,2005.
 
10) Sinico RA,et al:Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.Arthritis Rheum 52(9):2926-2935,2005.
PubMed
11) D'Cruz DP,et al:Difficult asthma or Churg-Strauss syndrome? BMJ 318(7182):475-476,1999.
PubMed
12) Hayakawa H,et al:Clinical features and prognosis of Churg-Strauss syndrome.Nihon Kyobu Shik-kan Gakkai Zasshi 31(1):59-64,1993.(in Japanese)
 
13) Bottero P,et al:The common allergens in the Churg-Strauss syndrome.Allergy 62(11):1288-1294,2007.
PubMed
14) Tsurikisawa N,et al:Aretrospective study of bronchial hyperresponsiveness in patients with asthma before the onset of Churg-Strauss syndrome.Allergy Asthma Proc 28(3):336-343,2007.
 
15) Cottin V,et al:Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up.Allergy 64(4):589-595,2009.
PubMed
16) Meziane H,et al:Sputum eosinophilia in Churg-Strauss syndrome.Respir Med 95(10):799-801,2001.
PubMed
17) Bacciu A,et al:Ear,nose and throat manifestations of Churg-Strauss syndrome.Acta Otolaryngol 126(5):503-509,2006.
PubMed
18) Pagnoux C,Wolter NE:Vasculitis of the upper airways.Swiss Med Wkly 142:w13541,2012.
PubMed
19) 谷口正実,秋山一男:Churg-Strauss症候群.アレルギーリウマチ膠原病診療 最新ガイドライン(足立満,笠間毅編),p58-64,総合医学社,2012.
 
20) 谷口正実:Churg-Strauss症候群.呼吸と循環 60(2):137-143,2012.
 
21) Szczeklik W,et al:Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission.Circ J 75(3):649-655,2011.
PubMed
22) Szczeklik W,et al:Pulmonary findings in CSS in chest X-ray and HRCT at the time of diagnosis.Clin Rheumatol 29:1127-1134,2010.
PubMed
23) Guillevin L,et al:Churg-Strauss syndrome.Clinical study and long-term follow-up of 96 patients.Medicine(Baltimore) 78:26-37,1999.
PubMed
24) Gayraud M,et al;French Vasculitis Study Group:Long-term followup of polyarteritis nodosa,microscopic polyangiitis,and Churg-Strauss syndrome:analysis of four prospective trials including 278 patients.Arthritis Rheum 44(3):666-675,2001.
 
25) Guillevin L,et al:The Five-Factor Score revised:assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group(FVSG) cohort.Medicine(Baltimore) 90:19-27,2011.
 
26) Bosch X,et al:Treatment of antineutrophil cytoplasmic antibody associated vasculitis:a systematic review.JAMA 298(6):655-669,2007.
PubMed
27) Guillevin L,et al:Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome.A pro-spective study in 342 patients.Medicine(Baltimore) 75:17-28,1996.
 
28) Cohen P,et al;French Vasculitis Study Group:Churg-Strauss syndrome with poor-prognosis fac-tors:A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.Arthritis Rheum 57(4):686-693,2007.
PubMed
29) Mohammad AJ,et al:The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index(VDI).Scand J Rheumatol 38(4):268-275,2009.
PubMed
30) 谷口正実:専門医のためのアレルギー学講座 アレルギー・免疫疾患の新規治療薬と治療法 Churg-Strauss Syndrome(アレルギー性肉芽腫性血管炎)の最近の治療 免疫グロブリン大量療法を含めて.アレルギー 59(8):923-930,2010.
 
31) Ozaki S:ANCA-associated vasculitis:diagnostic and therapeutic strategy.Allergol Int 56(2):87-96,2007.
PubMed
32) Guillevin L,Pagnoux C:Therapeutic strategies for systemic necrotizing vasculitides.Allergol Int 56(2):105-111,2007.
PubMed
33) Espinoza LR:Combination therapy to treat churg-strauss syndrome:corticosteroids with short-or long-term cyclophosphamide pulses.Curr Rheumatol Rep 10(6):427-429,2008.
PubMed
34) Tsurikisawa N,et al:Treatment of Churg-Strauss syndrome with high-dose intravenous immuno-globulin.Ann Allergy Asthma Immunol 92(1):80-87,2004.
 
35) Taniguchi M,et al:Treatment for Churg-Strauss syndrome:induction of remission and efficacy of intravenous immunoglobulin therapy.Allergol Int 56(2):97-103,2007.
PubMed
36) Danieli MG,et al:Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.Ann Rheum Dis 63(12):1649-1654,2004.
PubMed
37) Kim S,et al:Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.J Allergy Clin Immunol 125(6):1336-1343,2010.
PubMed
38) Wechsler ME,et al:Churg-strauss syndrome in patients treated with omalizumab.Chest 136(2):507-518,2009.
PubMed
39) Pabst S,et al:Apparent response to anti-IgE therapy in two patients with refractory"forme fruste"of Churg-Strauss syndrome.Thorax 63(8):747-748,2008.
PubMed
40) Saech J,et al:Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement.Ann Rheum Dis 69(6):1254-1255,2010.
 
P.308 掲載の参考文献
1) Fujimoto S,et al:Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associ-ated vasculitis between Japan and the UK.Rheumatology 50:1916-1920,2011.
 
2) Sugiyama K,et al:Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan.Clin Exp Nephrol,2012.[Epub ahead of print]
 
3) Lane SE,et al:Primary systemic vasculitis:clinical features and mortality.Q J Med 98:97-111,2005.
 
4) Guillevin L,et al:The Five-Factor Score revisited:assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group(FVSG)cohort.Medicine(Baltimore) 90:19-27,2011.
 
5) Dennert RM,et al:Cardiac involvement in Churg-Strauss syndrome.Arthritis Rheum 62:627-634,2010.
PubMed
6) Sinico RA,et al:Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.Arthritis Rheum 52:2926-2935,2005.
PubMed
7) Shimoi T,et al:Clinical and pathological features of Churg Strauss syndrome among a Japanese population:a case series of 18 patients.Asian Pac J Allergy Immunol 30:61-70,2012.
PubMed
P.314 掲載の参考文献
1) 樋口豊ほか:副鼻腔炎を認めたChurg-Strauss症候群の2症例.日鼻科会誌 42:333-338,2003.
 
2) 松島明美ほか:難治性好酸球中耳炎の治療中に発症したChurg-Strauss症候群の1例.耳鼻咽喉科展望 50:164-169,2007.
 
3) 富谷義徳ほか:難聴および耳漏を初発症状とした顕微鏡的多発血管炎の1症例.耳鼻咽喉科展望 50:24-29,2007.
 
4) 峯田穣治ほか:顕微鏡的多発血管炎に伴った変動する感音難聴例.耳鼻咽喉科臨床 98:691-697,2005.
 
5) 片田彰博ほか:肥厚性硬膜炎を合併したウェゲナー肉芽腫症例.耳鼻咽喉科臨床 95:1101-1106,2002.
 
P.320 掲載の参考文献
1) 吉田雅治:オーバービュー:肺血管炎の分類と将来展望.呼吸器科 14:261-268,2008.
 
2) 有村義宏ほか:ミエロペルオキシダーゼに対する抗好中球細胞質抗体陽性症例における肺病変の検討.リウマチ 35:46-55,1995.
 
3) 厚生労働省 難治性疾患克服研究事業:ANCA関連血管炎の診療ガイドライン,2011.
 
4) Ozaki S,et al:Severity-based treatment for Japanese patients with MPO-ANCA-associated vascu-litis:the JMAAV study.Mod Rheumatol 22:394-404,2012.
 
5) 蛇澤晶ほか:MPO-ANCA陽性症例における慢性間質性肺炎の病理.日本胸部臨床 3:210-219,2008.
 
6) Homma S,et al:Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associ-ated vasculitides.Respirology 9:190-196,2004.
 
7) Cottin V,et al:Combined pulmonary fibrosis and emphysema:a distinct underrecognised entity.Eur Respir J 26:586-593,2005.
PubMed
8) Cottin V,et al:Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease.Arthritis Rheum 63:295-304,2011.
PubMed
9) Takahashi K,et al:Development of microscopic polyangiitis in patients with chronic airway disease.Lung 183:273-281,2005.
PubMed
10) Matsuyama W,et al:Bronchiectasis with myeloperoxidase antineutrophil cytoplasmic antibody and bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibody.Intern Med 38:813-816,1999.
PubMed
11) Ananthakrishnan L,et al:Wegener's granulomatosis in the chest:high-resolution CT findings.AJR Am J Roentgenol 192:676-682,2009.
PubMed
12) Churg MP,et al:Imaging of pulmonary vasculitis.Radiology 255:322-341,2010.
 
13) 橋本憲一ほか:Wegener肉芽腫症の気管気管支病変.日胸疾会誌 22:32-38,1984.
 
14) Gomez-Puerta JA,et al:Antineutrophil cytoplasmic antibody-associated vasculitides and respira-tory disease.Chest 136:1101-1111,2009.
 
15) Stephen K,et al:Update in diagnosis and management of pulmonary vasculitis.Chest 129:452-465,2006.
 
P.330 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37(2):187-192,1994.
PubMed
2) Yamagata K,et al:ANCA-associated systemic vasculitis in Japan:clinical features and prognostic changes.Clin Exp Nephrol 16(4):580-588,2012.
PubMed
3) Bajema IM,et al:The renal histopathology in systemic vasculitis:an international survey study of inter-and intra-observer agreement.Nephrol Dial Transplant 11(10):1989-1995,1996.
PubMed
4) Joh K,et al:Renal pathology of ANCA-related vasculitis:Proposal for standardization of pathologi-cal diagnosis in Japan.Clin Exp Nephrol 12:277-291,2008.
 
5) Koyama A,et al;Japan RPGN Registry Group:A nationwide survey of rapidly progressive glomeru-lonephritis in Japan:etiology,prognosis and treatment diversity.Clin Exp Nephrol 13(6):633-650,2009.
 
6) Yamagata K,et al:ANCA-associated systemic vasculitis in Japan:clinical features and prognostic changes.Clin Exp Nephrol 16:580-588,2012.
PubMed
7) Annelies E,et al:Histopathologic classification of ANCA-associated glomerulonephritis.J Am Soc Nephrol 21:1628-1636,2010.
 
8) Chang DY,et al:Re-evaluation of the histopathologic classification of ANCA-associated glomeru-lonephritis:a study of 121 patients in a single center.Nephrol Dial Transplant 27(6):2343-2349,2012.
 
P.336 掲載の参考文献
1) Jennette JC,Falk RJ:Small-vessel vasculitis.N Engl J Med 337:1512-1523,1997.
PubMed
2) Guillevin L,et al:Churg Strauss syndrome:clinical study and long-term follow-up of 96 patients.Medicine(Baltimore) 78:26-37,1999.
PubMed
4) Duna GF,et al:Wegener's granulomatosis.Rheum Dis Clin North Am 21:949-986,1995.
PubMed
5) Chen KR,Carlson JA:Clinical approach to cutaneous vasculitis.Am J Clin Dermatol 9:71-92,2008.
PubMed
6) Falk RJ,et al:Granulomatosis with polyangiitis(Wegener's):An alternative name for Wegener's granulomatosis.J Am Soc Nephrol 22:587-588,2011.
 
7) Chen KR,et al:Granulomatous arteritis in cutaneous lesions of Churg-Strauss syndrome.J Cutan Pathol 34:330-337,2007.
PubMed
9) Sinico RA,et al:Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.Arthritis Rheum 52(9):2926-2935,2005.
PubMed
10) Dennert RM,et al:Cardiac involvement in Churg-Strauss syndrome.Arthritis Rheum 62:627-634,2010.
PubMed
11) Grau RG:Churg-Strauss syndrome:2005-2008 update.Curr Rheumatol Rep 10:453-458,2008.
PubMed
12) 氏原真弓ほか:抗甲状腺薬によるANCA関連血管炎:プロピルチオウラシル(PTU)による1例および既報44例の検討.日皮会誌 112:1229-1240,2002.
 
13) 坂井博之ほか:塩酸ミノサイクリンによる薬剤性血管炎の2例.アレルギー 51:1153-1158,2002.
Medical*Online
P.340 掲載の参考文献
1) Guillevin L,et al:Microscopic polyangiitis:clinical and laboratory findings in eighty-five patients.Arthritis Rheum 42:421-430,1999.
PubMed
2) Guillevin L,et al:Churg-Strauss syndrome.Clinical study and long-term follow-up of 96 patients.Medicine(Baltimore) 78:26-37,1999.
PubMed
3) Hoffman GS,et al:Wegener granulomatosis:an analysis of 158 patients.Ann Intern Med 116:488-498,1992.
PubMed
4) Finsterer J:Neurological manifestations of Churg-Strauss syndrome.Eur J Neurol 17:524-525,2010.
PubMed
5) Mattioli F,et al:Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides.J Neurol Sci 195:161-166,2002.
PubMed
6) Murphy JM,et al:Wegener granulomatosis:MR imaging findings in brain and meninges.Radiol-ogy 213:794-799,1999.
 
7) Sugiura M,et al:Clinicopathologic features of nonsystemic vasculitic neuropathy and microscopic polyangiitis-associated neuropathy:a comparative study.J Neurol Sci 241:31-37,2006.
PubMed
8) Collins MP,et al:Peripheral Nerve Society Guideline on the classification,diagnosis,investigation,and immunosupPressive therapy of non-systemic vasculitic neuropathy:executive summary.J Peripher Nerv Syst 15:176-184,2010.
 
9) Koike H,et al:Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy.Ann Neurol 54:19-29,2003.
 
10) 祖父江元ほか:結節性多発動脈炎に伴う末梢神経病変の分布とその意義.臨床神経 30:388-395,1990.
 
11) 小池春樹,祖父江元:膠原病における神経病理 末梢神経.日内会誌 99:1853-1857,2010.
 
12) Hattori N,et al:Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syn-drome and microscopic polyangiitis.J Rheumatol 29:1408-1414,2002.
 
13) Hattori N,et al:Clinicopathological features of Churg-Strauss syndrome-associated neuropathy.Brain 122:427-439,1999.
PubMed
14) Morozumi S,et al:Spatial distribution of nerve fiber pathology and vasculitis in microscopic polyangi-itis-associated neuropathy.J Neuropathol Exp Neurol 70:340-348,2011.
 
15) 祖父江元ほか:壊死性血管炎に伴う末梢神経障害の臨床病理学的特徴 結節性動脈周囲炎2剖検例の検討から.臨床神経 29:209-215,1989.
 
P.344 掲載の参考文献
1) Hoffman GS,Specks U:Antineutrophil cytoplasmic antibodies.Arthritis Rheum 41:1521-1537,1998.
PubMed
2) Hunder GG,et al:The American College of Rheumatology 1990 criteria for the classification of vasculitis.Introduction.Arthritis Rheum 33:1065-1067,1990.
PubMed
3) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
4) Jennette JC:Nomenclature and classification of vasculitis:lessons learned from granulomatosis with polyangiitis(Wegener's granulomatosis).Clin Exp Immunol 164(Suppl 1):7-10,2011.
 
5) Seo P,Stone JH:The antineutrophil cytoplasmic antibody-associated vasculitides.Am J Med 117:39-50,2004.
PubMed
6) Tarabishy AB,et al:Wegener's granulomatosis:clinical manifestations,differential diagnosis,and management of ocular and systemic disease.Surv Ophthalmol 55:429-444,2010.
PubMed
7) Soukiasian SH,et al:Diagnostic value of anti-neutrophil cytoplasmic antibodies in scleritis associ-ated with Wegener's granulomatosis.Ophthalmology 99:125-132,1992.
 
8) Rao JK,et al:The role of antineutrophil cytoplasmic antibody(c-ANCA) testing in the diagnosis of Wegener granulomatosis.A literature review and meta-analysis.Ann Intern Med 123:925-932,1995.
PubMed
9) Pulido JS,et al:Ocular manifestations of patients with circulating antineutrophil cytoplasmic antibodies.Arch Ophthalmol 108:845-850,1990.
PubMed
10) Caster JC,et al:Microscopic polyangiitis with ocular involvement.Arch Ophthalmol 114:346-348,1996.
PubMed
11) Matsuo T,Matsuo N:Progressive subretinal fibrosis in patients with rheumatoid arthritis and renal dysfunction.Ophthalmologica 212:289-294,1998.
PubMed
12) Darlington JK,et al:Peripheral nonulcerative keratitis as a presenting sign of microscopic polyangiitis.Cornea 20:522-524,2001.
PubMed
13) Matsuo T,etal:Acute posterior multifocal placoid pigment epitheliopathy and scleritis in a patient with pANCA-positive systemic vasculitis.Am J Ophthalmol 133:566-568,2002.
 
14) Dandekar SS,et al:Ocular involvement in systemic vasculitis associated with perinuclear antineutro-phil cytoplasmic antibodies.Arch Ophthalmol 122:786-787,2004.
 
15) Matsuo T:Eye manifestations in patients with perinuclear antineutrophil cytoplasmic antibody-asso-ciated vasculitis:case series and literature review.Jpn J Ophthalmol 51:131-138,2007.
 
P.349 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
2) Jennette JC,Falk RJ:Small-vessel vasculitis.N Engl J Med 337:1512-1523,1997.
PubMed
3) Ha HK,et al:Radiologic features of vasculitis involving the gastrointestinal tract.Radiographics 20:779-794,2000.
PubMed
4) Muller-Ladner U:Vasculitides of the gastrointestinal tract.Best Pract Res Clin Gastroenterol 15:59-82,2001.
PubMed
5) Morgan MD,Savage CO:Vasculitis in the gastrointestinal tract.Best Pract Res Clin Gastroenterol 19:215-233,2005.
 
6) Hokama A,et al:Endoscopic and radiographic features of gastrointestinal involvement in vasculitis.World J Gastrointest Endosc 4:50-56,2012.
PubMed
7) Pagnoux C,et al:Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides:analysis of 62 patients with polyarteritis nodosa,microscopic polyangiitis,Wegener granulomatosis,Churg-Strauss syndrome,or rheumatoid arthritis-associated vasculitis.Medicine(Baltimore) 84:115-128,2005.
PubMed
8) Hokama A,et al:Image of the month.Churg-Strauss syndrome.Gastroenterology 126:642,945,2004.
PubMed
9) 吉田健一ほか:血管炎症候群(Schonlein-Henoch紫斑病,Churg-Strauss症候群,結節性多発動脈炎).胃と腸 43:699-705,2008.
 
10) Villiger PM,Guillevin L:Microscopic polyangiitis:Clinical presentation.Autoimmun Rev 9:812-819,2010.
PubMed
11) Landzberg BR,Jacobson IM:An unusual case of acute colitis.Lancet 355:1786,2000.
PubMed
12) 市川珠紀ほか:膠原病に伴う消化器病変.画像診断 28:1199-1208,2008.
 
P.356 掲載の参考文献
1) 佐田憲映:わが国のANCA関連血管炎における臓器障害の頻度.医学のあゆみ 236:761-764,2011.
Medical*Online
2) Guillevin L,et al;French Vasculitis Study Group(FVSG):The Five-Factor Score revisited:assess-ment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.Medicine(Baltimore) 90:19-27,2011.
 
3) Falk RJ,et al:ANCA glomerulonephritis and vasculitis:a Chapel Hill perspective.Semin Nephrol 20:233-243,2000.
 
4) 津坂憲政:アレルギー性肉芽腫性血管炎.難治性血管炎の診療マニュアル(班長:橋本博史),p27-29,2002.
 
5) Guillevin L,et al:Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome.A pro-spective study in 342 patients.Medicine(Baltimore) 75:17-28,1996.
 
6) Tsurikisawa N,et al:The etiology,mechanisms,and treatment of Churg-Strauss syndrome.In:Advances in the Etiology,Pathogenesis and Pathology of Vasculitis(ed by Amezcua-Guerra LM),p235-254,Intech,Croatia,2011.
 
7) Churg J,Strauss L:Allergic granulomatosis,allergic angiitis,and periarteritis nodosa.Am J pathol 27:277-301,1951.
PubMed
8) Horiguchi Y,et al:1231-MIBG imaging detects cardiac involvement and predicts cardiac events in Churg-Strauss syndrome.Eur J Nucl Med Mol Imaging 38:221-229,2011.
 
9) Sable-Fourtassou R,et al:Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome.Ann Intern Med 143:632-638,2005.
PubMed
10) Neumann T,et al:Cardiac involvement in Churg-Strauss syndrome.Impact of endomyocarditis.Medicine 88:236-243,2009.
PubMed
11) Tsurikisawa N,et al:Treatment of Churg-Strauss syndrome with high-dose intravenous immuno-globulin.Ann Allergy Asthma Immunol 92:80-87,2004.
 
12) Ramakrishna G,Midthun DE:Churg-Strauss syndrome.Ann Allergy Asthma Immunol 86:603-616,2001.
PubMed
13) Miszalski-Jamka T,et al:Cardiac involvement in Wegener's granulomatosis resistant to induction therapy.Eur Radiol 21:2297-2304,2011.
PubMed
14) Sendoh W,et al:A case of microscopic polyangiitis with severe cardiac and respiratory muscle involvement.Ryumachi 39:757-762,1999.
PubMed
15) Mavrogeni S,et al:Detection of coronary artery lesions and myocardial necrosis by magnetic reso-nance in systemic necrotizing vasculitides.Arthritis Rheum 61:1121-1129,2009.
 
P.361 掲載の参考文献
1) Muller Kobold AC,et al:Monocyte activation in patients with Wegener's granulomatosis.Ann Rheum Dis 58:237-245,1999.
PubMed
2) Stegeman CA,et al:Trimethoprim-sulfamethoxazole(co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis.Dutch Co-Trimoxazole Wegener Study Group.N Engl J Med 335:16-20,1996.
 
3) Williams JM,et al:Antineutrophil cytoplasm antibody-stimulated neutrophil adhesion depends on diacylglycerol kinase-catalyzed phosphatidic acid formation.J Am Soc Nephrol 18:1112-1120,2007.
PubMed
4) Schreiber A,et al:Phosphoinositol 3-kinase-gamma mediates antineutrophil cytoplasmic autoanti-body-induced glomerulonephritis.Kidney Int 77:118-128,2010.
 
5) D'Cruz D,et al:Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis:potential markers for disease activity.J Rheumatol 26:103-109,1999.
PubMed
6) Abdulahad WH,et al:Urinary CD4+ effector memory T cells reflect renal disease activity in antineu-trophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum 60:2830-2838,2009.
 
7) Nogueira E,et al:Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis.Nephrol Dial Transplant 25:2209-2217,2010.
PubMed
8) Jovanovic DV,et al:IL-17 stimulates the production and expression of proinflammatory cytokines,IL-beta and TNF-alpha,by human macrophages.J Immunol 160:3513-3521,1998.
PubMed
9) Hoshino A,et al:MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classi-cal complement pathway-dependent manner.J Autoimmun 31:79-89,2008.
 
10) Afzali B,et al:Translational mini-review series on Th17 cells:induction of interleukin-17 pruduc-tion by regulatory T cells.Clin Exp Immunol 159:120-130,2010.
 
11) Crotty S:Follicular helper CD4 T cells(TFH).Annu Rev Immunol 29:621-663,2011.
PubMed
12) Lund FE,Randall TD:Effector and regulatory B cells:modulators of CD4(+) T cell immunity.Nat Rev Immunol 10:236-247,2010.
PubMed
13) Blair PA,et al:CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individu-als but are functionally impaired in systemic Lupus Erythematosus patients.Immunity 32:129-140,2010.
 
14) Bouaziz JD,et al:IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro.Eur J Immunol 40:2686-2691,2010.
 
15) Hruskova Z,et al:Intracellular cytokine production in ANCA-associated vasculitis:low levels of interleukin-10 in remission are associated with a higher relapse rate in the long-term follow-up.Arch Med Res 40:276-284,2009.
 
16) Lepse N,et al:Immune regulatory mechanisms in ANCA-associated vasculitides.Autoimmun Rev 11:77-83,2011.
PubMed
P.371 掲載の参考文献
1) 難病情報センターホームページ:特定疾患医療受給者証交付件数[http://www.nanbyou.or.jp].
 
2) Hoffman GS,et al:Wegener granulomatosis:an analysis of 158 patients.Ann Intern Med 116:488-498,1992.
PubMed
3) Jayne D,et al:A randomized trial of maintenance therapy for vasculitis associated with antineutro-phil cytoplasmic antibodies.N Engl J Med 349:36-44,2003.
 
4) 尾崎承一ほか:MPO-ANCA関連血管炎に対する重症度別治療プロトコールの有用性を明らかにする前向き臨床研究.厚生労働科学研究費補助金,難治性疾患克服研究事業,難治性血管炎に関する調査研究,平成17年度総括・分担研究報告書,p199-323,2006.
 
5) Ozaki S,et al:Severity-based treatment for Japanese patients with MPO-ANCA-associated vascu-litis:the JMAAV study.Mod Rheumatol 22(3):394-404,2012.
 
6) Suka M,et al:Improvement in health-related quality of life in MPO-ANCA-associated vasculitis pa-tients treated with cyclophosphamide plus prednisolone:an analysis of 18 months of follow-up data from the JMAAV study.Mod Rheumatol 22:877-884,2012.DOI 10.1007/s10165-012-0602-4.
 
7) Lapraik C,et al:BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.Rheumatology(Oxford) 46(10):1615-1616,2007.
PubMed
8) Mukhtyar C,et al:EULAR recommendations for the management of primary small and medium ves-sel vasculitis.Ann Rheum Dis 68(3):310-317,2009.
 
9) Pagnoux C,et al:Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.N Engl J Med 359(26):2790-2803,2008.
 
10) Hiemstra TF,et al:Mycophenolate mofetil vs azathioprine for remission maintenance in antineutro-phil cytoplasmic antibody-associated vasculitis:a randomized controlled trial.JAMA 304(21):2381-2388,2010.
 
11) Takakuwa Y,et al:AC13,a C-terminal fragment of apolipoprotein A-I,is a candidate biomarker for microscopic polyangiitis.Arthritis Rheum 63(11):3613-3624,2011.
 
12) Mindsホームページ:ANCA関連血管炎の診療ガイドライン[http://minds.jcqhc.or.jp/n/medical_user_main.php].
 
P.380 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
2) Fujimoto S,et al:Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associ-ated vasculitis between Japan and the U.K Rheumatology(Oxford) 50:1916-1920,2011.
 
3) Ozaki S:ANCA-associated vasculitis:diagnosis and therapeutic strategy.Allergol Int 56:87-96,2007.
PubMed
4) 山村昌弘ほか:「抗好中球細胞質抗体(ANCA)関連血管炎の寛解導入治療の現状とその有効性と安全性に関する観察研究(RemIT-JAV)」中間解析報告.厚生労働科学研究費補助金(難治性疾患克服研究事業)分担平成22年度研究終了報告書(2011年3月),p127-130.
 
5) Watts R,et al:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.Ann Rheum Dis 66:222-227,2007.
PubMed
6) Masi AT,et al:The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome(allergic granulomatosis and angiitis).Arthritis Rheum 33:1094-1110,1990.
PubMed
7) Leavitt RV,et al:The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.Arthritis Rheum 33:1101-1107,1990.
 
8) Sorensen SF,et al:A prospective study of vasculitis patients collected in a five year period:evidence of the Chapel Hill nomenclature.Ann Rheum Dis 59:478-482,2000.
 
9) Yamada H:ANCA:associated lung fibrosis.Semin Respir Crit Care Med 32:322-327,2011.
PubMed
10) Sada K,et al:Classification of Japanese patients with ANCA-associated vasculitis by using Euro-pean Medicines Agency algorism with surrogate markers for pulmonary vasculitis.(in preparation)
 
11) Liu L-J,et al:Evaluation of a new algorithm in classification of systemic vasculitis.Rheumatology 47:708-712,2008.
PubMed
12) Lionaki S,et al:Classification of antineutrophil cytoplasmic autoantibody vasculitides:The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease rec-ognition and prognosis.Arthritis Rheum 64:3452-3462,2012.
PubMed
13) Mahr A,et al:Revisiting the classiification of clinical phenotypes of anti-neutrophil cytoplasmic anti-body-associated vasculitis:a cluster analysis.Ann Rheum Dis,2012.[Epub ahead of print]
 
14) Chen M,et al:Renal histology in Chinese patients with anti-myeloperoxidase autoantibody-posi-tive Wegener's granulomatosis.Nephrol Dial Transplant 22:139-145,2007.
 
15) Hervier B,et al:Pulmonary fibrosis associated with ANCA-positive vasculitides.Retrospective study of 12 cases and review of the literature.Ann Rheum Dis 68:404-407,2009.
PubMed
P.384 掲載の参考文献
1) 針谷正祥ほか:抗好中球細胞質抗体関連血管炎・急速進行性糸球体腎炎の寛解導入治療の現状とその有効性と安全性に関する観察研究.厚生労働科学研究費補助金難治性疾患克服研究事業 難治性血管炎に関する調査研究平成23年度総括・分担研究報告書,p124-126,2012.
 
2) Watts R,et al:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.Ann Rheum Dis 66(2):222-227,2007.
PubMed
3) 山村昌弘ほか:「抗好中球細胞質抗体関連血管炎の寛解導入治療の現状とその有効性と安全性に関する観察研究」中間解析報告 厚生労働科学研究費補助金難治性疾患克服研究事業 難治性血管炎に関する調査研究平成22年度総括・分担研究報告書,p127-130,2011.
 
P.390 掲載の参考文献
1) Mukhtyar C,et al:EULAR recommendations for the management of primary small and medium ves-sel vasculitis.Ann Rheum Dis 68:310-317,2009.
 
2) Lapraik C,et al:BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.Rheumatology 46:1615-1616,2007.
PubMed
3) Sanders JS,et al:Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.Rheumatology 45:724-729,2006.
PubMed
4) Walsh M,et al:Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum 64(2):542-548,2012.
PubMed
5) Watts RA,et al:Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 23(12):3928-3931,2008.
PubMed
6) Ozaki S,et al:Severity-based treatment for Japanese patients with MPO-ANCA-associated vascu-litis:the JMAAV study.Mod Rheumatol 22(3):394-404,2011.
 
7) 急速進行性腎炎症候群の診療指針,第2版.日腎会誌 53(4):509-555,2011.
 
8) 厚生労働科学研究費補助金 難治性疾患克服研究事業 難治性血管炎に関する調査研究 平成22年度総括・分担研究報告書,2011.
 
9) ANCA関連血管炎の診療ガイドライン(尾崎承一ほか編),厚生労働省 難治性疾患克服研究事業,2011.
 
10) Wada T,et al:Risk factors associated with relapse in Japanese patients with microscopic polyangiitis.J Rheumatol 39(3):545-551,2012.
PubMed
P.398 掲載の参考文献
1) Jayne D,et al:Randomized trial of plasma exchange or high-dosage methylprednisolone as a adjunctive therapy for severe renal vasculitis.J Am Soc Nephrol 18:2180-2188,2007.
 
2) Wegener's Granulomatosis Etanercept Trial(WGET) Research Group:Etanercept plus standard therapy for Wegener's granulomatosis.N Engl J Med 352:351-361,2005.
 
3) Pusey CD,et al:Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies.Kidney Int 40:757-763,1991.
PubMed
4) Cole E,et al:A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis.The Canadian Apheresis Study Group.Am J Kidney Dis 20:261-269,1992.
 
5) Glockner WM,et al:Plasma exchange and immunosuppression in rapidly progressive glomeru-lonephritis:a controlled,multi-center study.Clin Nephrol 29:1-8,1988.
 
6) Yamagata K,et al:Apheresis for MPO-ANCA-associated RPGN-indications and efficacy:lesson learned from Japan nationwide survey of RPGN.J Clin Apher 20:244-251,2005.
PubMed
7) Rota S,et al:Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eico-sanoid synthesis.Kidney Int 42:981-990,1992.
 
8) Irakam A,et al:Dose-related inhibition of proinflammatory cytokine release from neutrophils of the newborn by dexamethasone,betamethasone,and hydrocortisone.Biol Neonate 82:89-95,2002.
PubMed
9) Wolfe F,et al:Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia:associations with prednisone,disease-modifying antirheumatic drugs,and anti-tumor necrosis fac-tor therapy.Arthritis Rheum 54:628-634,2006.
 
10) Illei GG,et al:Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.Rheumatology(Oxford) 46:952-956,2007.
PubMed
11) Saag KG,et al:Low dose long-term corticosteroid therapy in rheumatoid arthritis:an analysis of serious adverse events.Am J Med 96:115-123,1994.
PubMed
12) 猪原登志子:血管炎症候群up to date 欧州血管炎研究グループ(EUVAS)による血管炎の治療戦略について.リウマチ科 45:406-415,2011.
 

VI その他の血管炎の診断と治療

P.407 掲載の参考文献
1) 細野治:血管炎の基礎と臨床.ウイルス関連血管炎の診断と治療.医学のあゆみ 214:105-110,2005.
 
2) Arkin A:A clinical and pathological study of periarteritis nodosa.A report of five cases,one histo-logically healed.Am J pathol 6:401-426,1930.
 
3) 尾崎承一ほか:循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告).血管炎症候群の診療ガイドライン.V.結節性多発動脈炎.Circulation Journal 72(Suppl IV)336-1340,2008.
 
4) Leib ES,et al:Immunosuppressive and corticosteroid therapy of polyarteritis nodosa.Am J Med 67:941-947,1979.
PubMed
5) Guillevin L,et al:Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angi-itis with comparison of steroids,plasma exchange and cyclophosphamide to steroids and plasma exchange.A prospective randomized trial of 71 patients.The cooperative study group for polyarteri-tis nodosa.J Rheumatol 18:567-574,1991.
 
6) Gayraud M,et al:Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome:comparison of steroids and oral or pulse cyclophosphamide in 25 patients.French Cooperative Study Group for Vasculitides.Br J Rheumatol 36:1290-1297,1997.
PubMed
7) Guillevin L,et al:Treatment of polyarteritis nodosa and microscopic polyangiitis with poor progno-sis factors:a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.Arthritis Rheum 49:93-100,2003.
PubMed
8) Ribi C,et al:Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors.Arthritis Rheum 62:1186-1197,2010
PubMed
9) Guillevin L,et al:Lack of superiority of steroids plus plasma exchange to steroids alone in the treat-ment of polyarteritis nodosa and Churg-Strauss syndrome.A prospective,randomized trial in 78 patients.Arthritis Rheum 35:208-215,1992.
 
10) Guillevin L,et al:Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corti-costeroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis.A prospective,randomized trial in sixty-two patients.Arthritis Rheum 38:1638-1645,1995.
 
11) Mukhtyar C,et al:EULAR recommendations for the management of primary small and medium ves-sel vasculitis.Ann Rheum Dis 68:310-317,2009.
 
12) 難病医学研究財団/難病情報センター[http://www.nanbyou.or.jp/entry/245.htm],免疫疾患調査研究班(難治性血管炎に関する調査研究班)参考資料.
 
13) Balow JE:Renal vasculitis.Kidney Int 27:954-964,1985.
PubMed
14) Frohnert PP,Sheps SG:Long-term follow-up study of periarteritis nodosa.Am J Med 43:8-14,1967.
PubMed
15) Gayraud M,et al:Long-term followup of polyarteritis nodosa,microscopic polyangiitis,and Churg-Strauss syndrome:analysis of four prospective trials including 278 patients.Arthritis Rheum 44:666-675,2001.
PubMed
16) de Menthon M,Mahr A:Treating polyarteritis nodosa:current state of the art.Clin Exp Rheumatol 29(Suppl 64):S110-S116,2011.
 
P.412 掲載の参考文献
1) Katorn LW,Bernstein JC:Cutaneous manifestation of periarteritis nodosa.Arch Dermatol Syphilol 40:929-944,1939.
 
2) Cohen RD,et al:Clinical features,prognosis,and response to treatment in polyarteritis.Mayo Clin Proc 55:146-155,1980.
PubMed
3) 古川福実:皮膚型結節性多発動脈炎の疾患概念の確立に関する研究.厚生労働科学研究費補助金難治性疾患克服研究事業 難治性血管炎に関する調査研究 主任研究者尾崎承一 平成19年度総括・分担研究報告書,p107-109,2008.
 
4) 古川福実ほか:総説「時空をマーチする血管炎」.Visual Dermatology 6:452-457,2007.
 
5) Nakamura T,et al:Cutaneous polyarteritis nodosa:revisiting its definition and diagnostic criteria.Arch Dermatol Res 301:117-121,2009.
PubMed
6) 石黒直子:結節性多発動脈炎・皮膚型結節性多発動脈炎,日本皮膚科学会血管炎・血管障害診療ガイドライン(勝岡憲生委員長).日皮会誌 118:2095-2187,2008.
 
7) 免疫疾患調査研究班(難治性血管炎):結節性多発動脈炎,難病情報センター.[http://www.nanbyou.or.jp/sikkan/025_1_i.htm]
 
8) Arkin A:A clinical and pathological study of periarteritis nodosa.A report of five cases,one histo-logically healed.Am J pathol 6:401-426,1930.
 
9) Daoud MS,et al:Cutaneous periarteritis nodosa:a clinicopathological study of 79 cases.Br J Der-matol 136:706-713,1997.
 
10) Chen KR:Cutaneous polyarteritis nodosa:a clinical and histological study of 20 cases.J Dermatol 16:429-442,1989.
 
11) Kawakami T,et al:High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa.Arthritis Rheum 57:1507-1513,2007.
PubMed
12) 陳科榮:結節性多発動脈炎.カラーアトラス 皮膚病変から診る膠原病,第1版,p90-98,全日本病院出版会,2006.
 
13) 勝岡憲生ほか:日本皮膚科学会ガイドライン 血管炎・血管障害ガイドライン.日皮会誌 118:2095-2187,2008.
 
14) 石黒直子:結節性多発動脈炎-皮膚型の位置づけをふまえ-.日皮会誌 116:1980-1984,2006.
 
P.419 掲載の参考文献
1) Lie JT:Illustrated histopathologic classification criteria for selected vasculitis syndromes.Arthritis Rheum 33:1074-1087,1990.
PubMed
2) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
3) Ozen S,et al:EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.Ann Rheum Dis 65:936-941,2006.
PubMed
4) Takeuchi S,et al:IgM in lesional skin of adults with Henoch-Schonlein purpura is an indication of renal involvement.J Am Acad Dermatol 63:10260-1029,2010.
 
5) Kawakami T:A review of pediatric vasculitis with a focus on juvenile polyarteritis nodosa.Am J Clin Dermatol 13:389-398,2012.
PubMed
6) Weiss PF,et al:Effects of corticosteroid on Henoch-Schonlein purpura:a systematic review.Pedi-atrics 120:1079-1087,2007.
 
7) Chartapisak W,et al:Prevention and treatment of renal disease in Henoch-Schonlein purpura:a systematic review.Arch Dis Child 94:132-137,2009.
PubMed
P.426 掲載の参考文献
1) Brouet JC,et al:Biologic and clinical significance of cryoglobulins.A report of 86 cases.Am J Med 57:775-788,1974.
PubMed
2) Tedeschi A,et al:Cryoglobulinemia.Blood Rev 21:183-200,2007.
PubMed
3) Ferri C,et al:Mixed cryoglobulinemia:demographic,clinical,and serologic features and survival in 231 patients.Semin Arthritis Rheum 33:355-374,2004.
PubMed
4) Sansonno D,et al:Hepatitis C virus infection,cryoglobulinaemia,and beyond.Rheumatology(Oxford) 46:572-578,2007.
PubMed
5) Landau DA,et al:The pathophysiology of HCV induced B-cell clonal disorders.Autoimmun Rev 6:581-587,2007.
PubMed
6) 岸誠司,土井俊夫:クリオグロブリン血症.日内会誌 100:1289-1295,2011.
 
7) 山口純奈,南学正臣:クリオグロブリン血症.腎と透析 68:77-83,2010.
Medical*Online
8) Charles ED,Dustin LB:Hepatitis C virus-induced cryoglobulinemia.Kidney Int 76:818-824,2009.
PubMed
9) Cacoub P,Saadoun D:Hepatitis C virus infection induced vasculitis.Clin Rev Allergy Immunol 35:30-39,2008.
PubMed
10) Taneda S,et al:Protease nexin-1,tPA,and PAI-1 are upregulated in cryoglobulinemic membra-noproliferative glomerulonephritis.J Am Soc Nephrol 19:243-251,2008.
 
11) Mazzaro C,et al:Treatment with peg interferon alfa 2b and ribavirin of hepatitis C virus-associ-ated mixed cryoglobulinemia:a pilot study.J Hepatol 42:632-638,2005.
 
P.432 掲載の参考文献
1) Mehregan DR,et al:Urticarial vasculitis:a histopathologic and clinical review of 72 cases.J Am Acad Dermatol 26:441-448,1992.
 
2) 川名誠司:蕁麻疹様紅斑.皮膚病診療 20:105-110,1998.
 
3) 川名誠司ほか:好中球優位の細胞浸潤を伴う蕁麻疹様紅斑-Urticarial vasculitisの位置づけ-.日皮会誌 101:951-957,1991.
 
4) Davis MD,et al:Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis.J Am Acad Dermatol 38:899-905,1998.
PubMed
5) Wisnieski JJ,et al:Hypocomplementemic urticarial vasculitis syndrome.Clinical and serologic find-ings in 18 patients.Medicine(Baltimore) 74:24-41,1995.
 
6) Wisnieski JJ:Urticarial vasculitis.Curr Opin Rheumatol 12:24-31,2000.
PubMed
7) Buck A,et al:Hypocomplementemic urticarial vasculitis syndrome:a case report and literature review.J Clin Aesthet Dermatol 5:36-46,2012.
PubMed
8) Kato Y,et al:Urticarial vasculitis appearing in the progression of systemic sclerosis.J Dermatol 33:792-797,2006.
PubMed
9) Mannik M,Wener MH:Deposition of antibodies to the collagen-like region of Clq in renal glo-meruli of patients with proliferative lupus glomerulonephritis.Arthritis Rheum 40:1504-1511,1997.
 
10) Aydogan K,et al:Hypocomplementemic urticarial vasculitis:a rare presentation of systemic lupus erythematosus.Int J Dermatol 45:1057-1061,2006.
PubMed
11) de Castro FR,et al:Urticarial pathology in Schnitzler's(hyper-IgM)syndrome.Dermatology 193:94-99,1996.
 
12) Kawana S,et al:Value of the assay for IgA-containing circulating immune complexes in Henoch-Schonlein purpura.Dermatologica 172:245-253,1986.
PubMed
13) Alexander JL,et al:Plasmapheresis for refractory urticarial vasculitis in a patient with B-cell chronic lymphocytic leukemia.J Drug Dermatol 5:534-537,2006.
 
14) Yamazaki-Nakashimada MA,et al:Intravenous immunoglobulin therapy for hypocomplementemic urticarial vasculitis associated with systemic lupus erythematosus in a child.Pediatr Dermatol 26:445-447,2009.
 
15) Saigal K,et al:Hypocomplementemic urticarial vasculitis with angioedema,a rare presentation of systemic lupus erythematosus:rapid response to rituximab.J Am Acad Dermatol 49:S283-285,2003.
PubMed
P.436 掲載の参考文献
1) Goodpasture EW:The significance of certain pulmonary lesions in relation to the etiology of influenza.Am J Med Sci 158:863-870,1919.
 
2) Stanton MC,Tange JD:Goodpasture's syndrome(pulmonary haemorrhage associated With glomerulo-nephritis).Australas Ann Med 7:132-144,1958.
 
3) 松尾清一ほか:急速進行性腎炎症候群の診療指針 第2版.日腎会誌 53:509-555,2011.
 
4) Buffaloe GW,et al:Antibodies to human glomerular basement membrane:modified methodology for detection in human serum.Clin Exp Immunol 39:136-140,1980.
PubMed
5) Rutgers A,et al:Coexistence of anti-glomerular basement membrane antibodies and myeloperoxi-dase-ANCAs in crescentic glomerulonephritis.Am J Kidney Dis 46:253-262,2005.
 
6) Jayne DR,et al:Auroantibodies to GBM and neutrophil cytoplasmic in rapidly progressive glomerulonephritis.Kidney Int 37:965-970,1990.
PubMed
7) Huey B,et al:Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization.Kidney Int 44:307-312,1993.
PubMed
8) Kitagawa W,et al:The HLA-DRB1 1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease.Nephrol Dial Transplant 23:3126-3129,2008.
PubMed
P.441 掲載の参考文献
1) Hirohata S,et al:Behcet's disease.Arthritis Res Ther 5:139-146,2003.
PubMed
2) Mizuki N,et al:Genome-wide association studies identify IL23R-IL12RB2 and IL-10 as Behcet's disease susceptibility loci.Nat Genet 42:703-706,2010.
PubMed
3) Remmers EF,et al:Genome-wide association study identifies variants in the MHC class I,IL10,and IL23R-IL12RB2 regions associated with Behcet's disease.Nat Genet 42:698-702,2010.
PubMed
4) Hirohata S,et al:Clinical characteristics of neuro-Behcet's disease in Japan:a multicenter retro-spective analysis.Mod Rheumatol 22:405-413,2012.
 
5) Hirohata S:Is the long-term use of systemic corticosteroids beneficial in the management of Behcet's syndrome? Nat Clin Pract Rheumatol 2:358-359,2006.
 
6) Kotake S,et al:Central nervous system symptoms in patients with Behcet disease receiving cyclo-sporine therapy.Ophthalmology 106:586-589,1999.
 
7) Hirohata S,et al:Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease.J Neurol Sci 159:181-185,1998.
PubMed
8) Aramaki K,et al:HLA-B51 and cigarette smoking as risk factors for chronic progressive neurologi-cal manifestations in Behcet's disease.Mod Rheumatol 17:81-82,2007.
 
9) Kikuchi H,et al:ffect of infliximab in progressive Neuro-Behcet's syndrome.J Neurol Sci 272:99-105,2008.
 
10) Kobayashi K,et al:Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach.J Gastroenterol 42:737-745,2007.
PubMed
11) Naganuma M,et al:Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease.Inflamm Bowel Dis 14:1259-1264,2008.
PubMed
12) Hirohata S,Kikuchi H:Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behcet's disease.Clin Exp Rheumatol 27(2 Suppl 53):s91-95,2009.
 
13) Desbois AC,et al:Immunosuppressants reduce venous thrombosis relapse in Behcet's disease.Arthritis Rheum 64:2753-2760,2012.
PubMed
14) Adler S,et al:Behcet's disease:Successful treatment with infliximab in 7 patients with severe vascu-lar manifestations.A retrospective analysis.Arthritis Care Res 64:607-611,2012.
 
15) Ideguchi H,et al:Characteristics of vascular involvement in Behcet's disease:a retrospective cohort study.Clin Exp Rheumatol 29(4 Suppl 67):s47-53,2011.
 
P.446 掲載の参考文献
1) Mochizuki M,et al:Behcet's disease.In:Ocular Infection and Immunity(ed by Pepose JS,et al),p663-675,Mosby,St.Louis,1996.
 
2) Okada AA:Behcet's disease:general concepts and recent advances.Curr Opin Ophthalmol 17:551-556,2006.
PubMed
3) Goto H,et al:Epidemiological survey of intraocular inflammation in Japan.Jpn J Ophthalmol 51:41-44,2007.
PubMed
4) 中江公裕ほか:厚生省特定疾患ベーチェット病調査研究班平成4年度研究実績,p70-82,1993.
 
5) Verity DH,et al:Behcet's disease,the Silk Road and HLA-B51:historical and geographical perspectives.Tissue Antigen 54:213-220,1999.
PubMed
6) 大野重昭:眼疾患発症の外因と内因.日眼会誌 109:885-916,2005.
 
7) 大野重昭ほか:ベーチェット病眼病変診療ガイドライン 第2章 ベーチェット病の疫学.日眼会誌 116:402-405,2012.
 
8) Ohno S,et al:HLA-A5 and Behcet's disease.Lancet 2:1383-1384,1973.
 
9) Mizuki N,et al:Behcet's disease associated with one of the HLA-B51 subantigens,HLA-B 5101.Am J Ophthalmol 116:406-409,1993.
PubMed
10) Mizuki N,et al:Genome-wide association studies identify IL23R-IL12RB2 and ILIO as Behcet's dis-ease susceptibility loci.Nat Genet 42:703-706,2010.
 
11) Kaneko F,et al:The role of streptococcal hypersensitivity in the pathogenesis of Behcet's Disease.Eur J Dermatol 18:489-498,2008.
PubMed
12) Kaneko S,et al:Characterization of T cells specific for an epitope of human 60-kD heat shock pro-tein(hsp) in patients with Behcet's disease(BD) in Japan.Clin Exp Immunol 108:204-212,1997.
 
13) Lehner T:The role of heat shock protein,microbial and autoimmune agents in the aetiology of Behcet's disease.Int Rev Immunol 14:21-32,1997.
PubMed
14) Direskeneli H,et al:T cell response to 60/65kDa heat shock protein derived peptides in Turkish patients with Behcet's disease.J Rheumatol 27:708-713,2000.
 
15) Ergun T,et al:HSP 60 expression in mucocutaneous lesions of Behcet's disease.J Am Acad Derma-tol 45:904-909,2001.
 
16) Imamura Y,et al:Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intesti-nal of Behcet's disease.Clin.Exp Immunol 139:371-378,2005.
 
17) Akdeniz N,et al:Serum interleukin-2,interleukin-6,tumor necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease.Ann Acad Med Singapore 33:596-599,2004.
PubMed
18) Frassanito MA,et al:Th1 polarization of the immune response in Behcet's disease:a putative patho-genic role of interleukin-12.Arthritis Rheum 42:1967-1974,1999.
 
19) Bardak Y,Aridogan BC:The demonstration of serum interleukin 6-8,tumor necrosis factor-alpha,complement,and immunoglobulin levels in Behcet's disease with ocular involvement. Ocu-lar Immunol Inflamm 12:53-58,2004.
 
20) Yanagihori H,et al:Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease sus-ceptibility:An involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen.J Invest Dermatol 126:1534-1540,2006.
 
21) Chi W,et al:IL-23 and IL-17 are upregulated in Behcet's patients with active uveitis.Invest Oph-thalmol Vis Sci 49:3058-3064,2008.
 
22) Ohno S,et al:Efficacy,safety,and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis.J Rheumatol 31:1362-1368,2004.
PubMed
23) Okada AA,et al;Ocular Behcet's Disease Research Group Of Japan:Multicenter study of infliximab for refractory uveoretinitis in Behcet's disease.Arch Ophthalmol 130:592-598,2012.
 
24) Evereklioglu C:Current concepts in the etiology and treatment of Behcet's disease.Surv Ophthal-mol 50:297-350,2005.
 
25) Keino H,et al:Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.Br J Ophthalmol 95:1245-1250,2011.
PubMed
26) Sugita S,et al:Induction of regulatory T cells by infliXimab in Behcet's disease.Invest Ophthalmol Vis Sci 52:476-484,2011.
PubMed
27) Sugita S,et al:Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease.Arthritis Res Ther 14:R99,2012.
PubMed
28) Keino H,et al:Effect of infliximab on gene expression profiling in Behcet's disease.Invest Ophthal-mol Vis Sci 52:7681-7686,2011.
 
29) Do JE,et al:Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease.Rheumatology(Oxford) 47:840-848,2008.
PubMed
P.451 掲載の参考文献
1) St Clair EW,McCallum RM:Cogan's syndrome.In:Rheumatology;The Vasculitides(ed by Hochenberg MC,et al),p1625-1634,Elsevier,Philadelphia,2011.
 
2) Cogan DG:Syndrome of nonsyphilitis interstitial keratitis and vesibuloauditory symptoms.Arch Ophthalmol 33:144-149,1945.
 
3) Gluth MB,et al:Cogan syndrome:a retrospective review of 60 patients throughout a half century.Mayo Clin Proc 81:483-488,2006.
PubMed
4) Wolff D,et al:The pathology of Cogan's syndrome causing profound deafness.Ann Otol Rhinol Laryngol 74:507-520,1965.
PubMed
5) Haynes BF,et al:Studies in thirteen patients,long-term follow-up,and review of the literature.Medicine 59:426-441,1980.
PubMed
6) Vollertsen RS,et al:Cogan's syndrome:18 cases and a review of the literature.Mayo Clin Proc 61:344-361,1986.
 
7) Tsuno H,et al:Successful early treatment in a case of Cogan's syndrome.Jpn J Clin Immunol 35:92-96,2012.
 
8) Orsoni JG,et al:Rituximab ameliorated severe hearing loss in Cogan's syndrome:a case report.Orphanet J Rare Dis 5:18,2010.
PubMed
9) Shibuya M,et al:Successful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis.Mod Rheumatol,2012.[Epub ahead of print]
 
10) Mazlumzadeh M,Matteson EL:Cogan's syndrome:an audiovestibular,ocular,and systemic auto-immune disease.Rheum Dis Clin North Am 33:855-874,2007.
 
P.456 掲載の参考文献
1) Bevans M,et al:The systemic lesions of malignant rheumatoid arthritis.Am J Med 16:197-211,1954.
PubMed
2) Schneider HA,et al:Rheumatoid vasculitis:experience with 13 patients and review of the literature.Semin Arthritis Rheum 14:280-286,1985.
PubMed
3) 厚生省特定疾患,悪性関節リウマチ・結節性動脈周囲炎研究班,1973年報告書(班長:塩川優一),1974.
 
4) 松岡康夫:悪性関節リウマチ.難治性血管炎の診療マニュアル(難治性血管炎に関する調査研究班,班長:橋本博史),p35-40,2002.
 
5) Turesson C,et al:Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.Ann Rheum Dis 66:70-75,2007.
PubMed
6) Scott DG,et al:IgG rheumatoid factor,complement and immune complexes in rheumatoid synovi-tis and vasculitis:comparative and serial studies during cytotoxic therapy.Clin Exp Immunol 43:54-63,1981.
 
7) Kondoh Y,et al:Prognostic factors in rapidly progressive interstitial pneumonia.Respirology 15:257-264,2010.
PubMed
8) 橋本博史ほか:悪性関節リウマチの改訂診断基準の提唱.リウマチ 29:268-276,1989.
 

VII 血管炎の血管新生療法と免疫療法

P.462 掲載の参考文献
1) 田畑泰彦(編):再生医療へのブレイクスルー,遺伝子医学MOOK1,メディカル ドゥ,2004.
 
2) 田畑泰彦:再生医療のためのバイオマテリアル,コロナ社,2006.
 
3) 田畑泰彦:ますます重要になる細胞周辺環境(細胞ニッチ)の最新科学技術.メディカル ドゥ,2009.
 
4) Tabata Y:Biomaterial technology for tissue engineering applications.J R Soc Interface 6(Suppl3):S311-324,2009.
 
5) 田畑泰彦:ウィルスを用いない遺伝子導入法の材料,技術,方法論の新たな展開,メディカル ドゥ,2006.
 
6) 田畑泰彦(編):ドラッグデリバリーシステムDDS技術の新たな展開とその活用法,遺伝子医学別冊,メディカル ドゥ,2003.
 
7) 田畑泰彦(編):絵で見てわかるナノDDS,遺伝子医学MOOK別冊,メディカル ドゥ,2007.
 
8) Yamamoto M,Tabata Y:Tissue engineering by modulated gene delivery.Adv Drug Deliv Rev 58:535-554,2006.
PubMed
9) 松本邦夫,田畑泰彦(編):細胞増殖因子と再生医療,メディカルレビュー社,2006.
 
10) Iwakura A,et al:Gelatin sheet incorporating basic fibroblast growth factor enhances healing of devascularized sternum in diabetic rats.Circulation 104:1325-329,2001.
 
11) Arai Y,et al:Combined treatment with sustained-release basic fibroblast growth factor and heparin enhances neovascularization in hypercholesterolemic mouse hindlimb ischemia.Circ J 71:412-417,2007.
PubMed
12) Marui A et al:A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel:an initial report of the phase I-IIa study.Circ J 71:1181-1186,2007.
PubMed
13) 田畑泰彦:DDS技術の最前線-再生医療を実現しつづける-.Medical Science Digest 34:103-126,2008.
 
14) Kawanaka H,et al:Therapeutic angiogenesis by controlled-release fibroblast growth factor in a pa-tient with Churg-Strauss syndrome complicated by an intractable ischemic leg ulcer.Am J Med Sci 338:341-342,2009.
 
15) Nakagawa T,et al:Topical insulin-like groWth factor 1 treatment using gelatin hydrogels for gluco-corticoid-resistant sudden sensorineural hearing loss:a prospective clinical trial.BMC Med 8:76,2010.
 
16) Marui A,et al:Simultaneous application of basic fibroblast growth factor and hepatocyte growth fac-tor to enhance the blood vessels formation.J Vasc Surg 41:82-90,2005.
 
17) Young S,et al:Dose effect of dual delivery of vascular endothelial growth factor and bone morpho-genetic protein-2 on bone regeneration in a rat critical-size defect model.Tissue Eng Part A 15:2347-2362,2009.
 
18) 田畑泰彦:患者までとどいている再生誘導治療,遺伝子医学MOOK13,メディカル ドゥ,2009.
 
P.469 掲載の参考文献
1) Epstein SE,et al:Therapeutic interventions for enhancing collateral development by administration of growth factors:basic principles,early results and potential hazards.Cardiovasc Res 49:532-542,2001.
PubMed
2) Tabata Y,etal:Enhanced vascularization and tissue granulation by basic fibroblast growth factor impregnated in gelatin hydrogels.J Control Release 31:189-199,1994.
 
3) Sakakibara Y,et al:Toward surgical angiogenesis using slow-released basic fibroblast growth factor.Eur J Cardiothorac Surg 24:105-111;discussion 112,2003.
 
4) Takaba K,et al:A combination of omental flap and growth factor therapy induces arteriogenesis and increases myocardial perfusion in chronic myocardial ischemia:evolving concept of biologic coro-nary artery bypass grafting.J Thorac Cardiovasc Surg 132:891-899,2006.
 
5) Sakakibara Y,et al:Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation.J Thorac Cardiovasc Surg 124:50-56,2002.
PubMed
6) Iwakura A,et al:Gelatin sheet incorporating basic fibroblast growth factor enhances healing of devascularized sternum in diabetic rats.Circulation 104(12 Suppl 1):I325-329,2001.
 
7) Kanematsu A,et al:Type I collagen can function as a reservoir of basic fibroblast growth factor.J Control Release 99:281-292,2004.
PubMed
8) Marui A,et al:Simultaneous application of basic fibroblast growth factor and hepatocyte growth fac-tor to enhance the blood vessels formation.J Vasc Surg 41:82-90,2005.
 
9) Arai Y,et al:Combined treatment with sustained-release basic fibroblast growth factor and heparin enhances neovascularization in hypercholesterolemic mouse hindlimb ischemia.Circ J 71:412-417,2007.
PubMed
10) Bir SC,et al:Angiogenic properties of sustained release platelet-rich plasma:characterization in-vitro and in the ischemic hind limb of the mouse.J Vasc Surg 50:870-879,2009.
PubMed
11) Hirose K,et al:Novel approach with intratracheal administration of microgelatin hydrogel micro-spheres incorporating basic fibroblast growth factor for rescue of rats with monocrotaline-induced pulmonary hypertension.J Thorac Cardiovasc Surg 136:1250-1256,2008.
 
12) Hirose K,et al:Sustained-release vancomycin sheet may help to prevent prosthetic graft methicillin-resistant Staphylococcus aureus infection.J Vasc Surg 44:377-382,2006.
PubMed
13) Marui A,et al:Biologic anastomosis:the first case of biologic coronary bypass surgery.J Thorac Cardiovasc Surg 138:775-777,2009.
PubMed
14) Doi K,et al:Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth fac-tor in rabbit model of hind limb ischemia.Heart Vessels 22:104-108,2007.
 
15) Marui A,et al:A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic broblast growth factor using biodegradable gelatin hydrogel:an initial report of the phase I-IIa study.Circ J 71:1181-1186,2007.
 
P.475 掲載の参考文献
1) Asahara T,et al:Isolation of putative progenitor endothelial cells for angiogenesis.Science 275:964-967,1997.
PubMed
2) Jiang Y,et al:Pluripotency of mesenchymal stem cells derived from adult marrow.Nature 418:41-49,2002.
PubMed
3) Tateishi-Yuyama E,et al:Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells:a pilot study and a randomized controlled trial.Lancet 360:427-435,2002.
 
4) Matoba S,Matsubara H:Therapeutic angiogenesis for peripheral artery diseases by autologous bone marrow cell transplantation.Curr Pharm Des 15:2769-2777,2009.
PubMed
5) Fadini GP,et al:Autologous stem cell therapy for peripheral arterial disease meta-analysis and sys-tematic review of the literature.Atherosclerosis 209:10-17,2010.
 
6) Takahashi M,et al:Therapeutic neovascularization by the implantation of autologous mononuclear cells in patients with connective tissue diseases.Curr Pharm Des 15:2778-2783,2009.
PubMed
7) Matoba S,et al:Long-term clinical outcome after intramuscular implantation of bone marrow mono-nuclear cells(TACT trial) in patients with chronic limb ischemia.Am Heart J 156:1010-1018,2008.
 
8) Norgren L,et al:Inter-Society Consensus for the Management of Peripheral Arterial Disease(TASC II).Eur J Vasc Endovasc Surg 33(Suppl 1):S1-S75,2007.
 
9) Onodera R,et al:Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mono-nuclear cells for treatment of lower limb ASO:pooled analysis for long-term prognosis.Bone Mar-row Transplant 46:278-284,2011.
 
10) Idei N,et al:Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia:a comparison of atherosclerotic peripheral arterial disease and Buerger disease.Circ Caridiovasc Interv 4:15-25,2011.
PubMed
11) Mima Y,et al:Enhancement of cell-based therapeutic angiogenesis using a novel type of injectable scaffolds of hydroxyapatite-polymer nanocomposite microspheres.PloS One 7:e35199,2012.
PubMed
P.481 掲載の参考文献
1) Carmeliet P,Tessier-Lavigne M:Common mechanisms of nerve and blood vessel wiring.Nature 436:193-200,2005.
PubMed
2) Kruger RP,et al:Semaphorins command cells to move.Nat Rev Mol Cell Biol 6:789-800,2005.
PubMed
3) Harris SL,Levine AJ:The p53 pathway:positive and negative feedback loops.Oncogene 24:2899-2908,2005.
PubMed
4) Falanga V:Wound healing and its impairment in the diabetic foot Lancet 366:1736-1743,2005.
PubMed
5) Toyofuku T,et al:Semaphorin-4A,an activator for T-cell-mediated immunity,suppresses angio-genesis via Plexin-D1.EMBO J 26:1373-1384,2007.
 
6) Maione F,et al:Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.J Clin Invest 119:3356-3372,2009.
PubMed
7) Brodsky SV,et al:Prevention and reversal of premature endothelial cell senescence and vasculopa-thy in obesity-induced diabetes by ebselen.Circ Res 94:377-384,2004.
 
8) Moriya J,et al:Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis.Circ Res 106:391-398,2010.
PubMed
P.486 掲載の参考文献
1) Nishikawa T,et al:Transcriptional complex formation of c-Fos,STAT3 and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression.J Immunol 180(5):3492-3501,2008.
PubMed
2) Hagihara K et al:IL-6 plays a critical role in the synergistic induction of human serum amyloid A(SAA) gene when stimulated with pro-inflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system.Biochem Biophys Res Commun 314:363-369,2004.
 
3) Hagihara K,et al:Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amy-loid A gene expression.Genes Cells 1O:1051-1063,2005.
 
4) Prabha T,et al:Prediction and experimental validation of putative non-consensus binding sites for transcription factor STAT3 in serum amyloid A gene promoter.(submitted)
 
5) Nishimoto N,et al:Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody:a multicenter,double-bind,placebo-controlled trial.Arthritis Rheum 50:1761-1769,2004.
 
6) Elliot MJ,et al:Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.Arthritis Rheum 58(2):S92-S101,2008.
 
P.489 掲載の参考文献
1) Furusho K,et al:High-dose intravenous gammaglobulin for Kawasaki disease.Lancet 2(8411):1055-1058,1984.
PubMed
2) Newburger JW,et al:The treatment of Kawasaki syndrome with intravenous gamma globulin.N Engl J Med 315(6):341-347,1986.
PubMed
3) Samuelsson A,et al:Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.Science 291(5503):484-486,2001.
PubMed
4) Basta M,Dalakas MC:High-dose intravenous immunoglobulin exerts its beneficial effect in pa-tients with dermatomyositis by blocking endomysial deposition of activated complement fragments.J Clin Invest 94(5):1729-1735,1994.
 
5) Kondo N,et al:Intravenous immunoglobulins suppress immunoglobulin productions by suppress-ing Ca2+-dependent signal transduction through Fc gamma receptors in B lymphocytes.Scand J Immunol 40(1):37-42,1994.
 
6) Spahn JD,et al:Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intrave-nous immunoglobulin.J Allergy Clin Immunol 103(3 Pt 1):421-426,1999.
 
7) 佐地勉,高橋啓:第38回川崎病への新規治療法.炎症と免疫 20(3):304-311,2012.
 
8) 大原関利章ほか:川崎病動脈炎モデルにおける抗TNF-α療法の血管炎抑制効果の検討.PROGRESS IN MEDICINE 29(4):1173,2009.
Medical*Online
9) 永渕裕子ほか:血管炎症候群に対する抗体療法.医学のあゆみ 238(6):682-686,2011.
Medical*Online
10) Anthony RM,et al:Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.Nature 475(7354):110-113,2011.
 

VIII 最新の研究トピックス - AP - VAS 2012から

P.496 掲載の参考文献
1) Theofilopoulos AN,Kono DH:Genetics of systemic autoimmunity and glomerulonephritis in mouse models of lupus.Nephrol Dial Transplant 16(Suppl 6):65-67,2001.
 
2) Steinman L:Immune therapy for autoimmune diseases.Science 305(5681):212-216,2004.
PubMed
3) Wang Y,et al:Host modifier genes affect mouse autoimmunity induced by the lpr gene.Am J Pathol 151(6):1791-1798,1997.
PubMed
4) Nishihara M,et al:Genetic basis of autoimmune sialadenitis in MRL/lpr lupus-prone mice:addi-tive and hierarchical properties of polygenic inheritance.Arthritis Rheum 42(12):2616-2623,1999.
 
5) Nakatsuru S,et al:Genetic dissection of the complex pathological manifestations of collagen disease in MRL/lpr mice.Pathol Int 49(11):974-982,1999.
PubMed
6) Qu WM,et al:Genetic dissection of vasculitis in MRL/lpr lupus mice:a novel susceptibility locus involving the CD72c allele.Eur J Immunol 30(7):2027-2037,2000.
PubMed
7) Yamada A,et al:Genetic basis of tissue specificity of vasculitis in MRL/lpr mice.Arthritis Rheum 48(5):1445-1451,2002.
 
8) Oishi H,et al:Accelerating effect of an MRL gene locus on the severity and onset of arthropathy in DBA/1 mice.Arthritis Rheum 52(3):959-966,2005.
PubMed
9) Miyazaki T,et al:Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice.Eur J Immunol 35(5):1510-1520,2005.
PubMed
10) Cantor H,Shinohara ML:Regulation of T-helper-cell lineage development by osteopontin:the inside story.Nat Rev Immunol 9(2):137-141,2009.
PubMed
11) Kurokawa M,et al:Regulatory role of DC-derived osteopontin in systemic allergen sensitization.Eur J Immunol 39(12):3323-3330,2009.
PubMed
12) Kastenmuller W,et al:The in situ dynamics of dendritic cell interactions.Eur J Immunol 40(8):2103-2106,2010.
PubMed
13) Tanaka K,et al:Effect of osteopontin alleles on beta-glucan-induced granuloma formation in the mouse liver.Am J Pathol 164(1):567-575,2004.
 
P.500 掲載の参考文献
1) Lindqvist KJ,Osterland CK:Human antibodies to vascular endothelium.Clin Exp Immunol 96:753-760,1971.
 
2) Bloom O,et al:Generation of a unique small molecule peptidomimetic that neutralizes lupus autoan-tibody activity.Proc Natl Acad Sci USA 108:10255-10259,2011.
 
3) Racanelli V,et al:Autoantibodies to intracellular antigens:Generation and pathogenetic role.Auto-immun Rev 10:503-508,2011.
 
4) Guilpain P,Mouthon L:Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases.Clin Rev Allergy Immunol 35:59-65,2008.
PubMed
5) Shirai T,et al:A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus.Arthritis Res Ther 14:R157,2012.
PubMed
6) Kitamura T,et al:Retrovirus-mediated gene transfer and expression cloning:powerful tools in func-tional genomics.Exp Hematol 31:1007-1014,2003.
 
7) Lacy SE,et al:Identification of FLRT1,FLRT2,and FLRT3:a novel family of transmembrane leu-cine-rich repeat proteins.Genomics 62:417-426,1999.
 
8) Mihai C,Tervaert JW:Anti-endothelial cell antibodies in systemic sclerosis.Ann Rheum Dis 69:319-324,2010.
PubMed
9) Chauhan SK,et al:Antigenic targets and pathogenicity of ant-aortic endothelial cell antibodies in Takayasu arteritis.Arthritis Rheum 54:2326-2333,2006.
 
10) Del Papa N,et al:Anti-endothelial cell IgG antibodies from patients with Wegener's granulomato-sis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion.Arthritis Rheum 39:758-766,1996.
 
11) Ahmed SS,et al:Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing ant-endothelial cell antibodies.Arthritis Rheum 54:2250-2262,2006.
 
12) Roman MJ,et al:Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.N Engl J Med 349:2399-2406,2003.
PubMed
P.505 掲載の参考文献
1) Jennette JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
PubMed
2) Xiao H,et al:Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomeru-lonephritis and vasculitis in mice.J Clin Invest 110:955-963,2002.
 
3) Yoshiki T,et al:The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice.J Exp Med 140:1011-1127,1974.
PubMed
4) Yamazaki H,et al:A wide spectrum of collagen vascular and autoimmune diseases in transgenic rats carrying the env-pX gene of human T lymphocyte virus type I.Int Immunol 9:339-346,1997.
 
5) Nakamaru Y,et al:Immunological hyperresponsiveness in HTLV-I LTR-env-pX transgenic rats:a prototype animal model for collagen vascular and HTLV-1-related inflammatory diseases.Pathobiol-ogy 69:11-18,2001.
 
6) Fugo K,et al:The role of the thymus in development of necrotizing arteritis in transgenic rats car-rying the env-pX gene of human T-cell leukemia virus type-I.Am J Pathol 161:755-761,2002.
 
7) Wu L,et al:Invariant natural killer T cells:innate-like T cells with potent immunomodulatory activities.Tissue Antigens 73:535-545,2009.
PubMed
8) Matsuura A,et al:NKT cells in the rat:organ-specific distribution of NK T cells expressing distinct Vα 14 chains.J Immunol 164:3140-3148,2000.
 
9) Godfrey DI,et al:Raising the NKT cell family.Nat Immunol 11:197-206,2010.
PubMed
10) Coppieters K,et al:A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner.J Immunol 179:2300-2309,2007.
 
11) Bharhani MS,et al:Activation of invariant NKT cells confers protection against Chlamydia trachoma-tis-induced arthritis,Int Immunol 21:859-870,2009.
 
12) Michel ML,et al:Identification of an IL-17-producing NK1.1neg iNKT cell population involved in air-way neutrophilia.J Exp Med 204:995-1001,2007.
 
13) Jung S,et al:Natural killer T cells promote collagen-induced arthritis in DBA/1 mice.Biochem Biophys Res Commun 390:399-403,2009.
PubMed
14) Simoni Y,et al:NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes.Eur J Immunol 41:3574-3585,2011.
PubMed
P.511 掲載の参考文献
1) Smyth L,et al:Microscopic polyangiitis.Semin Respir Crit Care Med 25:523-533,2004.
PubMed
2) Ozaki S:ANCA-associated vasculitis:diagnostic and therapeutic strategy.Allergol Int 56:87-96,2007.
PubMed
3) Merkel PA,et al:Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients With connective tissue disease.Ann Intern Med 126:866-873,1997.
 
4) Kain R,et al:Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.Nat Med 14:1088-1096,2008.
PubMed
5) Monach PA,et al:Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplas-mic antibody-associated vasculitis.Arthritis Rheum 63:3988-3997,2011.
 
6) Karasawa R,et al:Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in sys-temic vasculitis.Cin Exp Immunol 161:459-470,2010.
 
7) Xiang Y,et al:Peptidomics:identification of pathogenic and marker peptides.Methods Mol Biol 615:259-271,2010.
PubMed
8) Xiang Y,et al:Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis:complement C3f-des-arginine,detected predominantly in systemic sclero-sis sera,enhances proliferation of vascular endothelial cells.Arthritis Rheum 56:2018-2030,2007.
 
9) Belka C,et al:Interleukin(IL)-6 signaling leads to phosphorylation of the small heat shock protein(Hsp)27 through activation of the MAP kinase and MAPKAP kinase 2 pathway in monocytes and monocytic leukemia cells.Leukemia 9:288-294,1995.
PubMed
10) Parcellier A,et al:HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation.Mol Cell Biol 23:5790-5802,2003.
PubMed
P.515 掲載の参考文献
1) Falk RJ,Jennette JC:Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.N Engl J Med 318:1651-1657,1988.
PubMed
2) Jennette JC,Falk RJ:Small-vessel vasculitis.N Engl J Med 337:1512-1523,1997.
PubMed
3) Takahashi K,Yamanaka S:Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.Cell 126:663-676,2006.
PubMed
4) Takahashi K,et al:Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell 131:861-872,2007.
PubMed
5) Saha K,Jaenisch R:Technical challenges in using human induced pluripotent stem cells to model disease.Cell Stem Cell 5:584-595,2009.
PubMed
6) Dimos JT,et al:Induced pluripotent stem cells generated from patients with ALS can be differenti-ated into motor neurons.Science 321:1218-1221,2008.
 
7) Ebert AD,et al:Induced pluripotent stem cells from a spinal muscular atrophy patient.Nature 457:269-270,2009.
 
8) Lee G,et al:Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.Nature 461:402-406,2009.
PubMed
9) Carvajal-Vergara X,et al:Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome.Nature 465:808-812,2010.
PubMed
10) Raya A,et al:Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripo-tent stem cells.Nature 460:53-59,2009.
 
11) Taura D,et al:Induction and isolation of vascular cells from human induced pluripotent stem cells-brief report.Atheroscler Thromb Vasc Biol 29:1100-1103,2009.
 
12) Niwa A,et al:A novel serum-free monolayer culture for orderly hematopoietic differentiation of human pluripotent cells via mesodermal progenitors.PLoS One 6:c22261,2011.
PubMed
13) NagaoT,et al:Direct activation of glomerular endothelial cells by ant-moesin activity of anti-myeloperoxidase antibody.Nephrol Dial Transplant 26:2752-2760,2011.
 
14) Lippmann ES,et al:Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells.Nat Biotechnol 30:783-7912012.
PubMed
15) Thatava T,et al:Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation.Stem Cell Res Ther 2:48,2011.
PubMed
P.519 掲載の参考文献
1) 横田俊平:平成22年度厚生労働科学研究報告書 小児期のリウマチ・膠原病の難治性病態と診断と治療に関する研究.
 
2) Ruperto N,et al:EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura,childhood polyar-teritis nodosa,childhood Wegener granulomatosis and childhood Takayasu arteritis:Ankara 2008.Part I:Overall methodology and clinical characterizarion.Ann Rheum Dis 69:790-797,2010.
 
3) Ozen S,et al:EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura,childhood polyarteri-tis nodosa,childhood Wegener granulomatosis and childhood Takayasu arteritis:Ankara 2008.Part II:Final classification criteria.Ann Rheum Dis 69:798-806,2010.
 
4) Ozen S,et al:EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.Ann Rheum Dis 65:936-941,2006.
PubMed
5) Fujikawa S,et al:A Nationwide surveillance study of rheumatic diseases among Japanese children.Acta Peadiatr Jap 39:242-244,1997.
 
6) Kerr GS,et al:Takayasu arteritis.Ann Intern Med 120:919-929,1994.
PubMed
7) Koening CL,et al:Novel therapeutic strategies for large vessel vasculitis.Rheum Dis Clin North Am 32:173-186,2006.
PubMed
8) Mori M,et al:Acquisition of expanded indications for intravenous cyclophosphamide in the manage-ment of childhood rheumatic disease in general.Mod Rheumatol 21:449-457,2011.
 
9) Ozen S,et al:Takayasu arteritis in children:preliminary experience with cyclophosphamide induc-tion and corticosteroids followed by methotrexate.J Pediatr 150:72-76,2007.
 
10) Filocamo G,et al:Treatment of Takayasu's arteritis with tumor necrosis factor antagonists.J Pedi-atr 153:432-434,2008.
 
11) Batu E,et al:Pediatric vasculitis.Curr Rheumatol Rep 14:121-129,2012.
PubMed
12) David J,et al:Polyarteritis nodosa associated with streptococcus.Arch Dis Child 69:685-688,1993.
PubMed
13) Schmidt WA,et al:Use of imaging studies in the diagnosis of vasculitis.Curr Rheumatol Rep 6:203-211,2004.
PubMed
14) Dillon MJ,et al:Medium-size-vesssel vasculitis.Pediatr Nephrol 25:1641-1652,2010.
 
15) Dillon MJ,et al:Vasculitis treatment:new therapeutic apProaches.Eur J pediatr 165:351-357,2006.
PubMed
P.524 掲載の参考文献
1) Ma J,et al:Circulation levels of acute phase proteins in patients with Takayasu arteritis.J Vasc Surg 51:700-706,2010.
PubMed
2) Koga T,et al:Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu's arteritis.Rheumatol Int 30:561-563,2010.
PubMed
3) Nishino Y,et al:Serum levels of BAFF for assessing the disease activity of Takayasu arteritis.Clin Exp Rheumatol 28:14-17,2010.
PubMed
4) Ishihara T,et al:Sensitive assessment of activity ofTakayasu's arteritis by pentraxin3,a new biomarker.J Am Coll Cardiol 57:1712-1713,2011.
 
5) Dagna L,et al:Pentraxin-3 as a marker of disease activity in Takayasu arteritis.Ann Intern Med 155:425-433,2011.
PubMed
6) Karasawa R et al:Peroxiredoxin 2 is a novel autoantigen for ant-endothelial cell antibodies in sys-temic vasculitis.Clin Exp Immunol 161:459-470,2010.
 
7) 唐澤里江:プロテオミクスを用いた血管炎症候群における疾患特異的マーカーの検出.聖マリアンナ医科大学雑誌 37:105-109,2009.
Medical*Online
8) Park MC,et al:Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu's arteri-tis:correlations of their titers and isotype distributions with disease activity.Clin Exp Rheumatol 24:S10-16,2006.
 
9) Yang YH,et al:The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schonlein purpura.Clin Exp Immunol 130:352-357,2002.
PubMed
10) Heurkens AH,et al:Anti-endothelial cell antibodies in patients with rheumatoid arthritis compli-cated by vasculitis.Clin Exp Immunol 78:7-12,1989.
 
11) Navarro M,et al:Anti-endothelial cell antibodies in systemic autoimmune diseases:prevalence and clinical significance.Lupus 6:521-526,1997.
PubMed
12) Aydintug AO,et al:Antibodies to endothelial cells in patients with Behcet's disease.Clin Immunol Immunopathol 67:157-162,1993.
PubMed
13) Fujieda M,et al:A novel anti-peroxiredoxin autoantibody in patients with Kawasaki disease.Micro-biol Immunol 56:56-61,2012.
 
14) Chevallet M,et al:Regeneration of peroxiredoxins during recovery after oxidative stress:only some overoxidized peroxiredoxins can be reduced during recovery after oxidative stress.J Biol Chem 278:37146-37153,2003.
PubMed
15) Lee SP,et al:Cyclophilin A binds to peroxiredoxins and activates its peroxidase activity.J Biol Chem 276:29826-29832,2001.
PubMed
P.528 掲載の参考文献
1) Fiedler U,Augustin HG:Angiopoietins:a link between angiogenesis and inflammation.Trends Immunol 27:552-558,2006.
PubMed
2) Thomus M,Augustin HG:The role of angiopoietins in vascular morphogenesis.Angiogenesis 12:125-137,2009.
 
3) Fiedler U,et al:Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation.Nat Med l2:235-239,2006.
 
4) Kumpers P,et al:The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.Ann Rheum Dis 68:1638-1643,2009.
PubMed
5) Westra J,et al:Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease.Rheumatology 50:665-673,2011.
PubMed
6) Kumpers P,et al:Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement.Nephrol Dial Transplant 24:1845-1850,2009.
PubMed
7) Yuan HT,et al:Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis.Kidney Int 61:2078-2089,2002.
PubMed
8) David S,et al:Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.Nephrol Dial Transplant 25:2571-2579,2010.
PubMed
9) Michalska-Jakubus M,et al:Angiopoietins-1 and-2 are differentially expressed in the sera of patients with systemic sclerosis:high angiopoietin-2 levels are associated with greater severity and higher activity of the disease.Rheumatology 50:746-755,2010.
PubMed
P.533 掲載の参考文献
1) Weaver CT,et al:IL-17 family cytokines and the expanding diversity of effector T cell lineages.Annu Rev Immunol 25:821-852,2007.
PubMed
2) Saadoun D,et al:Interleukin-25:key regulator of inflammatory and autoimmune diseases.Curr Pharm Des 17:3781-3785,2011.
PubMed
3) Tamachi T,et al:IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice.J Allergy Clin Immunol 118:606-614,2006.
PubMed
4) Ballantyne SJ,et al:Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma.J Allergy Clin Immunol 20:1324-1331,2007.
 
5) Corrigan CJ,et al:Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic air-ways and late-phase cutaneous responses.J Allergy Clin Immunol 128:116-124,2011.
 
6) Terrier B,et al:Interleukin-25:a cytokine linking eosinophils and adaptive immunity in Churg-syndrome.Blood 116:4523-4531,2010.
PubMed
7) DunogueB,et al:Churg-strauss syndrome:clinical symptoms,complementary investigations,prognosis and outcome,and treatment.Semin Respir Crit Care Med 32:298-309,2011.
PubMed
8) Petersen BC,et al:Interleukin-25 induces type 2 cytokine production in a steroid-resistant inter-leukin-17RB+ myeloid population that exacerbates asthmatic pathology.Nat Med 18:751-758,2012.
 
P.538 掲載の参考文献
1) 有村義宏,長澤俊彦:ANCA関連血管炎.日本臨牀 60(増刊号1):461-470,2002.
 
2) Falk RJ,et al:Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and pro-duce oxygen radicals in vitro.Proc Natl Acad Sci USA 87:4115-4119,1990.
 
3) Kawashima S,et al:MPO-ANCA関連腎炎における糸球体内MPO陽性細胞及び細胞外MPOについての腎病理組織学的検討.日腎会誌 51:56-67,2009.
 
4) Ramani P,et al:QBEND/10,a new monoclonal antibody to endothelium:Assessment of its diag-nostic utility in paraffin sections.Histopathology 17:237-242,1990.
 
5) Cockwell P,et al:Interleukin-8:A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis.Kidney Int 55:852-863,1999.
PubMed
6) Savage CO,et al:Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vascu-litis stimulate neutrophil cytotoxicity toward cultured endothelial cells.Am J Pathol 141(2):335-342,1992.
 
7) Minoshima S,et al:Increased release of myeloperoxidase in vitro from neutrophils of patients with myeloperoxidase-specific anti-neutrophil cytoplasmic antibody(MPO-ANCA) related glomerulo-nephritis.Nephrology 3:527-534,1997.
 
8) Arimura Y,et al:Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis.Clin Nephrol 40:256-264,1993.
PubMed
9) Bejama IM,et al:Colocalization of ANCA-antigens and fibrinoid necrosis in ANCA-associated vasculitis.Kidney Int 60:2025-2030,2001.
 
10) Johnson RJ,et al:New mechanism for glomerular injury myloperoxidase-hydrogen peroxidase-hal-ide system.J Clin Invest 79:1379-1387,1987.
 
11) Johnson RJ,et al:Morphologic correlates of glomerular oxidant injury induced by the myeloperoxi-dase-hydrogen peroxide-halide system of the neutrophil.Lab Invest 58:294-301,1988.
 
12) Fujii A,et al:Epitope analysis of mycloperoxidase(MPO) specific anti-neutrophil cytoplasmic auto-antibodies(ANCA) in MPO-ANCA associated glomerulonephritis.Clin Nephrol 53:242-252,2000.
 
13) Kobayashi K,et al:Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies.Kidney Int 47:454-463,1995.
PubMed
14) Kawashima S,et al:Immunopathologic co-localization of MPO,IgG,and C3 in glomeruli in human MPO-ANCA-associated glomerulonephritis.Clin Nephrol(in press)
 
15) Kessenbrock K,et al:Netting neutrophils in autoimmune small-vessel vasculitis.Nat Med 15(6):623,2009.
PubMed
P.546 掲載の参考文献
1) Nagano Y,Kojima Y:Immunizing property of vaccinia virus inactivated by ultraviolets rays.C R Seances Soc Biol Fil 148:1700-1702,1954.
 
2) Nagano Y,Kojima Y:Inhibition of vaccinia infection by a liquid factor in tissues infected by homolo-gous virus.C R Seances Soc Biol Fil 152:1627-1629,1958.
 
3) Isaacs A,Lindenmann J:Virus interference.I.The interferon.Proc R Soc Lond B Biol Sci 147:258-267,1957.
PubMed
4) Isaacs A,et al:Virus interference.II.Some properties of interferon.Proc R Soc Lond B Biol Sci 147:268-273,1957.
PubMed
5) Taniguchi T,et al:Construction and identification of a bacterial plasmid containing the human fbro-blast interferon gene sequence.Proc Jpn Acad 55B,464-469,1979.
 
6) Nagata S,et al:Synthesis in E.coli of a polypeptide with human leukocyte interferon activity.Nature 284:316-320,1980.
 
7) Kotenko SV,et al:IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.Nat Immunol 4:69-77,2003.
PubMed
8) Sheppard P,et al:IL-28,IL-29 and their class II cytokine receptor IL-28R.Nat Immunol 4:63-68,2003.
PubMed
9) Feldman M,Fitzgerald-Bocarsly P:Sequential enrichment and immunocytochemical visualization of human interferon-alpha-producing cells.J Interferon Res 10(4):435-446,1990.
 
10) Yoneyama M,et al:The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.Nat Immunol 5:730-737,2004.
PubMed
11) Reid LM,et al:Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice.Proc Natl Acad Sci USA 78(2):1171-1175,1981.
PubMed
12) Dunn GP,et al:Interferons,immunity and cancer immunoediting.Nat Rev Immunol 6(11)836-848,2006.
PubMed
13) Takaoka A,Taniguchi T:New aspects of IFN-alpha/beta signalling in immunity,oncogenesis and bone metabolism.Cancer Sci 94:405-411,2003.
PubMed
14) Uno K,et al:A bioassay for serum interferon based on induction of 2',5'-oligoadenylate synthetase activity.J Interferon Cytokine Res 18:1011-1018,1998.
PubMed
15) Onomoto K,et al:Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C.PLoS One 6(5):e19799,2011.
PubMed
16) Honda K,Taniguchi T:IRFs:master regulators of signalling by Toll-like receptors and cytosolic pat-tern-recognition receptors.Nat Rev Immunol 6(9):644-658,2006.
 
17) Takaoka A,et al:Integration of interferon-alpha/beta signalling to p53 responses in tumour sup-pression and antiviral defence.Nature 424(6948):516-523,2003.
 
18) Uno K,et al:Determination of IFN(-α) producing capacity in whole-blood cultures from patients with various diseases and from healthy persons.J Interferon Cytokine Res 16:911-918,1996.
 
19) Uno K,et al:Impaired IFN-alpha production and the risk of cancer development J Interferon Cyto-kine Res 27:1013-1017,2007.
 
P.553 掲載の参考文献
1) Kawakami T,et al:Elevated anti-lysosomal-associated membrane protein-2 antibody levels in patients with adult Henoch-Schonlein purpura.Br J Dermatol 166:1206-1212,2012.
PubMed
2) Kawakami T:New algorithm(KAWAKAMI algorithm) to diagnose primary cutaneous vasculitis.J Dermatol 37:113-124,2010.
PubMed
3) Kain R,et al:Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.Nat Med 14:1088-1096,2008.
PubMed
4) Kawakami T,et al:Elevated serum IgA anticardiolipin antibody levels in adult Henoch-Schonlein purpura.Br J Dermatol 155:983-987,2006.
PubMed
5) Kawakami T,et al:High titer of serum antiphospholipid antibody levels in adult Henoch-Schonlein purpura and cutaneous leukocytoclastic angiitis.Arthritis Rheum 59:561-567,2008.
PubMed
P.558 掲載の参考文献
1) Cervera R,et al:Antiphospholipid syndrome:Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Arthritis Rheum 46:1019,2002.
 
2) Frances C,et al:Dermatologic manifestations of the antiphospholipid syndrome:Two hundred con-secutive cases.Arthritis Rheum 52:1785,2005.
 
3) 宮崎龍彦,大西誠:血管炎を伴った抗リン脂質抗体症候群.病理と臨床 23(Suppl):218,2005.
 
4) Lee JS,et al:Lymphocytic thrombophilic arteritis:a newly described medium-sized vessel arteritis of the skin.Arch Dermatol 144:1175,2008.
PubMed
5) Pierangeli SS,et al:Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.Circulation 99:1997,1999.
PubMed
6) Girardi G,et al:Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting comple-ment activation.Nat Med 10:1222,2004.
 
7) Oku K,et al:Complement activation in patients with primary antiphospholipid syndrome.Ann Rheum Dis 68(6):1030-1035,2009.
PubMed
8) Girardi G,et al:Complement C5a receptors and neutrophils mediate fetal injury in the antiphos-pholipid syndrome.J Clin Invest 112:1644-1654,2003.
 
9) Pierangeli SS,et al:Requirement of activation of complement C3 and C5 for antiphospholipid anti-body-mediated thrombophilia.Arthritis Rheum 52:2120-2124,2005.
 
10) Lonze BE,et al:Eculizumab and renal transplantation in a patient with CAPS.N Engl J Med 362:1744-1745,2010.
 
P.563 掲載の参考文献
1) Kobayashi O:Clinical role of autoantibody against bactericidal/permeability-increasing protein in chronic airway infection.J Infect Chemother 4:83-93,1998.
 
2) Schultz H,et al:BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infec-tion and recognise exclusively the C-terminal part of the BPI molecule.Scand J Rheumatol 29:226-231,2000.
 
3) Schultz H,et al:Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein(BPI) in pediatric cystic fibrosis patients do not recognize N-termi-nal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.Pediat-ric Allergy Immunol 11:64-70,2000.
PubMed
4) Sediva A,et al:Antineutrophil cytoplasmic antibodies against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa.Microbes Infect 5:27-30,2003.
PubMed
5) Mahadeva R,et al:Anti-neutrophil cytoplasmic antibodies(ANCA) against bactericidal/permeability-increasing protein(BPI) and cystic fibrosis lung disease.Clin Exp Immunol 117:561-567,1999.
PubMed
6) Ohtami S,et al:Analysis of interactive factors in chronic airway infections.J Infect Chemother 7:228-238,2001.
 
7) Kaplan HB,Greenberg EP:Diffusion of autoinducer is involved in regulation of the Vibrio fischeri luminescence system.J Bacteriol 163:1210-1214,1985.
PubMed
8) Tateda K,et al:Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.Antimicrob Agents Chemother 45:1930-1933,2001.
PubMed
9) Jensen PO,et al:Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sens-ing-controlled production of rhamnolipid by Pseudomonas aeruginosa,Microbiology 153:1329-1338,2007.
 
10) Bjarnsholt T,et al:Pseudomonas aeruginosa tolerance to tobramycin,hydrogen peroxide and poly-morphonuclear leukocytes in quorum-sensing dependent.Microbiology 151:373-383,2005.
 

IX 特論

P.573 掲載の参考文献
1) Siegal FP,et al:The nature of the principal type 1 interferon-producing cells in human blood.Sci-ence 284:1835-1837,1999.
 
2) Serbina NV,et al:TNF/iNOS-producing dendritic cells mediate innate immune defense against bac-terial infection.Immunity 19:59-70,2003.
 
3) Saeki H,et al:Cutting edge:secondary lymphoid-tissue chemokine(SLC) and CC chemokine receptor 7(CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes.J Immunol 162:2472-2475,1999.
PubMed
4) Liu K,et al:Immune tolerance after delivery of dying cells to dendritic cells in situ.J Exp Med 196:1091-1097,2002.
 
5) Inaba K,et al:Efficient presentation of phagocytosed cellular fragments on the major histocompati-bility complex class II products of dendritic cells.J Exp Med 188:2163-2173,1998.
 
6) Grouard G,et al:The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin(IL)-3 and CD40-ligand.J Exp Med 158:1101-1112,1997.
 
7) Rimbert M,et al:Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis.PLoS One 6:e18734,2011.
PubMed
8) Wilde B,et al:Dendritic cells in renal biopsies of patients with ANCA-associated vasculitis.Neph-rol Dial Transplant 24:2151-2215,2009.
 
9) Scoppet M,et al:CD83+ dendritic cells in inflammatory infiltrates of Churg-Strauss myocarditis.Arch Pathol Lab Med 127:98-101,2003.
 
10) Csernok E,et al:Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway.Blood 107:4440-4448,2006.
PubMed
11) Ma-Krupa W,et al:Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis.J Exp Med 199:173-183,2004.
PubMed
12) Inder SJ,et al:Immunophenotypic analysis of the aortic wall in Takayasu's arteritis:involvement of lymphocytes,dendritic cells and granulocytes in immuno-inflammatory reactions.Cardiovasc Surg 8:141-148,2000.
PubMed
13) Yilmaz A,et al:Activated myeloid dendritic cells accumulate and co-localize with CD3+ T cells in coronary artery lesions in patients with Kawasaki disease.Exp Mol Pathol 83:93-103,2007.
PubMed
14) Han JW,et al:Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascu-lar inflammation.Circ Res 102:546-553,2009.
 
15) Wakim LM,et al:Dendritic cell-induced memory T cell activation in nonlymphoid tissues.Science 319:198-202,2008.
PubMed
P.580 掲載の参考文献
1) Brand D:D,et al:Collagen-induced arthritis.Nat Protoc 2(5):1269-1275,2007.
PubMed
2) Inglis JJ,et al:Protocol for the induction of arthritis in C57BL/6 mice.Nat Protoc 3(4):612-618,2008.
PubMed
3) Khachigian LM:Collagen antibody-induced arthritis.Nat Protoc 1(5):2512-2516,2006.
PubMed
4) Kouskoff V,et al:Organ-specific disease provoked by systemic autoimmunity.Cell 87(5):811-822,1996.
PubMed
5) Matsumoto I,et al:Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme.Sci-ence 286(5445):1732-1735,1999.
 
6) Monach PA,et al:The role of antibodies in mouse models of rheumatoid arthritis,and relevance to human disease.Adv Immunol 82:217-248,2004.
PubMed
7) Sakaguchi N,et al:Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.Nature 426(6965):454-460,2003.
PubMed
8) Yoshitomi H,et al:A role for fungal β-glucans and their receptor Dectin-1 in the induction of auto-immune arthritis in genetically susceptible mice.J Exp Med 201(6):949-960,2005.
 
9) Iwakura Y:Roles of IL-1 in the development of rheumatoid arthritis:consideration from mouse models.Cytokine Growth Factor Rev 13(4-5):341-355,2002.
 
10) Horai R,et al:Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice.J Exp Med 191(2):313-320,2000.
PubMed
12) Kontoyiannis D,et al:Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements:implications for joint and gut-associated immunopathologies.Immunity 10(3):387-398,1999.
PubMed
13) Kamimura D,et al:IL-6 signal transduction and its physiological roles:the signal orchestration model.Rev Physiol Biochem Pharmacol 149:1-38,2003.
PubMed
14) Ohtani T,et al:Dissection of signaling cascades through gp130 in vivo:reciprocal roles for STAT3-and SHP2-mediated signals in immune responses.Immunity 12(1):95-105,2000.
PubMed
15) Iwakura Y,et al:Functional specialization of interleukin-17 family members.Immunity 34(2):149-162,2011.
PubMed
16) Billiau A,Matthys P:Collagen-induced arthritis and related animal models:how much of their pathogenesis is auto-immune,how much is auto-inflammatory? Cytokine Growth Factor Rev 22(5-6):339-344,2011.
 
P.585 掲載の参考文献
1) Wick G,et al:Atherosclerosis,autoimmunity,and vascular-associated lymphoid tissue.FASEB J 11:1199-1207,1997.
PubMed
2) Jongstra-Bilen J,et al:Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis.J Exp Med 203:2073-2083,2006.
PubMed
3) Galkina E,et al:Lymphocyte recruitment into the aortic wall before and during development of athe-rosclerosis is partially L-selectin dependent.J Exp Med 203:1273-1282,2006.
 
4) Zhu J,et al:Differentiation of effector CD4 T cell populations.Annu Rev Immunol 28:445-489,2010.
PubMed
5) Staudt V,et al:Interferon-egulatory factor 4 is essential for the developmental program of T helper 9 cells.Immunity 33:192-202,2010.
 
6) Chang HC,et al:The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation.Nat Immunol 11:527-534,2010.
PubMed
7) Angkasekwinai P,et al:Regulation of IL-9 expression by IL-25 signaling.Nat Immunol 11:250-256,2010.
PubMed
8) Ye P,et al:Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulo-cyte colony-stimulating factor expression,neutrophil recruitment,and host defense.J Exp Med 194:519-527,2001.
 
9) Ivanov S,et al:Functional relevance of the IL-23-IL-17 axis in lungs in vivo.Am J Respir Cell Mol Biol 36:442-451,2007.
PubMed
10) Zheng Y,et al:Interleukin-22,a T(H)17 cytokine,mediates IL-23-induced dermal inflammation and acanthosis.Nature 445:648-651,2007.
 
11) Gottlieb A,et al:Ustekinumab,a human interleukin 12/23 monoclonal antibody,for psoriatic arthri-tis:randomised,double-blind,placebo-controlled,crossover trial.Lancet 373:633-640,2009.
 
12) von Vietinghoff S,et al:Interleukin 17 in vascular inflammation.Cytokine Growth Factor Rev 21:463-469,2010.
PubMed
13) Abdulahad WH,et al:T-helper cells as new players in ANCA-associated vasculitides.Arthritis Res Ther 13:236,2011.
PubMed
14) Kallenberg CG:Pathophysiology of ANCA-associated small vessel vasculitis.Curr Rheumatol Rep 12:399-405,2010.
PubMed
15) Xiao H,et al:Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomeru-lonephritis and vasculitis in mice.J Clin Invest 110:955-963,2002.
 
16) Finkielman JD,et al:Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.Ann Intern Med 147:611-619,2007.
PubMed
17) Falk RJ,Jennette JC:ANCA small-vessel vasculitis.J Am Soc Nephrol 8:314-322,1997.
PubMed
18) van der Geld YM,et al:Rats and mice immunised with chimeric human/mouse proteinase 3 pro-duce autoantibodies to mouse Pr3 and rat granulocytes.Ann Rheum Dis 66:1679-1682,2007.
 
19) Lockwood CM,et al:Long-term remission of intractable systemic vasculitis with monoclonal anti-body therapy.Lancet 341:1620-1622,1993.
 
20) Schmitt WH,et al:Treatment of refractory Wegener's granulomatosis with antithymocyte globulin(ATG):an open study in 15 paticnts.Kidney Int 65:1440-1448,2004.
 
21) Marinaki S,et al:Persistent T-cell activation and clinical correlations in patients with ANCA-asso-ciated systemic vasculitis.Nephrol Dial Transplant 21:1825-1832,2006.
 
22) Popa ER,et al:In vitro cytokine production and proliferation of T cells from patients with anti-pro-teinase 3- and antimyeloperoxidase-associated vasculitis,in response to proteinase 3 and myeloperoxidase.Arthritis Rheum 46:1894-1904,2002.
 
23) Brouwer E,et al:Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoan-tibodies(ANCA) in patients with Wegener's granulomatosis and clinically related disorders.Clin Exp Immunol 83:379-386,1991.
 
24) Ruth AJ,et al:Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis.J Am Soc Nephrol 17:1940-1949,2006.
PubMed
25) Abdulahad WH,et al:Skewed distribution of Th17 lymphocytes in patients with Wegener's granulo-matosis in remission.Arthritis Rheum 58:2196-2205,2008.
 
26) Nogueira E,et al:Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis.Nephrol Dial Transplant 25:2209-2217,2010.
PubMed
27) Saito H,et al:Cytokine production profile of CD4+ T cells from patients with active Churg-Strauss syndrome tends toward Th17.Int Arch Allergy Immunol 149(Suppl 1):61-65,2009.
 
28) Terrier B,et al:Interleukin-25:a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome.Blood 116:4523-4531,2010.
PubMed
29) Hori S:Developmental plasticity of Foxp3+ regulatory T cells.Curr Opin Immunol 22:575-582,2010.
PubMed
30) Ly KH,et al:Pathogenesis of giant cell arteritis:More than just an inflammatory condition? Auto-immun Rev 9:635-645,2010.
 
31) Deng J,et al:Th17 and Th1 T-cell responses in giant cell arteritis.Circulation 121:906-915,2010.
PubMed
32) Weyand CM,et al:IFN-gamma and IL-17:the two faces of T-cell pathology in giant cell arteritis.Curr Opin Rheumatol 23:43-49,2011.
PubMed
33) Arnaud L,et al:Pathogenesis of Takayasu's arteritis:a 2011 update.Autoimmun Rev 11:61-67,2011.
PubMed
34) Radtke F,et al:Notch regulation of lymphocyte development and function.Nat Immunol 5:247-253,2004.
PubMed
35) Piggott K,et al:Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis.Circulation 123:309-318,2011.
PubMed
36) Lubberts E:IL-17/Th17 targeting:on the road to prevent chronic destructive arthritis? Cytokine 41:84-91,2008.
PubMed
37) Genovese MC,et al:LY2439821,a humanized anti-interleukin-17 monoclonal antibody,in the treatment of patients with rheumatoid arthritis:A phase I randomized,double-blind,placebo-controlled,proof-of-concept study.Arthritis Rheum 62:929-939,2010.
PubMed
38) Hueber W,et al:Effects of AIN457,a fully human antibody to interleukin-17A,on psoriasis,rheu-matoid arthritis,and uveitis.Sci Transl Med 2:52ra72,2010.
 
P.592 掲載の参考文献
1) Direskeneli H,et al:Assessment of disease activity and progression in Takayasu's arteritis.Clin Exp Rheumatol 29:S86-S91,2011.
PubMed
2) Brunner J,et al:Takayasu arteritis in children and adolescents.Rheumatology(Oxford) 49:1806-1814,2010.
PubMed
3) Mason JC:Takayasu arteritis-advances in diagnosis and management.Nat Rev Rheumatol 6:406-415,2010.
PubMed
4) Kobayashi S,et al:Anti-neutrophil cytoplasmic antibody-associated vasculitis,large vessel vasculi-tis and Kawasaki disease in Japan.Kidney Blood Press Res 33:442-455,2010.
 
5) Miller DV,Maleszewski JJ:The pathology of large-vessel vasculitides.Clin Exp Rheumatol 29:S92-S98,2011.
PubMed
6) Blockmans D:PET in vasculitis.Ann N Y Acad Sci 1228:64-70,2011.
PubMed
7) Kobayashi S,et al:Expression profiling of PBMC-based diagnostic gene markers isolated from vas-culitis patients.DNA Res 15:253-265,2008.
 
8) Okuzaki D,et al:Genopal(TM):a novel hollow fiber array for focused microarray analysis.DNA Res 17:369-379,2010.
 
9) Lv N,et al:The role of tumor necrosis factor-α promoter genetic variation in Takayasu arteritis sus-ceptibility and medical treatment.J Rheumatol 38:2602-2607,2011.
 
10) Okuzaki D,et al:Ficolin 1 expression is elevated in the peripheral blood mononuclear cells of Taka-yasu's vasculitis patients.J Mol Biomark Diagn 3(3),2012.
 
11) Zhang J,et al:Secreted M-ficolin anchors onto monocyte transmembrane G protein-coupled receptor 43 and cross talks with plasma C-reactive protein to mediate immune signaling and regu-late host defense.J Immunol 185:6899-6910,2010.
 
12) Okuzaki D,et al:LeukoCatch,a quick and efficient tool for the preparation of leukocyte extracts from blood.BMC Clin Pathol 11(1):9,2011.
PubMed
13) Okamoto A,et al:A simple and efficient method for the preparation of live leukocytes from periph-eral blood using the LeukoCatch(TM) system.Adv Biosci Biotech 3(5):630-642,2012.
 
P.599 掲載の参考文献
1) Murata H,Naoe S:Experimental Candida-induced arteritis in mice-relation to arteritis in Kawa-saki disease.Prog Clin Biol Res 250:523,1987.
 
2) Ohno N:A murine model of vasculitis induced by fungal polysaccharide.Cardiovasc Hematol Agents Med Chem 6:44-52,2008.
PubMed
3) Shinohara H,et al:Beta-mannosyl linkages negatively regulate anaphylaxis and vasculitis in mice,induced by CAWS,fungal PAMPS composed of mannoprotein-beta-glucan complex secreted by Candida albicans.Biol Pharm Bull 29:1854-1861,2006.
PubMed
4) Hirata N,et al:A Histopathological examination and analysis of mortality in DBA/2 mouse vasculitis induced with CAWS,a water-soluble extracellular polysaccharide fraction obtained from Candida albicans.Yakugaku Zasshi 126:643-650,2006.
 
5) Hirata N,et al:Model of Left Ventricular Dysfunction Complicated by CAWS Arteritis in DBA/2 Mice.Int J Vasc Med 2012:570297,2012.
PubMed
6) Tada R,et al:Vasculitis and anaphylactoid shock in mice induced by the polysaccharide fraction secreted into culture supernatants by the fungus Candida metapsilosis.Microbiol Immunol 55:357-365,2011.
PubMed
7) Saijo S,et al:Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans.Immunity 32:681-691,2010.
PubMed
8) Miura NN,et al:IL-10 is a negative regulatory factor of CAWS-vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice.J Immunol 183:3417-3424,2009.
PubMed
9) Nagi-Miura N:The negative regulatory factor of CAWS(Candida albicans water-soluble fraction)-vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice.Med Mycol J 53:25-31,2012.
PubMed
10) Sargent J,et al:Candida albicans-associated necrotizing vasculitis producing life-threatening gas-trointestinal hemorrhage.Hum Pathol 41:602-604,2010.
 
大野尚仁:CAWSによって惹起される致死的血管炎モデル-CAWS惹起冠状動脈炎.医学のあゆみ 214(1):13-18,2005.
Medical*Online
高橋啓,直江史郎:分子誘導型モデル動物-Candida albicans菌体成分による動脈炎誘発モデル.医学のあゆみ 206(2):147-149,2003.
Medical*Online
三浦典子ほか:CAWS血管炎惹起の分子メカニズム.日医真菌会誌 49(4):287-292,2008.
 
P.604 掲載の参考文献
1) 布井博幸:慢性肉芽腫症研究の新たな展開.日臨免誌 30:1-10,2007.
 
2) Roos D,et al:Hematologically important mutations:the autosomal recessive forms of chronic granu-lomatous disease(second update).Blood Cells Mol Dis 44:291-299,2010.
 
3) Ishibashi F,et al:Improved superoxide-generating ability by interferon gamma due to splicing pat-tern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene.Blood 98:436-441,2001.
 
4) Kuhns DB,et al:Residual NADPH oxidase and survival in chronic granulomatous disease.N Engl J Med 363:2600-2610,2010.
PubMed
5) Roos D,et al:Hematologically important mutations:the autosomal recessive forms of chronic granu-lomatous disease(second update).Blood Cells Mol Dis 44:291-299,2010.
 
6) Roesler J,et al:Recombination events between the p47-phox gene and its highly homologous pseu-dogenes are the main cause of autosomal recessive chronic granulomatous disease.Blood 95:2150-2156,2000.
 
7) Dinauer MC,et al:Point mutation in the cytoplasmic domain of the neutrophil p22-phox cyto-chrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease.Proc Natl Acad Sci USA 88:11231-11235,1991.
 
8) Matute JD,et al:A new genetic subgroup of chronic granulomatous disease with autosomal reces-sive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity.Blood 114:3309-3315,2009.
 
9) Schappi M,et al:Branched fungal beta-glucan causes hyperinflammation and necrosis in phago-cyte NADPH oxidase-deficient mice.J Pathol 214:434-444,2008.
 
10) Frasch SC,et al:NADPH oxidase-dependent generation of lysophosphatidylserine enhances clear-ance of activated and dying neutrophils via G2A.J Biol Chem 283:33736-33749,2008.
 
11) van de Veerdonk FL,et al:Reactive oxygen species-independent activation of the IL-1β inflamma-some in cells from patients with chronic granulomatous disease.Proc Natl Acad Sci USA 107:3030-3033,2010.
 
P.610 掲載の参考文献
1) 有村義宏ほか:ミエロペルオキシダーゼに対する抗好中球細胞質抗体陽性症例における肺病変の検討.リウマチ 35:46-55,1995.
 
2) Homma S,et al:Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associ-ated vasculitis.Respirology 9:190-196,2004.
 
3) Fujimoto S,et al:Incidence of ANCA associated primary renal vasculitis in Miyazaki Prefecture:The first population-based,retrospective epidemiological survey in Japan.Clin J Am Soc Nephrol 1:1016-1022,2006.
PubMed
4) Guillevin L,et al:Microscopic polyangiitis.Arthritis Rheum 42:421-430,1999.
PubMed
5) Foulon G,et al:ANCA-associated lung fibrosis:analysis of 17 patients.Respir Med 102:1392-1398,2008.
PubMed
6) 徳永大道ほか:臨床的にIPF/UIPと診断した症例の9.6%がMPO-ANCA陽性であった.日呼吸会誌 41(Suppl 1):102,2003.
 
7) Nozu T,et al:A comparison of the clinical features of ANCA-positive and ANCA-negative idio-pathic pulmonary fibrosis patients.Respiration 77:407-415,2009.
 
8) Cottin V,et al:Pulmonary hypertension in patients with combined pulmonary fibrosis and emphy-sema syndrome.Eur Respir J 35:105-111,2010.
 
9) Hervier B,et al:Pulmonary fibrosis associated with ANCA-positive vasculitides.Retrospective study of 12 cases and review of the literature.Ann Rheum Dis 68:404-407,2009.
PubMed
10) Tzelepis GE,et al:Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis.Eur Respir J 36:116-121,2010.
PubMed
11) Arulkumaran N,et al:Interstitial lung disease and ANCA-associated vasculitis:a retrospective observational cohort study.Rheumatology 50:2035-2043,2011.
PubMed
12) Yamada H:ANCA-associated lung fibrosis.Semin Respir Crit Care Med 32:322-327,2011.
PubMed
13) Ozaki S,et al:Severity-based treatment for Japanese patients with MPO-ANCA-associated vascu-litis:the JMAAV study.Mod Rheumatol 23:394-404,2012.
 
14) Schnabel A,et al:Subclinical alveolar bleeding in pulmonary vasculitides:correlation with indices of disease activity.Eur Respir J 14:118-124,1999.
PubMed
15) Foucher P,et al:Antimyeloperoxidase-associated lung disease.An experimental model.Am J Respir Crit Care Med 160:987-994,1999.
PubMed
P.616 掲載の参考文献
1) Gaskin G,et al:Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis.Nephrol Dial Transplant 6:689-694,1991.
PubMed
2) Boomsm MM,et al:Prediction of relapses in Wegener's granulomatosis by measurement of antineu-trophil cytoplasmic antibody levels:a prospective study.Arthritis Rheum 43:2025-2033,2000.
 
3) Terrier B,et al:Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutro-phil cytoplasmic antibody-associated vasculitides.Ann Rheum Dis 68:1564-1571,2009.
 
4) Finkielman JD,et al:Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.Ann Intern Med 147:611-619,2007.
PubMed
5) Tomasson G,et al:Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis.-a meta analysis.Rheumatology 51:100-109,2012.
PubMed
P.622 掲載の参考文献
1) Nishioka Y,et al:Mizoribine induces remission of relapsed ANCA-associated renal vasculitis.Nephrol Dial Transplant 21(4):1087-1088,2006.
PubMed
2) 森雅亮,横田俊平:顕微鏡的結節性多発動脈炎.小児内科 28(4):558-562,1996.
 
3) 岸本憲明ほか:治療前後において病理組織学的改善を認めたMPO-ANCA陽性の急速進行性糸球体腎炎の1例.砂川市立病院医学雑誌 15(5):5-7,1998.
 
4) 井上康ほか:IgG型リウマトイド因子が病勢に関与していると考えられるP-ANCA陽性壊死性血管炎の一症例.臨床リウマチ 10(4):287-292,1998.
 
5) 武田誠司ほか:MPO-ANCA関連血管炎に関する臨床的検討.九州リウマチ 23(2):217-221,2004.
 
6) 有村義宏ほか:ANCA関連血管炎-顕微鏡的多発血管炎の臨床像・予後の変遷およびMPO-ANCA関連血管炎におけるミゾリビン治療についての検討-.臨床リウマチ 17(4):290-296,2005.
 
7) 岡村和美ほか:学校検尿を契機に発見されたANCA関連腎炎の1例.日小児腎臓病会誌 20(1):48-51,2007.
 
8) 折口智樹ほか:ANCA関連血管炎の病態と治療における最近の知見.日臨免疫会誌 30(6):432-443,2007.
 
9) 橋本有紀子,川勝秀一:ANCA関連腎炎の1女児例.日小児腎臓病会誌 21(2):176-181,2008.
 
10) 川尻真也ほか:肺胞出血および急速進行性糸球体腎炎により再燃した顕微鏡的多発血管炎の一例.日臨免疫会誌 32(3):189-194,2009.
 
11) Tokunaga M,et al:A case report of steroid-resistant antineutrophil cytoplasmic antibody-related vasculitis successfully treated by mizoribine in a hemodialysis patient.Ther Apher Dial 13(1):77-79,2009.
 
12) Fujita S,et al:Mizoribine reduces serum KL-6 levels in ANCA-associated vasculitis.Clin Exp Nephrol 14(2):203-204,2010.
PubMed
13) Hirayama K,et al:Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis.Am J Kidney Dis 44(1):57-63,2004.
PubMed
14) Sonda K,et al:Clinical pharmacokinetic study of mizoribine in renal transplantation patients.Trans-plant Proc 28(6):3643-3648,1996.
 
15) 湯村和子ほか:ループス腎炎における免疫抑制剤ミゾリビンの血中濃度の評価.腎と透析 47(5):705-708,1999.
 
16) 高田寛治ほか:腎移植患者における Bredinin の clinical pharmacokinetic study.移植 17(Suppl):595-601,1982.
 
17) 越川昭三ほか:ステロイド抵抗性ネフローゼ症候群に対する HE-69(mizoribine)の臨床評価多施設オープン試験.腎と透析 23(5):971-980,1987.
 
P.628 掲載の参考文献
1) Nishimoto N,Kishimoto T:Interleukin-6:from bench to bedside.Nat Clin Pract Rheumatol 2:619-626,2006.
PubMed
2) Hirao M,et al:Serum level of oxidative stress marker is dramatically low in patients with rheuma-toid arthritis treated with tocilizumab.Rheumatol Int 32:4041-4045,2012.
 
3) Taga T,et al:Interleukin-6 triggers the association of its receptor with a possible signal transducer,gp130.Cell 58:573-581,1989.
PubMed
4) Scheller J,et al:Interleukin-6 trans-signaling in chronic inflammation and cancer.Scand J Immu-nol 63:321-329,2006.
 
5) Sato K,et al:Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.Cancer Res 53:851-856,1993.
PubMed
6) Nishimoto N,et al:Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.Blood 95:56-61,2000.
PubMed
7) Nishimoto N,et al:Humanized anti-interleukin-6 receptor antibody treatment of multicentric Cas-tleman's disease.Blood 106:2627-2632,2005.
 
8) Nishimoto N,et al:Study of active controlled monotherapy used for rheumatoid arthritis,an IL-6 inhibitor(SAMURAI):evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab.Ann Rheum Dis 66:1162-1167,2007.
 
9) Jones G,et al:Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis:the AMBITION study.Ann Rheum Dis 69:88-96,2010.
PubMed
10) Nishimoto N,et al:Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis:meta-analysis of six initial trials and five long-term extensions.Mod Rheuma-tol 20:222-232,2010.
 
11) Yokota S,et al:Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis:a randomised,double-blind,placebo-controlled,withdrawal phase III trial.Lancet 371:998-1006,2008.
PubMed
12) Imagawa T,et al:Safety and efficacy of tocilizumab,an anti-IL-6-receptor monoclonal antibody,in patients with polyarticular-course juvenile idiopathic arthritis.Mod Rheumatol 22:109-115,2012.
PubMed
13) Nishimoto N,et al:Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.Arthritis Rheum 58:1197-1200,2008.
PubMed
14) Sumida K,et al:Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody.Rheumatology(Oxford) 50:1928-1930,2011.
PubMed
15) Murakami M,Nishimoto N:The value of blocking IL-6 outside of rheumatoid arthritis:current perspective.Curr Opin Rheumatol 23:273-277,2011.
PubMed
P.636 掲載の参考文献
1) 高崎芳成:自己抗原,自己抗体と膠原病,自己抗原の構造・機能と自己抗体産生.Molecular Medi-cine 41:183-1190,2004.
 
2) 高崎芳成:リウマチ・膠原病.内科 4:1125-1133,1999.
 
3) Suzuki A,et al:Functional haplotypes of PADI4,encoding citrullinating enzyme peptidylarginine deiminase 4,are associated with rheumatoid arthritis.Nat Genet 34:395-402,2003.
PubMed
4) van der Helm-van Mil AH,et al:The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for develop-ment of rheumatoid arthritis.Arthritis Rheum 54:1117-1121,2006.
 
5) 高崎芳成:全身性エリテマトーデスとToll-like receptor(TLR).臨床免疫・アレルギー科 49:439-446,2008.
 
6) Kelly KM,et al:"Endogenous adjuvant"activity of the RNA components of lupus autoantigens Sm/RNP and Ro60.Arthritis Rheum 54(5):1557-1567,2006.
PubMed
7) Cen LF,Greene WC:Shaping the nuclear action of NF-kappaB.Nat Rev Mol Cell Biol 5:392-401,2004.
 
8) Krieg AM,et al:CpG motifs in bacterial DNA trigger direct B-cell activation.Nature 374:546-549,1995.
PubMed
9) Leadbetter EA,et al:Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.Nature 416:603-607,2002.
PubMed
10) Anders HJ,et al:Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.Faseb J 18:534-536,2004.
PubMed
11) Krystosek A:Preferential sites of early DNA cleavage in apoptosis and the pathway of nuclear damage.Histochem Cell Biol 111:265-276,1999.
PubMed
12) Sano H,Morimoto C:DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content.J Immunol 128:1341-1345,1982.
 
13) Yasutomo K,et al:Mutation of DNASEI in people with systemic lupus erythematosus.Nat Genet 28:313-314,2001.
 
14) Herrmann M,et al:Impaired phagocytosis of apoptotic cell material by monocyte-derived macro-phages from patients with systemic lupus erythematosus.Arthritis Rheum 41:1241-1250,1998.
 
15) Viglianti GA,et al:Activation of autoreactive B cells by CpG dsDNA.Immunity 19:837-847,2003.
 
16) Crow MK,Kirou KA:Interferon-alpha in systemic lupus erythemtosus.Curr Opin Rheumatol 16:541-547,2004.
 
17) Richardson B:DNA methylation and autoimmune disease.Clin lmmunol 109:72-79,2003.
PubMed
18) Yung RL,Richardson B:Role of T cell DNA methylation in lupus syndromes.Lupus 3:487-491,1994.
PubMed
19) Leffler J,et al:Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease.J Immunol 188:3522-3531,2012.
 
20) Sangaletti S,et al:Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells towards ANCA induction and associated autoimmunity.Blood 120:3007-3018,2012.
 
21) Sugiyama D,et al:Impact of smoking as a risk factor for developing rheumatoid arthritis:a meta-analysis of observational studies.Ann Rheum Dis 69:70-81,2010.
PubMed
22) 高崎芳成:自己抗体とその臨床的意義.Annual Review免疫1992(菊地浩吉ほか編),p266-277,中外医学社,1992.
 
P.643 掲載の参考文献
1) Nakashima R,Mimori T:Clinical and pathophysiological significance of myositis-specific and myosi-tis-associated autoantibodies.Int J Clin Rheumatol 5:523-536,2010.
 
2) Howard OM,et al:Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase,autoantigens in myositis,activate chemokine receptors on T lymphocytes and immature dendritic cells.J Exp Med 196:781-791,2002.
 
3) Hengstman GJ,et al:Anti-signal recognition particle autoantibodies:marker of a necrotising myopathy.Ann Rheum Dis 65:1635-1638,2006.
PubMed
4) Seelig HP,et al:Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen.Arthritis Rheum 39:1769-1771,1996.
PubMed
5) Sato S,et al:Autoantibodies to a 140-kd polypeptide,CADM-140,in Japanese patients with clini-cally amyopathic dermatomyositis.Arthritis Rheum 52:1571-1576,2005.
 
6) Nakashima R,et al:The RIG-1-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoanti-gen identified by the anti-CADM-140 antibody.Rheumatology(Oxford) 49:433-440,2010.
 
7) Gono T,et al:Clinical manifestation and prognostic factor in anti-melanoma differentiation-associ-ated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.Rheu-matology(Oxford) 49:1713-1719,2010.
 
8) Sato S,et al:RNA helicase encoded by melanoma differentiation-associated gene 5 is a major auto-antigen in patients with clinically amyopathic dermatomyositis:Association with rapidly progressive interstitial lung disease.Arthritis Rheum 60:2193-2200,2009.
 
9) Targoff IN,et al:A novel autoantibody to a 155-kd protein is associated with dermatomyositis.Arthritis Rheum 54:3682-3689,2006.
PubMed
10) Kaji K,et al:Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis:an association with malignancy.Rheumatology(Oxford) 46:25-28,2007.
 
11) Gunawardena H,et al:Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associ-ated with calcinosis.Arthritis Rheum 60:1807-1814,2009.
 
12) Espada G,et al:Clinical and serologic characterization of an Argentine pediatric myositis cohort:identification of a novel autoantibody(anti-MJ) to a 142-kDa protein.J Rheumatol 36:2547-2551,2009.
 
13) Betteridge ZE,et al:Clinical and human leucocyte antigen class II haplotype associations of autoan-tibodies to small ubiquitin-like modifier enzyme,a dermatomyositis-specific autoantigen target,in UK Caucasian adult-onset myositis.Ann Rheum Dis 68:1621-1625,2009.
 
14) Christopher-Stine L,et al:A novel autoantibody recognizing 200-kd and 100-kd proteins is associ-ated with an immune-mediated necrotizing myopathy.Arthritis Rheum 62:2757-2766,2010.
 
15) Mammen AL,et al:Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.Arthritis Rheum 63:713-721,2011.
PubMed
P.647 掲載の参考文献
1) 日本における血管外科手術数調査[http://jsvs.jp/enquete/result/index.html].
 
2) Dueck AD,et al:Survival after ruptured abdominal aortic aneurysms:effect of patient,surgeon,and hospital factors.J Vasc Surg 39:1253-1260,2004.
PubMed
3) Heikkinen M,et al:Ruptured abdominal aortic aneurysm in well-defined geographic area.J Vasc Surg 36:291-296,2002.
PubMed
4) Cho JS,et al:Contemporary results of open repair of ruptured abdominal aortoiliac aneurysms:ef-fect of surgeon volume on mortality.J Vasc Surg 48:10-18,2008.
 
5) Zarins CK,Harris EJ:Operative repair for aortic aneurysms:the gold standard.J Endovasc Surg 4:232-241,1997.
 
6) Hertzer NR,et al:Open infrarenal abdominal aortic aneurysm repair:the Cleveland Clinic experi-ence from 1989 to 1998.J Vasc Surg 35:1145-1154,2002.
 
7) Greenhalgh RM:Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm(EVAR trial 1),30-day operative mortality results:randomized con-trolled trial.Lancet 364:843-848,2004.
 
8) Prinssen M,et al:A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms.N Engl J Med 351:1607-1618,2004.
PubMed
9) Schermerhorn ML,et al:Endovascular vs.open repair of abdominal aortic aneurysms in the Medi-care population.N Engl J Med 358:464-474,2008.
 
10) 日本胸部外科学会学術調査[http://ceter6.umin.ac.jp/oasis/jats/member/suv/index.html].
 
11) 大北裕:日本の心臓・大血管外科レベルは欧米を超えているか? 4.大動脈疾患.日外会誌 113:283-287,2012.
 
12) Trimarchi SK,et al:Role of age in acute type A aortic dissection outcome:report from the Interna-tional Registry of Acute Aortic Dissection(IRAD).J Thorac Cardiovasc Surg 140:784-789,2010.
 
13) Bridgewater B,et al:Surgery on the aorta.Six national adult cardiac surgical database report-dem-onstrating quality.Dendrite Clinical Systems,Henley-on-Thames.United Kingdom,p324-332,2008.
 
14) Sundt TM 3rd,et al:Improving results of open arch replacement.Ann Thorac Surg 86:787-796,2008.
PubMed
15) Cowan JA,et al:Surgical treatment of intact thoracoabdominal aortic aneurysms in the United States:hospital and surgeon volume-related outcomes.J Vasc Surg 37:1169-1174,2003.
PubMed
P.654 掲載の参考文献
1) 小川俊一ほか:循環器病の診断と治療に関するガイドライン(2007年度合同研究班報告).川崎病心臓血管後遺症の診断と治療に関するガイドライン(2008年改訂版).[http://www.j-circ.or.jp/guideline/pdf/JCS2008_ogawasy_h.pdf](2012年7月閲覧)
 
2) Newburger JW,et al;Committee on Rheumatic Fever,Endocarditis,and Kawasaki Disease,Coun-cil on Cardiovascular Disease in the Young,American Heart Association:Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the Com-mittee on Rheumatic Fever,Endocarditis,and Kawasaki Disease,Council on Cardiovascular Dis-ease in the Young,American Heart Association.Pediatrics 114:1708-1733,2004.
 
3) Burns JC,et al:Sequelae of Kawasaki disease in adolescents and young adults.J Am Coll Cardiol 28:253-257,1996.
 
4) Yagi S,et al:Two adults requiring implantable defibrillators because of ventricular tachycardia and left ventricular dysfUnction caused by presumed Kawasaki disease.Circ J 69:870-874,2005.
PubMed
5) Tsuda E,et al:Acute coronary syndrome in adult patients with coronary artery lesions caused by Kawasaki disease:review of case reports.Cardiol Young 21:74-82,2011.
PubMed
6) Satoda M,et al:Images in cardiovascular medicine.Sudden death due to rupture of coronary aneu-rysm in a 26-year-old man.Circulation 97:705-706,1998.
 
7) Kato H:Cardiovascular complications in Kawasaki disease:coronary artery lumen and long-term consequences.Progress Pediatr Cardiol 19:137-145,2004.
 
8) Suda K,et al:Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease.Circ J 73:1319-1323,2009.
PubMed
9) Tsuda E,et al:National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan.Circulation 110(11 Suppl 1):II61-66,2004.
 
10) Muta H,Ishi M:Percutaneous coronary intervention versus coronary artery bypass grafting for stenotic lesions after Kawasaki disease.J Pediatr 157:120-126,2010.
 
11) Noma M,et al:Isolated coronary ostial stenosis in Takayasu's arteritis:case report and review of the literature.Angiology 4:839-844,1993.
 
12) Furukawa Y,et al:Sirolimus-eluting stent for in-stent restenosis of left main coronary in Takayasu arteritis.Circ J 69:752-755,2005.
PubMed
13) Hunsaker JC 3rd,et al:Spontaneous coronary arterial dissection and isolated eosinophilic coronary arteritis:sudden cardiac death in a patient with a limited variant of Curg-Strauss syndrome.Mayo Clin Proc 67:761-766,1992.
 
14) Cacoub P,et al:Causes of death in systemic vasculitis of polyarteritis nodosa.Analysis of a series of 165 patients.Ann Med Interne 139:381-390,1998.
 
15) Wenger M,Schneider J:Sudden cardiac death in giant cell arteritis.Vasa 25:373-377,1996.
PubMed
P.660 掲載の参考文献
1) 尾崎承一ほか:循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告) 血管炎症候群の診療ガイドライン.Circulation J 72(Suppl IV):1253-1318,2008.
 
2) 尾崎承一ほか:ANCA関連血管炎の診療ガイドライン,厚生労働省難治疾患克服研究事業3班合同委員会,2011.
 
3) Lapraik C,et al:BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.Rheumatology 46:1615-1616,2007.
PubMed
4) Mukhtyar C,et al:EULAR recommendations for the management of primary small and medium ves-sel vasculitis.Ann Rheum Dis 68:310-317,2009.
 
5) Ozaki S,et al:Severity-based treatment for Japanese patients with MPO-ANCA-associated vascu-litis:the JMAAV study.Mod Rheumatol 22:394-404,2012.
 
6) 急速進行性糸球体腎炎診療指針作成合同委員会:厚生労働省進行性腎障害に関する調査研究班報告:急速進行性糸球体腎炎症候群の診療指針.日腎会誌 44:55-82,2002.
 
7) 松尾清一ほか:厚生労働省特定疾患進行性腎障害に関する調査研究班報告-急速進行性腎炎症候群の診療指針第2版.日腎会誌 53:509-555,2011.
 
8) 吉田雅治ほか:中・小型血管炎の臨床に関する小委員会報告 厚生労働科学研究費補助金難治性疾患克服研究事業難治性血管炎に関する調査研究 平成14-16年度総合研究報告書,p361-372,2005.
 
P.665 掲載の参考文献
1) 勝岡憲生ほか:血管炎・血管障害ガイドライン.日皮会誌 118:2095-2187,2008.
 
2) Jorizzo JL:Classification of vasculitis.J Invest Dermatol 100:106s-110s,1993.
PubMed
3) Jennete JC,et al:Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum 37:187-192,1994.
 
4) 勝岡憲生:血管炎の分類の今昔-皮膚科からのメッセージ.Visual Dermatology 6:458-463,2007.
 
5) 勝岡憲生(編):皮膚科医が考える血管炎の分類とは.皮膚科臨床アセット5,皮膚の血管炎・血行障害.p17-21,中山書店,2011.
 
6) Kawakami T:New algorithm(KAWAKAMI algorithm) to diagnose primary cutaneous vasculitis.J Dermatol 37:113-124,2010.
PubMed
P.670 掲載の参考文献
1) Davies DJ,et al:Segmental necrotizing glomerulonephritis with anti neutrophil antibody:possible arbovirus aetiology? Br Med J 285:606,1982.
 
2) 湯村和子ほか:ANCA関連血管炎の予後.腎と透析 47:55-60,1999.
 
3) Okano K,et al:Evaluation of prognostic factors for myeloperoxidase anti-neutrophil cytoplasmic antibody-(MPO-ANCA) associated glomerulonephritis.Clin Nephrol 55:275-281,2000.
 
4) Ozaki S,et al:Severity-based treatment for Japanese patients with MPO-ANCA-associated vascu-litis:the JMAAV study.Mod Rheumatol 22:394-404,2012.
 
5) 板橋美津世ほか:MPO-ANCA関連血管炎の臨床病理学的アプローチによる病態の解析.日腎誌 50:927-933,2009.
 
6) 国際交流分科会(鈴木和男分科会長)報告:厚生労働省難治性疾患克服研究事業「難治性血管炎に関する調査研究班」総括・分担研究者報告書,p109,2010,p142-143,2011.
 
7) Yumura W,et al:Urinalysis is the clue for early detection of ANCA-associated vasculitis.The Asia Pacific Meeting of Vasculitis and ANCA Workshop 2012,Shinagawa Conference Center,March 30,2012.
 
8) 日本透析医学会透析調査委員会(編):わが国の慢性透析療法の現状,2011年12月31日現在,p11,2012.
 
9) 湯村和子:血管炎の新分類基準,新治療や発症機構研究の世界的動向(2) 血管炎の評価基準BVAS.日本医事新報 No4472:47-50,2009.
 
10) 湯村和子:検尿の見方・考え方 尿所見でわかること.Medicina 49:1889-1893,2012.
 
P.680 掲載の参考文献
11) Keffer J,et al:Transgenic mice expressing human tumour necrosis factor:a predictive genetic model of arthritis.Embo J 10(13):4025-4031,1991.
PubMed

書評

最近チェックした商品履歴

Loading...